Tables | Volume 28 Number 4 | HIV Surveillance | Reports | Resource Library | HIV/AIDS

Table 1a. Stage of disease at time of diagnosis of HIV infection during 2021 among persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
Gender
Male	26,654	1,927	7.2	6,404	24.0	8,564	32.1	5,689	21.3	4,070	15.3
Female	6,069	361	5.9	1,796	29.6	1,651	27.2	1,283	21.1	978	16.1
Transgender woman^c	785	69	8.8	256	32.6	271	34.5	94	12.0	95	12.1
Transgender man^c	55	11	20.0	23	41.8	17	30.9	2	3.6	2	3.6
Additional gender identity^d	43	3	7.0	9	20.9	18	41.9	6	14.0	7	16.3
Age at diagnosis (yr)
13–24	6,561	648	9.9	1,765	26.9	2,483	37.8	649	9.9	1,016	15.5
25–34	12,337	944	7.7	3,332	27.0	4,042	32.8	2,100	17.0	1,919	15.6
35–44	7,087	437	6.2	1,752	24.7	1,999	28.2	1,806	25.5	1,093	15.4
45–54	4,153	187	4.5	911	21.9	1,140	27.5	1,335	32.1	580	14.0
≥55	3,468	155	4.5	728	21.0	857	24.7	1,184	34.1	544	15.7
Race/ethnicity
American Indian/Alaska Native	220	19	8.6	49	22.3	70	31.8	42	19.1	40	18.2
Asian	699	44	6.3	140	20.0	254	36.3	182	26.0	79	11.3
Black/African American	13,650	872	6.4	3,328	24.4	4,330	31.7	2,688	19.7	2,432	17.8
Hispanic/Latino^e	9,416	740	7.9	2,342	24.9	3,120	33.1	2,088	22.2	1,126	12.0
Native Hawaiian/other Pacific Islander	74	3	4.1	23	31.1	19	25.7	18	24.3	11	14.9
White	8,580	619	7.2	2,372	27.6	2,415	28.1	1,846	21.5	1,328	15.5
Multiracial	967	74	7.7	234	24.2	313	32.4	210	21.7	136	14.1
Transmission category^f
Male-to-male sexual contact^g	22,659	1,725	7.6	5,621	24.8	7,479	33.0	4,530	20.0	3,306	14.6
Injection drug use^h	2,326	134	5.8	582	25.0	610	26.2	508	21.8	492	21.1
Male	1,311	75	5.7	284	21.7	355	27.1	307	23.5	290	22.1
Female	1,015	60	5.9	298	29.4	255	25.1	201	19.8	201	19.8
Male-to-male sexual contact^g and injection drug use^h	1,301	106	8.2	379	29.1	383	29.4	209	16.1	224	17.3
Heterosexual contactⁱ	7,244	401	5.5	1,888	26.1	2,030	28.0	1,807	24.9	1,118	15.4
Male	2,178	92	4.2	380	17.4	629	28.9	733	33.7	345	15.8
Female	5,065	309	6.1	1,508	29.8	1,402	27.7	1,074	21.2	773	15.3
Other^j	76	5	6.5	19	25.3	19	24.9	20	26.9	12	16.5
Male	27	2	5.6	5	19.2	6	24.1	9	33.1	5	18.0
Female	49	3	6.9	14	28.6	12	25.3	11	23.5	8	15.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	27,010	2,011	7.4	6,815	25.2	8,570	31.7	5,517	20.4	4,097	15.2
Metropolitan areas (pop. 50,000–499,999)	4,224	247	5.8	1,098	26.0	1,293	30.6	945	22.4	641	15.2
Nonmetropolitan areas (pop. <50,000)	2,254	107	4.7	551	24.4	621	27.6	593	26.3	382	16.9
Total	33,606	2,371	7.1	8,488	25.3	10,521	31.3	7,074	21.0	5,152	15.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.
^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact)
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 1b. Stage of disease at time of diagnosis of HIV infection during 2021 among persons aged ≥13 years, by area of residence—47 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
Alabama	625	19	3.0	179	28.6	181	29.0	115	18.4	131	21.0
Alaska	30	6	20.0	4	13.3	9	30.0	10	33.3	1	3.3
Arizona	781	60	7.7	224	28.7	243	31.1	146	18.7	108	13.8
Arkansas	338	6	1.8	88	26.0	84	24.9	82	24.3	78	23.1
California	4,399	332	7.5	1,144	26.0	1,437	32.7	906	20.6	580	13.2
Colorado	406	88	21.7	107	26.4	103	25.4	72	17.7	36	8.9
Connecticut	233	23	9.9	62	26.6	76	32.6	48	20.6	24	10.3
Delaware	81	8	9.9	16	19.8	20	24.7	25	30.9	12	14.8
District of Columbia	195	14	7.2	49	25.1	58	29.7	37	19.0	37	19.0
Florida	4,072	194	4.8	1,116	27.4	1,332	32.7	847	20.8	583	14.3
Georgia	2,371	84	3.5	592	25.0	782	33.0	543	22.9	370	15.6
Hawaii	65	4	6.2	20	30.8	17	26.2	15	23.1	9	13.8
Illinois	1,195	99	8.3	290	24.3	352	29.5	212	17.7	242	20.3
Indiana	528	13	2.5	150	28.4	156	29.5	106	20.1	103	19.5
Iowa	124	5	4.0	37	29.8	41	33.1	31	25.0	10	8.1
Kansas	154	3	1.9	49	31.8	55	35.7	41	26.6	6	3.9
Kentucky	390	42	10.8	93	23.8	114	29.2	71	18.2	70	17.9
Louisiana	899	107	11.9	193	21.5	284	31.6	206	22.9	109	12.1
Maine	31	0	0.0	7	22.6	7	22.6	14	45.2	3	9.7
Maryland	749	74	9.9	199	26.6	222	29.6	183	24.4	71	9.5
Massachusetts	440	23	5.2	133	30.2	145	33.0	103	23.4	36	8.2
Michigan	633	64	10.1	165	26.1	193	30.5	121	19.1	90	14.2
Minnesota	297	27	9.1	64	21.5	94	31.6	66	22.2	46	15.5
Mississippi	419	11	2.6	73	17.4	85	20.3	87	20.8	163	38.9
Missouri	549	21	3.8	121	22.0	150	27.3	99	18.0	158	28.8
Montana	22	3	13.6	6	27.3	6	27.3	5	22.7	2	9.1
Nebraska	105	4	3.8	22	21.0	33	31.4	23	21.9	23	21.9
Nevada	501	27	5.4	139	27.7	169	33.7	120	24.0	46	9.2
New Hampshire	32	2	6.3	11	34.4	9	28.1	9	28.1	1	3.1
New Mexico	149	8	5.4	45	30.2	54	36.2	20	13.4	22	14.8
New York	2,116	216	10.2	523	24.7	702	33.2	479	22.6	196	9.3
North Carolina	1,390	120	8.6	281	20.2	402	28.9	265	19.1	322	23.2
North Dakota	37	0	0.0	15	40.5	10	27.0	10	27.0	2	5.4
Ohio	909	39	4.3	260	28.6	273	30.0	206	22.7	131	14.4
Oklahoma	387	16	4.1	72	18.6	115	29.7	69	17.8	115	29.7
Oregon	202	25	12.4	50	24.8	57	28.2	43	21.3	27	13.4
Rhode Island	68	2	2.9	20	29.4	19	27.9	17	25.0	10	14.7
South Carolina	652	30	4.6	161	24.7	218	33.4	168	25.8	75	11.5
South Dakota	31	1	3.2	11	35.5	5	16.1	9	29.0	5	16.1
Tennessee	831	28	3.4	214	25.8	258	31.0	140	16.8	191	23.0
Texas	4,363	376	8.6	1,021	23.4	1,390	31.9	912	20.9	664	15.2
Utah	133	23	17.3	24	18.0	45	33.8	26	19.5	15	11.3
Vermont	12	1	8.3	4	33.3	1	8.3	5	41.7	1	8.3
Virginia	792	62	7.8	197	24.9	231	29.2	180	22.7	122	15.4
Washington	461	32	6.9	140	30.4	158	34.3	94	20.4	37	8.0
West Virginia	149	11	7.4	26	17.4	34	22.8	31	20.8	47	31.5
Wisconsin	253	18	7.1	67	26.5	92	36.4	55	21.7	21	8.3
Wyoming	7	0	0.0	4	57.1	0	0.0	2	28.6	1	14.3
Region of residence^c
Northeast (excluding NJ & PA)	2,932	267	9.1	760	25.9	959	32.7	675	23.0	271	9.2
Midwest	4,815	294	6.1	1,251	26.0	1,454	30.2	979	20.3	837	17.4
South	18,703	1,202	6.4	4,570	24.4	5,810	31.1	3,961	21.2	3,160	16.9
West (excluding ID)	7,156	608	8.5	1,907	26.6	2,298	32.1	1,459	20.4	884	12.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and VL test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.
^c Data should be interpreted with caution as areas with incomplete reporting to CDC are not included.

Table 1c. Stage of disease at time of diagnosis of HIV infection during 2021 among persons aged ≥13 years, by race/ethnicity and selected characteristics—47 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	164	14	8.5	35	21.3	53	32.3	33	20.1	29	17.7
Female	46	4	8.7	12	26.1	14	30.4	7	15.2	9	19.6
Transgender woman^c	10	1	10.0	2	20.0	3	30.0	2	20.0	2	20.0
Transgender man^c	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	30	3	10.0	7	23.3	8	26.7	3	10.0	9	30.0
25-34	73	7	9.6	12	16.4	29	39.7	15	20.5	10	13.7
35-44	40	3	7.5	17	42.5	7	17.5	7	17.5	6	15.0
45-54	18	1	5.6	1	5.6	9	50.0	5	27.8	2	11.1
≥55	13	1	7.7	0	0.0	3	23.1	5	38.5	4	30.8
Transmission category^e
Male-to-male sexual contact^f	139	13	9.4	27	19.5	46	33.3	28	20.0	25	17.8
Injection drug use^g	10	0	0.0	2	21.4	4	44.9	1	11.2	2	19.4
Male-to-male sexual contact^f and injection drug use^g	16	0	0.0	6	37.6	3	19.7	3	19.7	3	20.4
Heterosexual contact^h	10	1	12.2	2	20.4	2	23.5	3	31.6	1	12.2
Otherⁱ	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	96	8	8.3	17	17.7	34	35.4	16	16.7	21	21.9
Metropolitan areas (pop. 50,000-499,999)	33	4	12.1	11	33.3	8	24.2	6	18.2	4	12.1
Nonmetropolitan areas (pop. <50,000)	45	3	6.7	9	20.0	14	31.1	13	28.9	6	13.3
Subtotal	174	15	8.6	37	21.3	56	32.2	35	20.1	31	17.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	3	1	33.3	1	33.3	0	0.0	0	0.0	1	33.3
25-34	17	2	11.8	5	29.4	4	23.5	2	11.8	4	23.5
35-44	9	0	0.0	3	33.3	4	44.4	2	22.2	0	0.0
45-54	14	1	7.1	2	14.3	4	28.6	3	21.4	4	28.6
≥55	3	0	0.0	1	33.3	2	66.7	0	0.0	0	0.0
Transmission category^e
Injection drug use^g	17	4	23.3	6	33.7	4	23.8	2	8.7	2	10.5
Heterosexual contact^h	29	0	0.0	6	21.5	10	34.4	6	19.1	7	25.0
Otherⁱ	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	25	2	8.0	8	32.0	7	28.0	2	8.0	6	24.0
Metropolitan areas (pop. 50,000-499,999)	9	1	11.1	1	11.1	2	22.2	3	33.3	2	22.2
Nonmetropolitan areas (pop. <50,000)	12	1	8.3	3	25.0	5	41.7	2	16.7	1	8.3
Subtotal	46	4	8.7	12	26.1	14	30.4	7	15.2	9	19.6
Total	220	19	8.6	49	22.3	70	31.8	42	19.1	40	18.2
Asian
Gender
Male	594	39	6.6	116	19.5	223	37.5	150	25.3	66	11.1
Female	86	3	3.5	20	23.3	21	24.4	29	33.7	13	15.1
Transgender woman^c	17	2	11.8	4	23.5	8	47.1	3	17.6	0	0.0
Transgender man^c	2	0	0.0	0	0.0	2	100	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0	0	0.0	0	0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	105	7	6.7	22	21.0	51	48.6	11	10.5	14	13.3
25-34	240	23	9.6	54	22.5	91	37.9	43	17.9	29	12.1
35-44	135	7	5.2	30	22.2	52	38.5	34	25.2	12	8.9
45-54	82	1	1.2	11	13.4	25	30.5	38	46.3	7	8.5
≥55	49	3	6.1	3	6.1	12	24.5	27	55.1	4	8.2
Transmission category^e
Male-to-male sexual contact^f	545	37	6.8	109	20.0	215	39.3	124	22.7	61	11.1
Injection drug use^g	13	0	0.0	2	18.0	4	27.1	7	49.6	1	4.5
Male-to-male sexual contact^f and injection drug use^g	16	2	12.8	4	25.0	6	35.9	3	17.9	1	8.3
Heterosexual contact^h	36	2	4.7	5	12.4	7	19.9	20	54.1	3	8.8
Otherⁱ	1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	556	38	6.8	113	20.3	207	37.2	139	25.0	59	10.6
Metropolitan areas (pop. 50,000-499,999)	44	2	4.5	6	13.6	20	45.5	11	25.0	5	11.4
Nonmetropolitan areas (pop. <50,000)	9	1	11.1	1	11.1	3	33.3	3	33.3	1	11.1
Subtotal	611	41	6.7	120	19.6	231	37.8	153	25.0	66	10.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	9	0	0.0	2	22.2	4	44.4	2	22.2	1	11.1
25-34	21	1	4.8	8	38.1	8	38.1	4	19.0	0	0.0
35-44	31	2	6.5	5	16.1	6	19.4	10	32.3	8	25.8
45-54	12	0	0.0	3	25.0	3	25.0	4	33.3	2	16.7
≥55	15	0	0.0	2	13.3	2	13.3	9	60.0	2	13.3
Transmission category^e
Injection drug use^g	6	0	1.7	2	25.4	2	39.0	2	27.1	0	6.8
Heterosexual contact^h	80	3	3.5	17	21.6	21	25.8	27	33.5	13	15.6
Otherⁱ	2	0	4.8	1	57.1	0	4.8	1	28.6	0	4.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	70	2	2.9	15	21.4	19	27.1	22	31.4	12	17.1
Metropolitan areas (pop. 50,000-499,999)	14	1	7.1	4	28.6	4	28.6	5	35.7	0	0.0
Nonmetropolitan areas (pop. <50,000)	4	0	0.0	1	25.0	0	0.0	2	50.0	1	25.0
Subtotal	88	3	3.4	20	22.7	23	26.1	29	33.0	13	14.8
Total	699	44	6.3	140	20.0	254	36.3	182	26.0	79	11.3
Black/African American
Gender
Male	9,985	660	6.6	2,251	22.5	3,253	32.6	1,944	19.5	1,877	18.8
Female	3,274	175	5.3	958	29.3	935	28.6	699	21.4	507	15.5
Transgender woman^c	363	33	9.1	110	30.3	133	36.6	43	11.8	44	12.1
Transgender man^c	17	4	23.5	8	47.1	4	23.5	0	0.0	1	5.9
Additional gender identity^d	11	0	0.0	1	9.1	5	45.5	2	18.2	3	27.3
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	3,059	291	9.5	770	25.2	1,171	38.3	282	9.2	545	17.8
25-34	4,035	275	6.8	953	23.6	1,374	34.1	725	18.0	708	17.5
35-44	1,605	62	3.9	350	21.8	429	26.7	425	26.5	339	21.1
45-54	801	28	3.5	137	17.1	227	28.3	257	32.1	152	19.0
≥55	858	37	4.3	152	17.7	189	22.0	300	35.0	180	21.0
Transmission category^e
Male-to-male sexual contact^f	8,451	605	7.2	2,015	23.8	2,848	33.7	1,452	17.2	1,531	18.1
Injection drug use^g	336	19	5.6	59	17.4	85	25.2	86	25.6	88	26.2
Male-to-male sexual contact^f and injection drug use^g	226	15	6.5	61	26.9	65	28.9	31	13.9	54	23.8
Heterosexual contact^h	1,333	55	4.1	226	16.9	388	29.1	416	31.2	249	18.6
Otherⁱ	13	0	0.0	2	15.1	4	31.7	4	29.4	3	20.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	8,497	591	7.0	1,933	22.7	2,826	33.3	1,592	18.7	1,555	18.3
Metropolitan areas (pop. 50,000-499,999)	1,206	75	6.2	292	24.2	374	31.0	233	19.3	232	19.2
Nonmetropolitan areas (pop. <50,000)	619	27	4.4	131	21.2	176	28.4	158	25.5	127	20.5
Subtotal	10,358	693	6.7	2,362	22.8	3,390	32.7	1,989	19.2	1,924	18.6
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	452	36	8.0	139	30.8	148	32.7	47	10.4	82	18.1
25-34	885	60	6.8	285	32.2	269	30.4	126	14.2	145	16.4
35-44	811	40	4.9	217	26.8	230	28.4	207	25.5	117	14.4
45-54	601	28	4.7	155	25.8	159	26.5	179	29.8	80	13.3
≥55	543	15	2.8	170	31.3	134	24.7	140	25.8	84	15.5
Transmission category^e
Injection drug use^g	276	9	3.3	77	28.0	76	27.4	65	23.4	50	17.9
Heterosexual contact^h	2,983	167	5.6	881	29.5	856	28.7	626	21.0	452	15.2
Otherⁱ	33	3	8.3	7	22.3	8	25.7	8	24.5	6	19.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	2,676	154	5.8	799	29.9	753	28.1	555	20.7	415	15.5
Metropolitan areas (pop. 50,000-499,999)	410	15	3.7	118	28.8	128	31.2	98	23.9	51	12.4
Nonmetropolitan areas (pop. <50,000)	193	9	4.7	47	24.4	56	29.0	45	23.3	36	18.7
Subtotal	3,292	179	5.4	966	29.3	940	28.6	699	21.2	508	15.4
Total	13,650	872	6.4	3,328	24.4	4,330	31.7	2,688	19.7	2,432	17.8
Hispanic/Latino^j
Gender
Male	8,101	656	8.1	1,928	23.8	2,722	33.6	1,833	22.6	962	11.9
Female	1,041	63	6.1	316	30.4	305	29.3	221	21.2	136	13.1
Transgender woman^c	246	19	7.7	89	36.2	83	33.7	29	11.8	26	10.6
Transgender man^c	14	2	14.3	5	35.7	4	28.6	2	14.3	1	7.1
Additional gender identity^d	14	0	0.0	4	28.6	6	42.9	3	21.4	1	7.1
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	1,602	183	11.4	412	25.7	650	40.6	182	11.4	175	10.9
25-34	3,479	288	8.3	893	25.7	1,230	35.4	613	17.6	455	13.1
35-44	1,867	134	7.2	435	23.3	562	30.1	548	29.4	188	10.1
45-54	894	42	4.7	196	21.9	235	26.3	324	36.2	97	10.9
≥55	518	28	5.4	85	16.4	134	25.9	197	38.0	74	14.3
Transmission category^e
Male-to-male sexual contact^f	7,340	613	8.4	1,819	24.8	2,509	34.2	1,544	21.0	855	11.7
Injection drug use^g	282	19	6.7	56	19.8	69	24.6	89	31.6	49	17.3
Male-to-male sexual contact^f and injection drug use^g	314	27	8.5	83	26.4	101	32.1	63	20.2	40	12.8
Heterosexual contact^h	418	16	3.9	62	14.9	130	31.2	165	39.6	44	10.5
Otherⁱ	6	0	0.0	2	26.2	2	24.6	2	35.4	1	10.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	7,343	615	8.4	1,779	24.2	2,475	33.7	1,607	21.9	867	11.8
Metropolitan areas (pop. 50,000-499,999)	694	44	6.3	162	23.3	234	33.7	171	24.6	83	12.0
Nonmetropolitan areas (pop. <50,000)	290	11	3.8	75	25.9	92	31.7	80	27.6	32	11.0
Subtotal	8,360	675	8.1	2,021	24.2	2,811	33.6	1,864	22.3	989	11.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	140	14	10.0	61	43.6	31	22.1	15	10.7	19	13.6
25-34	301	21	7.0	97	32.2	98	32.6	47	15.6	38	12.6
35-44	274	20	7.3	83	30.3	81	29.6	53	19.3	37	13.5
45-54	198	6	3.0	44	22.2	65	32.8	56	28.3	27	13.6
≥55	143	4	2.8	36	25.2	34	23.8	53	37.1	16	11.2
Transmission category^e
Injection drug use^g	151	12	8.2	39	25.8	43	28.5	32	21.4	24	16.0
Heterosexual contact^h	899	52	5.8	279	31.0	265	29.4	191	21.2	112	12.5
Otherⁱ	6	0	0.0	3	54.4	1	19.3	1	14.0	1	8.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	915	59	6.4	279	30.5	265	29.0	188	20.5	124	13.6
Metropolitan areas (pop. 50,000-499,999)	106	5	4.7	32	30.2	34	32.1	26	24.5	9	8.5
Nonmetropolitan areas (pop. <50,000)	33	1	3.0	10	30.3	9	27.3	9	27.3	4	12.1
Subtotal	1,056	65	6.2	321	30.4	309	29.3	224	21.2	137	13.0
Total	9,416	740	7.9	2,342	24.9	3,120	33.1	2,088	22.2	1,126	12.0
Native Hawaiian/other Pacific Islander
Gender
Male	60	3	5.0	18	30.0	16	26.7	15	25.0	8	13.3
Female	8	0	0.0	4	50.0	1	12.5	1	12.5	2	25.0
Transgender woman^c	6	0	0.0	1	16.7	2	33.3	2	33.3	1	16.7
Transgender man^c	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Additional gender identity^d	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	10	1	10.0	2	20.0	5	50.0	1	10.0	1	10.0
25-34	26	2	7.7	10	38.5	6	23.1	3	11.5	5	19.2
35-44	17	0	0.0	2	11.8	5	29.4	8	47.1	2	11.8
45-54	7	0	0.0	2	28.6	2	28.6	3	42.9	0	0.0
≥55	6	0	0.0	3	50.0	0	0.0	2	33.3	1	16.7
Transmission category^e
Male-to-male sexual contact^f	59	3	5.1	18	30.5	16	27.1	14	23.9	8	13.3
Injection drug use^g	1	0	0.0	0	0.0	0	0.0	1	85.7	0	0.0
Male-to-male sexual contact^f and injection drug use^g	4	0	0.0	1	31.4	1	28.6	0	11.4	1	28.6
Heterosexual contact^h	3	0	0.0	0	0.0	1	40.0	1	56.0	0	0.0
Otherⁱ	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	56	2	3.6	18	32.1	15	26.8	14	25.0	7	12.5
Metropolitan areas (pop. 50,000-499,999)	4	1	25.0	1	25.0	1	25.0	1	25.0	0	0.0
Nonmetropolitan areas (pop. <50,000)	6	0	0.0	0	0.0	2	33.3	2	33.3	2	33.3
Subtotal	66	3	4.5	19	28.8	18	27.3	17	25.8	9	13.6
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-34	2	0	0.0	1	50.0	0	0.0	0	0.0	1	50.0
35-44	4	0	0.0	2	50.0	1	25.0	0	0.0	1	25.0
45-54	2	0	0.0	1	50.0	0	0.0	1	50.0	0	0.0
≥55	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Transmission category^e
Injection drug use^g	3	0	0.0	1	39.4	1	30.3	1	30.3	0	0.0
Heterosexual contact^h	5	0	0.0	3	57.4	0	0.0	0	0.0	2	42.6
Otherⁱ	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	7	0	0.0	3	42.9	1	14.3	1	14.3	2	28.6
Metropolitan areas (pop. 50,000-499,999)	1	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0
Nonmetropolitan areas (pop. <50,000)	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal	8	0	0.0	4	50.0	1	12.5	1	12.5	2	25.0
Total	74	3	4.1	23	31.1	19	25.7	18	24.3	11	14.9
White
Gender
Male	6,999	497	7.1	1,885	26.9	2,040	29.1	1,554	22.2	1,023	14.6
Female	1,435	104	7.2	436	30.4	329	22.9	282	19.7	284	19.8
Transgender woman^c	112	11	9.8	38	33.9	34	30.4	10	8.9	19	17.0
Transgender man^c	19	4	21.1	9	47.4	6	31.6	0	0.0	0	0.0
Additional gender identity^d	15	3	20.0	4	26.7	6	40.0	0	0.0	2	13.3
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	769	76	9.9	233	30.3	276	35.9	71	9.2	113	14.7
25-34	2,493	203	8.1	778	31.2	728	29.2	397	15.9	387	15.5
35-44	1,697	114	6.7	445	26.2	483	28.5	390	23.0	265	15.6
45-54	1,136	63	5.5	263	23.2	314	27.6	345	30.4	151	13.3
≥55	1,029	55	5.3	207	20.1	279	27.1	361	35.1	127	12.3
Transmission category^e
Male-to-male sexual contact^f	5,478	399	7.3	1,490	27.2	1,611	29.4	1,230	22.5	749	13.7
Injection drug use^g	631	35	5.6	155	24.6	185	29.3	117	18.5	139	22.0
Male-to-male sexual contact^f and injection drug use^g	675	60	8.9	205	30.3	194	28.7	102	15.1	115	17.0
Heterosexual contact^h	333	16	4.8	75	22.5	90	27.0	113	33.9	39	11.8
Otherⁱ	6	1	13.1	1	21.3	1	9.8	2	36.1	1	19.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	5,074	402	7.9	1,394	27.5	1,486	29.3	1,056	20.8	736	14.5
Metropolitan areas (pop. 50,000-499,999)	1,234	71	5.8	322	26.1	376	30.5	285	23.1	180	14.6
Nonmetropolitan areas (pop. <50,000)	796	38	4.8	203	25.5	212	26.6	221	27.8	122	15.3
Subtotal	7,124	511	7.2	1,926	27.0	2,080	29.2	1,564	22.0	1,043	14.6
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	148	11	7.4	58	39.2	43	29.1	10	6.8	26	17.6
25-34	408	35	8.6	137	33.6	88	21.6	56	13.7	92	22.5
35-44	407	39	9.6	118	29.0	87	21.4	76	18.7	87	21.4
45-54	278	13	4.7	80	28.8	66	23.7	80	28.8	39	14.0
≥55	215	10	4.7	53	24.7	51	23.7	60	27.9	41	19.1
Transmission category^e
Injection drug use^g	529	30	5.7	161	30.5	123	23.2	93	17.6	122	23.0
Heterosexual contact^h	919	77	8.4	283	30.7	210	22.9	187	20.3	163	17.7
Otherⁱ	8	0	0.0	2	30.3	2	30.3	2	26.3	1	9.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	955	81	8.5	278	29.1	232	24.3	173	18.1	191	20.0
Metropolitan areas (pop. 50,000-499,999)	315	14	4.4	112	35.6	66	21.0	69	21.9	54	17.1
Nonmetropolitan areas (pop. <50,000)	179	13	7.3	53	29.6	36	20.1	40	22.3	37	20.7
Subtotal	1,456	108	7.4	446	30.6	335	23.0	282	19.4	285	19.6
Total	8,580	619	7.2	2,372	27.6	2,415	28.1	1,846	21.5	1,328	15.5
Multiracial
Gender
Male	751	58	7.7	171	22.8	257	34.2	160	21.3	105	14.0
Female	179	12	6.7	50	27.9	46	25.7	44	24.6	27	15.1
Transgender woman^c	31	3	9.7	12	38.7	8	25.8	5	16.1	3	9.7
Transgender man^c	3	1	33.3	1	33.3	1	33.3	0	0.0	0	0.0
Additional gender identity^d	3	0	0.0	0	0.0	1	33.3	1	33.3	1	33.3
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	208	23	11.1	47	22.6	89	42.8	25	12.0	24	11.5
25-34	303	22	7.3	82	27.1	99	32.7	61	20.1	39	12.9
35-44	140	12	8.6	31	22.1	41	29.3	32	22.9	24	17.1
45-54	79	2	2.5	10	12.7	25	31.6	29	36.7	13	16.5
≥55	54	2	3.7	13	24.1	12	22.2	19	35.2	8	14.8
Transmission category^e
Male-to-male sexual contact^f	647	55	8.5	143	22.1	235	36.2	138	21.3	77	12.0
Injection drug use^g	38	1	3.1	10	26.1	9	22.5	7	17.8	12	30.5
Male-to-male sexual contact^f and injection drug use^g	52	2	4.6	20	37.5	13	25.6	6	12.1	11	20.2
Heterosexual contact^h	45	3	5.5	10	22.9	10	20.9	15	32.4	8	18.3
Otherⁱ	1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	603	48	8.0	140	23.2	217	36.0	121	20.1	77	12.8
Metropolitan areas (pop. 50,000-499,999)	123	11	8.9	29	23.6	34	27.6	29	23.6	20	16.3
Nonmetropolitan areas (pop. <50,000)	53	2	3.8	13	24.5	14	26.4	13	24.5	11	20.8
Subtotal	784	61	7.8	183	23.3	266	33.9	166	21.2	108	13.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	26	2	7.7	11	42.3	7	26.9	0	0.0	6	23.1
25-34	54	5	9.3	17	31.5	18	33.3	8	14.8	6	11.1
35-44	50	4	8.0	14	28.0	11	22.0	14	28.0	7	14.0
45-54	31	2	6.5	6	19.4	6	19.4	11	35.5	6	19.4
≥55	22	0	0.0	3	13.6	5	22.7	11	50.0	3	13.6
Transmission category^e
Injection drug use^g	33	4	11.7	12	37.8	6	19.4	6	19.4	4	11.7
Heterosexual contact^h	150	9	6.1	39	25.8	40	26.9	38	25.1	24	16.1
Otherⁱ	1	0	0.0	0	0.0	1	55.6	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	137	9	6.6	39	28.5	33	24.1	31	22.6	25	18.2
Metropolitan areas (pop. 50,000-499,999)	31	3	9.7	7	22.6	12	38.7	8	25.8	1	3.2
Nonmetropolitan areas (pop. <50,000)	15	1	6.7	5	33.3	2	13.3	5	33.3	2	13.3
Subtotal	183	13	7.1	51	27.9	47	25.7	44	24.0	28	15.3
Total	967	74	7.7	234	24.2	313	32.4	210	21.7	136	14.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.
^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^j Hispanic/Latino persons can be of any race.

TTable 1d. Stage of disease at time of diagnosis of HIV infection during 2021 among males, based on assigned sex at birth, aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—47 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	29	3	10.5	7	23.1	8	26.9	3	10.1	8	29.4
25–34	58	6	10.1	8	13.5	23	40.6	13	21.9	8	13.9
35–44	32	3	9.5	13	40.0	7	22.2	5	17.1	4	11.1
45–54	11	1	7.2	0	0.0	6	55.0	3	23.4	2	14.4
≥55	10	1	5.1	0	0.0	2	20.2	4	42.4	3	32.3
Subtotal	139	13	9.4	27	19.5	46	33.3	28	20.0	25	17.8
Asian
13–24	101	7	6.9	21	20.8	50	49.6	9	8.8	14	13.9
25–34	224	22	9.8	47	21.1	86	38.5	40	17.7	29	12.9
35–44	115	5	4.4	29	25.0	46	40.2	25	22.1	10	8.3
45–54	71	1	1.1	11	14.9	24	34.5	30	41.7	6	7.8
≥55	35	2	6.8	2	5.4	8	22.4	20	57.2	3	8.2
Subtotal	545	37	6.8	109	20.0	215	39.3	124	22.7	61	11.1
Black/African American
13–24	2,888	279	9.7	733	25.4	1,105	38.3	265	9.2	506	17.5
25–34	3,525	246	7.0	847	24.0	1,207	34.2	625	17.7	599	17.0
35–44	1,143	43	3.8	266	23.2	317	27.7	281	24.6	237	20.7
45–54	488	16	3.2	90	18.5	136	28.0	146	30.0	99	20.3
≥55	407	21	5.0	79	19.4	83	20.4	135	33.1	90	22.0
Subtotal	8,451	605	7.2	2,015	23.8	2,848	33.7	1,452	17.2	1,531	18.1
Hispanic/Latino^c
13–24	1,496	174	11.6	384	25.6	611	40.8	165	11.0	162	10.8
25–34	3,134	259	8.3	819	26.1	1,105	35.3	549	17.5	402	12.8
35–44	1,602	122	7.6	384	24.0	492	30.7	445	27.8	159	9.9
45–54	729	38	5.2	166	22.8	199	27.3	247	33.8	79	10.9
≥55	379	21	5.5	65	17.3	102	26.9	138	36.5	53	13.9
Subtotal	7,340	613	8.4	1,819	24.8	2,509	34.2	1,544	21.0	855	11.7
Native Hawaiian/other Pacific Islander
13–24	8	1	12.5	2	25.0	4	50.0	1	12.5	0	0.0
25–34	24	2	8.4	9	37.8	5	21.0	3	11.8	5	21.0
35–44	16	0	0.0	2	12.3	5	30.1	7	45.4	2	12.3
45–54	7	0	0.0	2	28.4	2	29.9	3	41.8	0	0.0
≥55	4	0	0.0	3	78.9	0	0.0	0	0.0	1	21.1
Subtotal	59	3	5.1	18	30.5	16	27.1	14	23.9	8	13.3
White
13–24	669	67	10.0	206	30.7	245	36.5	59	8.9	92	13.8
25–34	1,921	155	8.1	597	31.1	580	30.2	321	16.7	268	13.9
35–44	1,199	88	7.3	318	26.5	317	26.5	302	25.2	174	14.5
45–54	863	48	5.6	201	23.3	241	27.9	256	29.7	117	13.6
≥55	827	41	4.9	169	20.4	228	27.6	291	35.2	98	11.8
Subtotal	5,478	399	7.3	1,490	27.2	1,611	29.4	1,230	22.5	749	13.7
Multiracial
13–24	194	21	10.6	42	21.6	86	44.4	25	12.8	21	10.6
25–34	250	21	8.3	59	23.6	87	34.9	55	22.1	28	11.1
35–44	106	10	9.4	22	21.1	34	32.4	24	23.0	15	14.2
45–54	60	2	3.3	8	14.0	19	32.1	23	37.6	8	13.0
≥55	38	2	4.2	11	30.0	8	20.3	11	29.2	6	16.3
Subtotal	647	55	8.5	143	22.1	235	36.2	138	21.3	77	12.0
All
13–24	5,384	552	10.2	1,394	25.9	2,109	39.2	527	9.8	803	14.9
25–34	9,135	711	7.8	2,387	26.1	3,094	33.9	1,605	17.6	1,339	14.7
35–44	4,212	270	6.4	1,033	24.5	1,218	28.9	1,091	25.9	600	14.2
45–54	2,228	106	4.7	478	21.5	627	28.2	707	31.7	310	13.9
≥55	1,699	86	5.1	329	19.4	431	25.3	600	35.3	253	14.9
Total	22,659	1,725	7.6	5,621	24.8	7,479	33.0	4,530	20.0	3,306	14.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Persons whose transmission category is classified as male-to-male sexual contact are presented based on assigned sex at birth and include transgender and additional gender identity persons.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.
^c Hispanic/Latino persons can be of any race..

Table 1e. Stage of disease at time of diagnosis of HIV infection during 2021 among transgender and additional gender identity persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
Transgender woman^c
Age at diagnosis (yr)
13-24	280	27	9.6	97	34.6	103	36.8	17	6.1	36	12.9
25-34	323	32	9.9	107	33.1	104	32.2	44	13.6	36	11.1
35-44	125	7	5.6	35	28.0	43	34.4	24	19.2	16	12.8
45-54	36	2	5.6	10	27.8	16	44.4	5	13.9	3	8.3
≥55	21	1	4.8	7	33.3	5	23.8	4	19.0	4	19.0
Race/ethnicity
American Indian/Alaska Native	10	1	10.0	2	20.0	3	30.0	2	20.0	2	20.0
Asian	17	2	11.8	4	23.5	8	47.1	3	17.6	0	0.0
Black/African American	363	33	9.1	110	30.3	133	36.6	43	11.8	44	12.1
Hispanic/Latino^d	246	19	7.7	89	36.2	83	33.7	29	11.8	26	10.6
Native Hawaiian/other Pacific Islander	6	0	0.0	1	16.7	2	33.3	2	33.3	1	16.7
White	112	11	9.8	38	33.9	34	30.4	10	8.9	19	17.0
Multiple races	31	3	9.7	12	38.7	8	25.8	5	16.1	3	9.7
Exposure category^e
Sexual contact^f	692	61	8.8	229	33.1	245	35.4	82	11.8	75	10.8
Injection drug use^g	3	0	0.0	0	0.0	1	33.3	0	0.0	2	66.7
Sexual contact^f & injection drug use^g	54	8	14.8	14	25.9	14	25.9	6	11.1	12	22.2
Other^h	36	0	0.0	13	36.1	11	30.6	6	16.7	6	16.7
Subtotal	785	69	8.8	256	32.6	271	34.5	94	12.0	95	12.1
Transgender man^c
Age at diagnosis (yr)
13-24	14	1	7.1	3	21.4	7	50.0	2	14.3	1	7.1
25-34	30	6	20.0	15	50.0	8	26.7	0	0.0	1	3.3
35-44	8	3	37.5	4	50.0	1	12.5	0	0.0	0	0.0
45-54	1	0	0.0	1	100	0	0.0	0	0.0	0	0.0
≥55	2	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0
Race/ethnicity
American Indian/Alaska Native	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Asian	2	0	0.0	0	0.0	2	100	0	0.0	0	0.0
Black/African American	17	4	23.5	8	47.1	4	23.5	0	0.0	1	5.9
Hispanic/Latino^d	14	2	14.3	5	35.7	4	28.6	2	14.3	1	7.1
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
White	19	4	21.1	9	47.4	6	31.6	0	0.0	0	0.0
Multiple races	3	1	33.3	1	33.3	1	33.3	0	0.0	0	0.0
Exposure category^e
Sexual contact^f	46	8	17.4	21	45.7	14	30.4	2	4.3	1	2.2
Injection drug use^g	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Sexual contact^f & injection drug use^g	1	0	0.0	1	100	0	0.0	0	0.0	0	0.0
Other^h	8	3	37.5	1	12.5	3	37.5	0	0.0	1	12.5
Subtotal	55	11	20.0	23	41.8	17	30.9	2	3.6	2	3.6
Additional gender identityⁱ
Age at diagnosis (yr)
13-24	25	3	12.0	4	16.0	9	36.0	5	20.0	4	16.0
25-34	11	0	0.0	3	27.3	7	63.6	0	0.0	1	9.1
35-44	3	0	0.0	0	0.0	1	33.3	0	0.0	2	66.7
45-54	4	0	0.0	2	50.0	1	25.0	1	25.0	0	0.0
≥55	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Race/ethnicity
American Indian/Alaska Native	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Asian	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Black/African American	11	0	0.0	1	9.1	5	45.5	2	18.2	3	27.3
Hispanic/Latino^d	14	0	0.0	4	28.6	6	42.9	3	21.4	1	7.1
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
White	15	3	20.0	4	26.7	6	40.0	0	0.0	2	13.3
Multiple races	3	0	0.0	0	0.0	1	33.3	1	33.3	1	33.3
Exposure category^e
Sexual contact^f	37	3	8.1	8	21.6	15	40.5	5	13.5	6	16.2
Injection drug use^g	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Sexual contact^f & injection drug use^g	5	0	0.0	0	0.0	3	60.0	1	20.0	1	20.0
Other^h	1	0	0.0	1	100	0	0.0	0	0.0	0	0.0
Subtotal	43	3	7.0	9	20.9	18	41.9	6	14.0	7	16.3
Total	883	83	9.4	288	32.6	306	34.7	102	11.6	104	11.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.
^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Hispanic/Latino persons can be of any race.
^e Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^f For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
ⁱ Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 2a. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
		Linkage to Care				Viral Suppression
		≤1 month
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%
Gender
Male	26,654	21,833	81.9	4,821	18.1	18,413	69.1
Female	6,069	4,961	81.7	1,108	18.3	4,126	68.0
Transgender woman^a	785	654	83.3	131	16.7	557	71.0
Transgender man^a	55	51	92.7	4	7.3	50	90.9
Additional gender identity^b	43	36	83.7	7	16.3	29	67.4
Age at diagnosis (yr)
13–24	6,561	5,263	80.2	1,298	19.8	4,589	69.9
25–34	12,337	10,074	81.7	2,263	18.3	8,546	69.3
35–44	7,087	5,824	82.2	1,263	17.8	4,847	68.4
45–54	4,153	3,462	83.4	691	16.6	2,880	69.3
≥55	3,468	2,912	84.0	556	16.0	2,313	66.7
Race/ethnicity
American Indian/Alaska Native	220	182	82.7	38	17.3	144	65.5
Asian	699	608	87.0	91	13.0	542	77.5
Black/African American	13,650	10,889	79.8	2,761	20.2	9,022	66.1
Hispanic/Latino^c	9,416	7,958	84.5	1,458	15.5	6,897	73.2
Native Hawaiian/other Pacific Islander	74	59	79.7	15	20.3	51	68.9
White	8,580	7,048	82.1	1,532	17.9	5,854	68.2
Multiracial	967	791	81.8	176	18.2	665	68.8
Transmission category^d
Male-to-male sexual contact^e	22,659	18,717	82.6	3,942	17.4	16,124	71.2
Injection drug use^f	2,326	1,757	75.5	569	24.5	1,217	52.3
Male	1,311	975	74.3	337	25.7	671	51.2
Female	1,015	783	77.1	232	22.9	546	53.8
Male-to-male sexual contact^e and injection drug use^f	1,301	1,026	78.8	276	21.2	811	62.3
Heterosexual contact^g	7,244	5,972	82.4	1,272	17.6	4,967	68.6
Male	2,178	1,779	81.7	399	18.3	1,370	62.9
Female	5,065	4,192	82.8	873	17.2	3,597	71.0
Other^h	76	63	83.7	12	16.3	55	73.0
Male	27	23	87.2	3	12.8	19	72.2
Female	49	40	81.8	9	18.2	36	73.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	27,010	22,266	82.4	4,744	17.6	18,755	69.4
Metropolitan areas (pop. 50,000-499,999)	4,224	3,395	80.4	829	19.6	2,831	67.0
Nonmetropolitan areas (pop. <50,000)	2,254	1,787	79.3	467	20.7	1,507	66.9
Total	33,606	27,535	81.9	6,071	18.1	23,175	69.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^c Hispanic/Latino persons can be of any race.
^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 2b. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among persons aged ≥13 years, by area of residence—47 states and the District of Columbia
		Linkage to Care				Viral Suppression
		≤1 month
	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%
Alabama	625	502	80.3	123	19.7	427	68.3
Alaska	30	28	93.3	2	6.7	27	90.0
Arizona	781	661	84.6	120	15.4	557	71.3
Arkansas	338	261	77.2	77	22.8	200	59.2
California	4,399	3,628	82.5	771	17.5	2,984	67.8
Colorado	406	343	84.5	63	15.5	318	78.3
Connecticut	233	204	87.6	29	12.4	174	74.7
Delaware	81	68	84.0	13	16.0	58	71.6
District of Columbia	195	154	79.0	41	21.0	126	64.6
Florida	4,072	3,366	82.7	706	17.3	2,828	69.4
Georgia	2,371	1,934	81.6	437	18.4	1,585	66.8
Hawaii	65	55	84.6	10	15.4	45	69.2
Illinois	1,195	1,022	85.5	173	14.5	845	70.7
Indiana	528	401	75.9	127	24.1	373	70.6
Iowa	124	106	85.5	18	14.5	106	85.5
Kansas	154	139	90.3	15	9.7	127	82.5
Kentucky	390	289	74.1	101	25.9	202	51.8
Louisiana	899	725	80.6	174	19.4	615	68.4
Maine	31	27	87.1	4	12.9	26	83.9
Maryland	749	650	86.8	99	13.2	511	68.2
Massachusetts	440	403	91.6	37	8.4	357	81.1
Michigan	633	547	86.4	86	13.6	478	75.5
Minnesota	297	254	85.5	43	14.5	216	72.7
Mississippi	419	299	71.4	120	28.6	249	59.4
Missouri	549	427	77.8	122	22.2	388	70.7
Montana	22	21	95.5	1	4.5	18	81.8
Nebraska	105	88	83.8	17	16.2	75	71.4
Nevada	501	439	87.6	62	12.4	384	76.6
New Hampshire	32	32	100	0	0.0	25	78.1
New Mexico	149	127	85.2	22	14.8	106	71.1
New York	2,116	1,814	85.7	302	14.3	1,624	76.7
North Carolina	1,390	1,115	80.2	275	19.8	986	70.9
North Dakota	37	31	83.8	6	16.2	26	70.3
Ohio	909	757	83.3	152	16.7	623	68.5
Oklahoma	387	303	78.3	84	21.7	254	65.6
Oregon	202	159	78.7	43	21.3	142	70.3
Rhode Island	68	58	85.3	10	14.7	50	73.5
South Carolina	652	557	85.4	95	14.6	494	75.8
South Dakota	31	25	80.6	6	19.4	17	54.8
Tennessee	831	583	70.2	248	29.8	530	63.8
Texas	4,363	3,431	78.6	932	21.4	2,723	62.4
Utah	133	111	83.5	22	16.5	100	75.2
Vermont	12	12	100	0	0.0	10	83.3
Virginia	792	633	79.9	159	20.1	557	70.3
Washington	461	407	88.3	54	11.7	352	76.4
West Virginia	149	107	71.8	42	28.2	48	32.2
Wisconsin	253	226	89.3	27	10.7	204	80.6
Wyoming	7	6	85.7	1	14.3	5	71.4
Region of residence^a
Northeast (excluding NJ and PA)	2,932	2,550	87.0	382	13.0	2,266	77.3
Midwest	4,815	4,023	83.6	792	16.4	3,478	72.2
South	18,703	14,977	80.1	3,726	19.9	12,393	66.3
West (excluding ID)	7,156	5,985	83.6	1,171	16.4	5,038	70.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and viral load test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

^a Data should be interpreted with caution as areas with incomplete reporting to CDC are included.

Table 2c. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among persons aged ≥13 years, by race/ethnicity and selected characteristics—47 states and the District of Columbia
		Linkage to Care				Viral Suppression
		≤1 month
	Total diagnoses	≥ CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	164	138	84.1	26	15.9	108	65.9
Female	46	35	76.1	11	23.9	29	63.0
Transgender woman^a	10	9	90.0	1	10.0	7	70.0
Transgender man^a	0	0	0.0	0	0.0	0	0.0
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	30	23	76.7	7	23.3	22	73.3
25-34	73	61	83.6	12	16.4	46	63.0
35-44	40	35	87.5	5	12.5	28	70.0
45-54	18	18	100	0	0.0	12	66.7
≥55	13	10	76.9	3	23.1	7	53.8
Transmission category^c
Male-to-male sexual contact^d	139	115	83.1	24	16.9	97	69.7
Injection drug use^e	10	9	95.9	0	0.0	4	41.8
Male-to-male sexual contact^d and injection drug use^e	16	14	89.2	2	10.8	10	62.4
Heterosexual contact^f	10	8	85.7	1	14.3	4	44.9
Other^g	0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	96	78	81.3	18	18.8	65	67.7
Metropolitan areas (pop. 50,000-499,999)	33	29	87.9	4	12.1	24	72.7
Nonmetropolitan areas (pop. <50,000)	45	40	88.9	5	11.1	26	57.8
Subtotal	174	147	84.5	27	15.5	115	66.1
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	3	1	33.3	2	66.7	2	66.7
25-34	17	13	76.5	4	23.5	10	58.8
35-44	9	8	88.9	1	11.1	6	66.7
45-54	14	10	71.4	4	28.6	8	57.1
≥55	3	3	100	0	0.0	3	100
Transmission category^c
Injection drug use^e	17	14	80.2	3	19.8	11	65.1
Heterosexual contact^f	29	21	73.6	8	26.4	18	61.8
Other^g	0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	25	19	76.0	6	24.0	14	56.0
Metropolitan areas (pop. 50,000-499,999)	9	7	77.8	2	22.2	6	66.7
Nonmetropolitan areas (pop. <50,000)	12	9	75.0	3	25.0	9	75.0
Subtotal	46	35	76.1	11	23.9	29	63.0
Total	220	182	82.7	38	17.3	144	65.5
Asian
Gender
Male	594	516	86.9	78	13.1	465	78.3
Female	86	75	87.2	11	12.8	61	70.9
Transgender woman^a	17	15	88.2	2	11.8	14	82.4
Transgender man^a	2	2	100	0	0.0	2	100
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	105	87	82.9	18	17.1	81	77.1
25-34	240	208	86.7	32	13.3	195	81.3
35-44	135	119	88.1	16	11.9	113	83.7
45-54	82	74	90.2	8	9.8	59	72.0
≥55	49	43	87.8	6	12.2	31	63.3
Transmission category^c
Male-to-male sexual contact^d	545	473	86.7	73	13.3	430	78.9
Injection drug use^e	13	12	87.2	2	12.8	10	76.7
Male-to-male sexual contact^d and injection drug use^e	16	14	92.9	1	7.1	11	69.9
Heterosexual contact^f	36	32	87.6	5	12.4	27	74.9
Other^g	1	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	556	482	86.7	74	13.3	438	78.8
Metropolitan areas (pop. 50,000-499,999)	44	40	90.9	4	9.1	35	79.5
Nonmetropolitan areas (pop. <50,000)	9	8	88.9	1	11.1	5	55.6
Subtotal	611	531	86.9	80	13.1	479	78.4
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	9	9	100	0	0.0	9	100
25-34	21	20	95.2	1	4.8	18	85.7
35-44	31	26	83.9	5	16.1	23	74.2
45-54	12	10	83.3	2	16.7	4	33.3
≥55	15	12	80.0	3	20.0	9	60.0
Transmission category^c
Injection drug use^e	6	6	96.6	0	0.0	4	59.3
Heterosexual contact^f	80	69	86.6	11	13.4	57	71.9
Other^g	2	2	95.2	0	0.0	2	95.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	70	60	85.7	10	14.3	48	68.6
Metropolitan areas (pop. 50,000-499,999)	14	14	100	0	0.0	13	92.9
Nonmetropolitan areas (pop. <50,000)	4	3	75.0	1	25.0	2	50.0
Subtotal	88	77	87.5	11	12.5	63	71.6
Total	699	608	87.0	91	13.0	542	77.5
Black/African American
Gender
Male	9,985	7,858	78.7	2,127	21.3	6,478	64.9
Female	3,274	2,710	82.8	564	17.2	2,275	69.5
Transgender woman^a	363	297	81.8	66	18.2	246	67.8
Transgender man^a	17	15	88.2	2	11.8	16	94.1
Additional gender identity^b	11	9	81.8	2	18.2	7	63.6
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	3,059	2,387	78.0	672	22.0	2,050	67.0
25-34	4,035	3,214	79.7	821	20.3	2,651	65.7
35-44	1,605	1,242	77.4	363	22.6	984	61.3
45-54	801	640	79.9	161	20.1	514	64.2
≥55	858	680	79.3	178	20.7	531	61.9
Transmission category^c
Male-to-male sexual contact^d	8,451	6,690	79.2	1,761	20.8	5,637	66.7
Injection drug use^e	336	246	73.4	89	26.6	174	51.9
Male-to-male sexual contact^d and injection drug use^e	226	162	71.8	64	28.2	120	53.0
Heterosexual contact^f	1,333	1,054	79.1	279	20.9	790	59.2
Other^g	13	11	84.1	2	15.9	10	78.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	8,497	6,746	79.4	1,751	20.6	5,541	65.2
Metropolitan areas (pop. 50,000-499,999)	1,206	927	76.9	279	23.1	776	64.3
Nonmetropolitan areas (pop. <50,000)	619	465	75.1	154	24.9	391	63.2
Subtotal	10,358	8,163	78.8	2,195	21.2	6,730	65.0
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	452	364	80.5	88	19.5	314	69.5
25-34	885	733	82.8	152	17.2	617	69.7
35-44	811	675	83.2	136	16.8	559	68.9
45-54	601	501	83.4	100	16.6	441	73.4
≥55	543	453	83.4	90	16.6	361	66.5
Transmission category^c
Injection drug use^e	276	222	80.5	54	19.5	170	61.6
Heterosexual contact^f	2,983	2,477	83.0	506	17.0	2,098	70.3
Other^g	33	26	80.1	7	19.9	24	72.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	2,676	2,224	83.1	452	16.9	1,872	70.0
Metropolitan areas (pop. 50,000-499,999)	410	346	84.4	64	15.6	281	68.5
Nonmetropolitan areas (pop. <50,000)	193	148	76.7	45	23.3	132	68.4
Subtotal	3,292	2,726	82.8	566	17.2	2,292	69.6
Total	13,650	10,889	79.8	2,761	20.2	9,022	66.1
Hispanic/Latino^h
Gender
Male	8,101	6,859	84.7	1,242	15.3	5,925	73.1
Female	1,041	861	82.7	180	17.3	760	73.0
Transgender woman^a	246	212	86.2	34	13.8	189	76.8
Transgender man^a	14	13	92.9	1	7.1	13	92.9
Additional gender identity^b	14	13	92.9	1	7.1	10	71.4
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	1,602	1,342	83.8	260	16.2	1,178	73.5
25-34	3,479	2,915	83.8	564	16.2	2,572	73.9
35-44	1,867	1,627	87.1	240	12.9	1,390	74.5
45-54	894	760	85.0	134	15.0	643	71.9
≥55	518	439	84.7	79	15.3	340	65.6
Transmission category^c
Male-to-male sexual contact^d	7,340	6,233	84.9	1,106	15.1	5,467	74.5
Injection drug use^e	282	221	78.6	60	21.4	155	55.1
Male-to-male sexual contact^d and injection drug use^e	314	265	84.5	49	15.5	208	66.3
Heterosexual contact^f	418	357	85.4	61	14.6	289	69.2
Other^g	6	6	93.8	0	0.0	4	53.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	7,343	6,244	85.0	1,099	15.0	5,422	73.8
Metropolitan areas (pop. 50,000-499,999)	694	565	81.4	129	18.6	481	69.3
Nonmetropolitan areas (pop. <50,000)	290	246	84.8	44	15.2	193	66.6
Subtotal	8,360	7,083	84.7	1,277	15.3	6,123	73.2
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	140	117	83.6	23	16.4	108	77.1
25-34	301	249	82.7	52	17.3	227	75.4
35-44	274	229	83.6	45	16.4	201	73.4
45-54	198	165	83.3	33	16.7	134	67.7
≥55	143	115	80.4	28	19.6	104	72.7
Transmission category^c
Injection drug use^e	151	124	82.5	26	17.5	88	58.4
Heterosexual contact^f	899	745	82.8	154	17.2	681	75.8
Other^g	6	6	96.5	0	0.0	5	80.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	915	758	82.8	157	17.2	674	73.7
Metropolitan areas (pop. 50,000-499,999)	106	89	84.0	17	16.0	77	72.6
Nonmetropolitan areas (pop. <50,000)	33	26	78.8	7	21.2	21	63.6
Subtotal	1,056	875	82.9	181	17.1	774	73.3
Total	9,416	7,958	84.5	1,458	15.5	6,897	73.2
Native Hawaiian/other Pacific Islander
Gender
Male	60	48	80.0	12	20.0	42	70.0
Female	8	6	75.0	2	25.0	5	62.5
Transgender woman^a	6	5	83.3	1	16.7	4	66.7
Transgender man^a	0	0	0.0	0	0.0	0	0.0
Additional gender identity^b	0	0	0.0	0	0.0	0	0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	10	9	90.0	1	10.0	8	80.0
25-34	26	18	69.2	8	30.8	17	65.4
35-44	17	14	82.4	3	17.6	11	64.7
45-54	7	6	85.7	1	14.3	6	85.7
≥55	6	6	100	0	0.0	4	66.7
Transmission category^c
Male-to-male sexual contact^d	59	48	81.4	11	18.6	41	70.1
Injection drug use^e	1	1	100	0	0.0	1	92.9
Male-to-male sexual contact^d and injection drug use^e	4	1	40.0	2	60.0	1	34.3
Heterosexual contact^f	3	3	100	0	0.0	2	96.0
Other^g	0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	56	46	82.1	10	17.9	39	69.6
Metropolitan areas (pop. 50,000-499,999)	4	2	50.0	2	50.0	2	50.0
Nonmetropolitan areas (pop. <50,000)	6	5	83.3	1	16.7	5	83.3
Subtotal	66	53	80.3	13	19.7	46	69.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	0	0	0.0	0	0.0	0	0.0
25-34	2	1	50.0	1	50.0	1	50.0
35-44	4	3	75.0	1	25.0	3	75.0
45-54	2	2	100	0	0.0	1	50.0
≥55	0	0	0.0	0	0.0	0	0.0
Transmission category^c
Injection drug use^e	3	3	100	0	0.0	2	69.7
Heterosexual contact^f	5	3	57.4	2	42.6	3	57.4
Other^g	0	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	7	5	71.4	2	28.6	4	57.1
Metropolitan areas (pop. 50,000-499,999)	1	1	100	0	0.0	1	100
Nonmetropolitan areas (pop. <50,000)	0	0	0.0	0	0.0	0	0.0
Subtotal	8	6	75.0	2	25.0	5	62.5
Total	74	59	79.7	15	20.3	51	68.9
White
Gender
Male	6,999	5,800	82.9	1,199	17.1	4,876	69.7
Female	1,435	1,130	78.7	305	21.3	875	61.0
Transgender woman^a	112	88	78.6	24	21.4	77	68.8
Transgender man^a	19	18	94.7	1	5.3	16	84.2
Additional gender identity^b	15	12	80.0	3	20.0	10	66.7
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	769	617	80.2	152	19.8	552	71.8
25-34	2,493	2,029	81.4	464	18.6	1,711	68.6
35-44	1,697	1,381	81.4	316	18.6	1,158	68.2
45-54	1,136	962	84.7	174	15.3	807	71.0
≥55	1,029	910	88.4	119	11.6	734	71.3
Transmission category^c
Male-to-male sexual contact^d	5,478	4,616	84.2	863	15.8	3,986	72.8
Injection drug use^e	631	458	72.5	173	27.5	308	48.8
Male-to-male sexual contact^d and injection drug use^e	675	529	78.4	146	21.6	432	64.0
Heterosexual contact^f	333	291	87.4	42	12.6	230	69.2
Other^g	6	5	90.2	1	9.8	5	82.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	5,074	4,244	83.6	830	16.4	3,541	69.8
Metropolitan areas (pop. 50,000-499,999)	1,234	994	80.6	240	19.4	842	68.2
Nonmetropolitan areas (pop. <50,000)	796	648	81.4	148	18.6	565	71.0
Subtotal	7,124	5,899	82.8	1,225	17.2	4,962	69.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	148	121	81.8	27	18.2	95	64.2
25-34	408	314	77.0	94	23.0	238	58.3
35-44	407	311	76.4	96	23.6	243	59.7
45-54	278	226	81.3	52	18.7	177	63.7
≥55	215	177	82.3	38	17.7	139	64.7
Transmission category^c
Injection drug use^e	529	388	73.3	141	26.7	252	47.7
Heterosexual contact^f	919	755	82.2	164	17.8	634	69.0
Other^g	8	6	76.3	2	23.7	5	68.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	955	752	78.7	203	21.3	579	60.6
Metropolitan areas (pop. 50,000-499,999)	315	253	80.3	62	19.7	191	60.6
Nonmetropolitan areas (pop. <50,000)	179	139	77.7	40	22.3	117	65.4
Subtotal	1,456	1,149	78.9	307	21.1	892	61.3
Total	8,580	7,048	82.1	1,532	17.9	5,854	68.2
Multiracial
Gender
Male	751	614	81.8	137	18.2	519	69.1
Female	179	144	80.4	35	19.6	121	67.6
Transgender woman^a	31	28	90.3	3	9.7	20	64.5
Transgender man^a	3	3	100	0	0.0	3	100
Additional gender identity^b	3	2	66.7	1	33.3	2	66.7
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	208	167	80.3	41	19.7	152	73.1
25-34	303	254	83.8	49	16.2	203	67.0
35-44	140	112	80.0	28	20.0	97	69.3
45-54	79	66	83.5	13	16.5	54	68.4
≥55	54	45	83.3	9	16.7	35	64.8
Transmission category^c
Male-to-male sexual contact^d	647	543	83.8	105	16.2	467	72.1
Injection drug use^e	38	27	69.5	12	30.5	18	46.5
Male-to-male sexual contact^d and injection drug use^e	52	40	76.2	12	23.8	29	56.2
Heterosexual contact^f	45	35	76.2	11	23.8	27	58.6
Other^g	1	1	75.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	603	499	82.8	104	17.2	426	70.6
Metropolitan areas (pop. 50,000-499,999)	123	101	82.1	22	17.9	81	65.9
Nonmetropolitan areas (pop. <50,000)	53	39	73.6	14	26.4	30	56.6
Subtotal	784	644	82.1	140	17.9	541	69.0
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	26	19	73.1	7	26.9	18	69.2
25-34	54	45	83.3	9	16.7	40	74.1
35-44	50	42	84.0	8	16.0	31	62.0
45-54	31	22	71.0	9	29.0	20	64.5
≥55	22	19	86.4	3	13.6	15	68.2
Transmission category^c
Injection drug use^e	33	25	77.8	7	22.2	19	57.8
Heterosexual contact^f	150	121	80.9	29	19.1	105	69.9
Other^g	1	1	66.7	0	0.0	1	66.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	137	109	79.6	28	20.4	92	67.2
Metropolitan areas (pop. 50,000-499,999)	31	27	87.1	4	12.9	21	67.7
Nonmetropolitan areas (pop. <50,000)	15	11	73.3	4	26.7	11	73.3
Subtotal	183	147	80.3	36	19.7	124	67.8
Total	967	791	81.8	176	18.2	665	68.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^c Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^d Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^h Hispanic/Latino persons can be of any race.

Table 2d. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among males, based on assigned sex at birth, aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—47 states and the District of Columbia
		Linkage to Care				Viral Suppression
		≤1 month
	Total diagnoses	≥ CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	29	22	77.6	6	22.4	22	75.2
25-34	58	47	80.9	11	19.1	38	65.8
35-44	32	28	88.9	4	11.1	24	77.1
45-54	11	11	100	0	0.0	7	64.9
≥55	10	7	73.7	3	26.3	6	58.6
Subtotal	139	115	83.1	24	16.9	97	69.7
Asian
13–24	101	84	83.2	17	16.8	77	76.2
25-34	224	193	86.3	31	13.7	181	81.1
35-44	115	102	89.1	13	10.9	98	85.3
45-54	71	63	89.3	8	10.7	52	73.3
≥55	35	31	86.4	5	13.6	23	63.7
Subtotal	545	473	86.7	73	13.3	430	78.9
Black/African American
13–24	2,888	2,264	78.4	624	21.6	1,962	68.0
25-34	3,525	2,831	80.3	694	19.7	2,372	67.3
35-44	1,143	888	77.7	255	22.3	726	63.5
45-54	488	386	79.1	102	20.9	316	64.9
≥55	407	321	78.9	86	21.1	260	64.0
Subtotal	8,451	6,690	79.2	1,761	20.8	5,637	66.7
Hispanic/Latino^a
13–24	1,496	1,253	83.7	243	16.3	1,108	74.0
25-34	3,134	2,639	84.2	495	15.8	2,365	75.5
35-44	1,602	1,398	87.2	204	12.8	1,204	75.1
45-54	729	619	84.9	110	15.1	535	73.3
≥55	379	325	85.8	54	14.2	255	67.4
Subtotal	7,340	6,233	84.9	1,106	15.1	5,467	74.5
Native Hawaiian/other Pacific Islander
13–24	8	8	100	0	0.0	7	87.5
25-34	24	17	70.6	7	29.4	16	66.4
35-44	16	13	81.6	3	18.4	11	65.0
45-54	7	6	86.6	1	13.4	6	85.1
≥55	4	4	100	0	0.0	2	52.6
Subtotal	59	48	81.4	11	18.6	41	70.1
White
13–24	669	545	81.4	124	18.6	492	73.5
25-34	1,921	1,608	83.7	314	16.3	1,394	72.5
35-44	1,199	997	83.2	202	16.8	861	71.9
45-54	863	728	84.4	135	15.6	629	72.9
≥55	827	738	89.3	88	10.7	610	73.8
Subtotal	5,478	4,616	84.2	863	15.8	3,986	72.8
Multiracial
13–24	194	159	81.8	35	18.2	144	74.2
25-34	250	215	86.0	35	14.0	177	71.1
35-44	106	87	82.0	19	18.0	79	74.5
45-54	60	52	86.0	8	14.0	43	72.5
≥55	38	31	81.1	7	18.9	23	61.3
Subtotal	647	543	83.8	105	16.2	467	72.1
All
13–24	5,384	4,334	80.5	1,050	19.5	3,811	70.8
25-34	9,135	7,549	82.6	1,586	17.4	6,543	71.6
35-44	4,212	3,513	83.4	699	16.6	3,003	71.3
45-54	2,228	1,865	83.7	364	16.3	1,588	71.3
≥55	1,699	1,457	85.7	243	14.3	1,179	69.4
Total	22,659	18,717	82.6	3,942	17.4	16,124	71.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Persons whose transmission category is classified as male-to-male sexual contact are presented based on assigned sex at birth and include transgender and additional gender identity persons. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a Hispanic/Latino persons can be of any race.

Table 2e. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among transgender and additional gender identity persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
		Linkage to Care				Viral Suppression
		≤1 month
	Total diagnoses	≥ CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
	No.	No.	%	No.	%	No.	%
Transgender woman^a
Age at diagnosis (yr)
13-24	280	225	80.4	55	19.6	193	68.9
25-34	323	272	84.2	51	15.8	228	70.6
35-44	125	106	84.8	19	15.2	95	76.0
45-54	36	32	88.9	4	11.1	26	72.2
≥55	21	19	90.5	2	9.5	15	71.4
Race/ethnicity
American Indian/Alaska Native	10	9	90.0	1	10.0	7	70.0
Asian	17	15	88.2	2	11.8	14	82.4
Black/African American	363	297	81.8	66	18.2	246	67.8
Hispanic/Latino^b	246	212	86.2	34	13.8	189	76.8
Native Hawaiian/other Pacific Islander	6	5	83.3	1	16.7	4	66.7
White	112	88	78.6	24	21.4	77	68.8
Multiple races	31	28	90.3	3	9.7	20	64.5
Exposure category^c
Sexual contact^d	692	582	84.1	110	15.9	508	73.4
Injection drug use^e	3	1	33.3	2	66.7	0	0.0
Sexual contact^d & injection drug use^e	54	41	75.9	13	24.1	28	51.9
Other^f	36	30	83.3	6	16.7	21	58.3
Subtotal	785	654	83.3	131	16.7	557	71.0
Transgender man^a
Age at diagnosis (yr)
13-24	14	13	92.9	1	7.1	12	85.7
25-34	30	28	93.3	2	6.7	28	93.3
35-44	8	8	100	0	0.0	8	100
45-54	1	1	100	0	0.0	1	100
≥55	2	1	50.0	1	50.0	1	50.0
Race/ethnicity
American Indian/Alaska Native	0	0	0.0	0	0.0	0	0.0
Asian	2	2	100	0	0.0	2	100
Black/African American	17	15	88.2	2	11.8	16	94.1
Hispanic/Latino^b	14	13	92.9	1	7.1	13	92.9
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0.0	0	0.0
White	19	18	94.7	1	5.3	16	84.2
Multiple races	3	3	100	0	0.0	3	100
Exposure category^c
Sexual contact^d	46	44	95.7	2	4.3	44	95.7
Injection drug use^e	0	0	0.0	0	0.0	0	0.0
Sexual contactd & injection drug use^e	1	1	100	0	0.0	1	100
Other^f	8	6	75.0	2	25.0	5	62.5
Subtotal	55	51	92.7	4	7.3	50	90.9
Additional gender identity^g
Age at diagnosis (yr)
13-24	25	21	84.0	4	16.0	17	68.0
25-34	11	10	90.9	1	9.1	7	63.6
35-44	3	1	33.3	2	66.7	1	33.3
45-54	4	4	100	0	0.0	4	100
≥55	0	0	0.0	0	0.0	0	0.0
Race/ethnicity
American Indian/Alaska Native	0	0	0.0	0	0.0	0	0.0
Asian	0	0	0.0	0	0.0	0	0.0
Black/African American	11	9	81.8	2	18.2	7	63.6
Hispanic/Latino^b	14	13	92.9	1	7.1	10	71.4
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0.0	0	0.0
White	15	12	80.0	3	20.0	10	66.7
Multiple races	3	2	66.7	1	33.3	2	66.7
Exposure category^c
Sexual contact^d	37	32	86.5	5	13.5	27	73.0
Injection drug use^e	0	0	0.0	0	0.0	0	0.0
Sexual contactd & injection drug use^e	5	4	80.0	1	20.0	2	40.0
Other^f	1	0	0.0	1	100	0	0.0
Subtotal	43	36	83.7	7	16.3	8729	67.4
Total	883	741	83.9	142	16.1	636	72.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Hispanic/Latino persons can be of any race.
^c Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^f Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^g Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 3a. Receipt of HIV medical care and viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
	Persons alive at year-end 2021	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
Gender
Male	733,871	553,173	75.4	395,057	53.8	486,719	66.3
Female	217,656	162,841	74.8	116,999	53.8	140,231	64.4
Transgender woman^c	11,674	9,627	82.5	7,058	60.5	7,757	66.4
Transgender man^c	499	438	87.8	298	59.7	370	74.1
Additional gender identity^d	302	261	86.4	213	70.5	223	73.8
Age at year-end 2020 (yr)
13–24	27,140	21,599	79.6	15,013	55.3	17,677	65.1
25–34	152,935	117,976	77.1	79,208	51.8	97,532	63.8
35–44	183,689	137,728	75.0	94,672	51.5	117,369	63.9
45–54	233,009	175,697	75.4	125,588	53.9	154,813	66.4
≥55	367,229	273,340	74.4	205,144	55.9	247,909	67.5
Race/ethnicity
American Indian/Alaska Native	2,992	2,254	75.3	1,569	52.4	1,908	63.8
Asian^e	15,188	11,321	74.5	8,327	54.8	10,614	69.9
Black/African American	386,688	283,784	73.4	200,781	51.9	238,353	61.6
Hispanic/Latino^f	227,387	164,738	72.4	123,552	54.3	146,163	64.3
Native Hawaiian/other Pacific Islander	855	622	72.7	424	49.6	542	63.4
White	280,199	220,753	78.8	154,168	55.0	200,892	71.7
Multiracial	50,067	42,824	85.5	30,769	61.5	36,786	73.5
Transmission category^g
Male-to-male sexual contact^h	561,493	433,734	77.2	308,936	55.0	385,254	68.6
Injection drug useⁱ	96,246	63,798	66.3	45,988	47.8	53,923	56.0
Male	54,849	33,996	62.0	24,719	45.1	28,778	52.5
Female	41,397	29,802	72.0	21,269	51.4	25,145	60.7
Male-to-male sexual contact^h and injection drug useⁱ	53,043	41,363	78.0	29,568	55.7	34,514	65.1
Heterosexual contact^j	239,228	177,248	74.1	127,973	53.5	153,516	64.2
Male	69,386	48,979	70.6	35,713	51.5	42,133	60.7
Female	169,842	128,269	75.5	92,260	54.3	111,383	65.6
Other^k	13,992	10,198	72.9	7,160	51.2	8,094	57.8
Male	7,039	4,960	70.5	3,364	47.8	3,996	56.8
Female	6,953	5,239	75.3	3,796	54.6	4,099	58.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	792,024	597,277	75.4	428,524	54.1	522,654	66.0
Metropolitan areas (pop. 50,000–499,999)	94,410	72,773	77.1	51,794	54.9	63,423	67.2
Nonmetropolitan areas (pop. <50,000)	56,132	42,356	75.5	30,416	54.2	37,105	66.1
Total^l	964,002	726,340	75.3	519,625	53.9	635,300	65.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a Performed ≥3 months apart during 2021.
^b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^e Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^f Hispanic/Latino persons can be of any race.
^g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
ⁱ Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^l Includes 626 persons of unknown race/ethnicity.

Table 3a. Receipt of HIV medical care and viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
	Persons alive at year-end 2021	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
Alabama	13,774	9,898	71.9	6,336	46.0	8,146	59.1
Alaska	718	631	87.9	411	57.2	572	79.7
Arizona	17,490	12,733	72.8	9,464	54.1	10,955	62.6
Arkansas	5,900	3,953	67.0	2,691	45.6	3,097	52.5
California	131,709	98,344	74.7	69,411	52.7	87,675	66.6
Colorado	13,022	8,584	65.9	5,449	41.8	7,890	60.6
Connecticut	10,406	8,270	79.5	5,877	56.5	7,484	71.9
Delaware	3,439	2,822	82.1	1,924	55.9	2,525	73.4
District of Columbia	13,401	8,798	65.7	5,699	42.5	7,418	55.4
Florida	113,218	87,864	77.6	70,379	62.2	77,793	68.7
Georgia	57,083	41,473	72.7	31,048	54.4	35,470	62.1
Hawaii	2,323	2,007	86.4	1,450	62.4	1,839	79.2
Illinois	34,556	26,373	76.3	16,789	48.6	21,881	63.3
Indiana	11,821	9,376	79.3	6,371	53.9	8,322	70.4
Iowa	2,923	2,576	88.1	1,844	63.1	2,389	81.7
Kansas	3,340	2,749	82.3	2,112	63.2	2,523	75.5
Kentucky	7,759	6,236	80.4	4,265	55.0	5,062	65.2
Louisiana	20,700	16,273	78.6	12,330	59.6	14,263	68.9
Maine	1,650	1,360	82.4	950	57.6	1,279	77.5
Maryland	32,719	23,559	72.0	15,589	47.6	20,214	61.8
Massachusetts	20,672	15,742	76.2	10,192	49.3	14,483	70.1
Michigan	16,652	13,486	81.0	8,702	52.3	11,987	72.0
Minnesota	8,915	6,531	73.3	3,464	38.9	5,962	66.9
Mississippi^c	9,474	6,727	71.0	4,524	47.8	5,646	59.6
Missouri	12,570	9,697	77.1	6,772	53.9	8,403	66.8
Montana	698	614	88.0	430	61.6	564	80.8
Nebraska	2,274	1,751	77.0	1,057	46.5	1,541	67.8
Nevada	10,921	8,033	73.6	5,566	51.0	6,971	63.8
New Hampshire	1,333	1,076	80.7	700	52.5	1,006	75.5
New Mexico	3,873	2,957	76.3	1,812	46.8	2,183	56.4
New York	122,351	89,211	72.9	70,433	57.6	79,119	64.7
North Carolina	32,933	25,496	77.4	17,097	51.9	22,383	68.0
North Dakota	506	402	79.4	262	51.8	317	62.6
Ohio	23,181	17,368	74.9	10,995	47.4	15,307	66.0
Oklahoma	6,585	4,720	71.7	3,548	53.9	4,046	61.4
Oregon	7,268	6,237	85.8	3,451	47.5	5,616	77.3
Rhode Island	2,647	1,969	74.4	893	33.7	1,809	68.3
South Carolina	17,474	14,315	81.9	11,139	63.7	12,679	72.6
South Dakota	687	606	88.2	394	57.4	380	55.3
Tennessee	17,938	14,133	78.8	10,326	57.6	12,005	66.9
Texas	96,292	72,212	75.0	51,418	53.4	60,494	62.8
Utah	3,317	2,518	75.9	1,610	48.5	2,338	70.5
Vermont	712	561	78.8	354	49.7	531	74.6
Virginia	23,635	16,959	71.8	11,574	49.0	15,378	65.1
Washington	14,141	12,012	84.9	7,711	54.5	11,121	78.6
West Virginia^c	2,056	1,417	68.9	838	40.8	1,118	54.4
Wisconsin	6,579	5,409	82.2	3,765	57.2	4,869	74.0
Wyoming	367	302	82.3	209	56.9	247	67.3
Region of residence^d
Northeast (excluding NJ & PA)	159,771	118,189	74.0	89,399	56.0	105,711	66.2
Midwest	124,004	96,324	77.7	62,527	50.4	83,881	67.6
South	474,380	356,855	75.2	260,725	55.0	307,737	64.9
West (excluding ID)	205,847	154,972	75.3	106,974	52.0	137,971	67.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and VL test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

^a Performed ≥3 months apart during 2021.
^b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
^c Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.
^d Data should be interpreted with caution as areas with incomplete reporting to CDC are not included.

Table 3c. Receipt of HIV medical care and viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by race/ethnicity and selected characteristics—47 states and the District of Columbia
	Persons alive at year-end 2021	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
Gender
Male	2,203	1,647	74.8	1,148	52.1	1,416	64.3
Female	731	559	76.5	389	53.2	453	62.0
Transgender woman^c	53	44	83.0	29	54.7	35	66.0
Transgender man^c	4	3	75.0	3	75.0	3	75.0
Additional Gender identity^d	1	1	100	0	0.0	1	100
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	92	71	77.2	42	45.7	61	66.3
25-34	503	405	80.5	270	53.7	327	65.0
35-44	527	402	76.3	282	53.5	348	66.0
45-54	534	397	74.3	281	52.6	347	65.0
≥55	601	417	69.4	302	50.2	369	61.4
Transmission category^e
Male-to-male sexual contact^f	1,614	1,231	76.3	859	53.2	1,078	66.8
Injection drug use^g	212	144	68.1	97	46.0	113	53.3
Male-to-male sexual contact^f and injection drug use^g	275	203	73.8	145	52.8	168	61.0
Heterosexual contact^h	139	100	72.0	69	49.6	82	58.8
Otherⁱ	17	14	81.8	7	38.8	12	68.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	1,225	877	71.6	624	50.9	771	62.9
Metropolitan areas (pop. 50,000-499,999)	389	325	83.5	232	59.6	271	69.7
Nonmetropolitan areas (pop. <50,000)	597	459	76.9	304	50.9	385	64.5
Subtotal	2,257	1,692	75.0	1,177	52.1	1,452	64.3
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	11	7	63.6	5	45.5	5	45.5
25-34	93	62	66.7	44	47.3	49	52.7
35-44	190	156	82.1	103	54.2	112	58.9
45-54	201	148	73.6	98	48.8	123	61.2
≥55	240	189	78.8	142	59.2	167	69.6
Transmission category^e
Injection drug use^g	248	181	73.0	120	48.3	139	56.0
Heterosexual contact^h	470	372	79.2	268	57.1	311	66.2
Otherⁱ	17	9	53.2	4	23.7	6	35.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	345	239	69.3	158	45.8	203	58.8
Metropolitan areas (pop. 50,000-499,999)	146	126	86.3	101	69.2	100	68.5
Nonmetropolitan areas (pop. <50,000)	226	183	81.0	127	56.2	144	63.7
Subtotal	735	562	76.5	392	53.3	456	62.0
Total	2,992	2,254	75.3	1,569	52.4	1,908	63.8
Asian^j
Gender
Male	12,402	9,278	74.8	6,805	54.9	8,709	70.2
Female	2,577	1,870	72.6	1,394	54.1	1,741	67.6
Transgender woman^c	195	162	83.1	120	61.5	154	79.0
Transgender man^c	9	7	77.8	4	44.4	7	77.8
Additional Gender identity^d	5	4	80.0	4	80.0	3	60.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	410	334	81.5	227	55.4	307	74.9
25-34	2,574	1,984	77.1	1,412	54.9	1,862	72.3
35-44	2,940	2,211	75.2	1,583	53.8	2,077	70.6
45-54	3,596	2,746	76.4	2,019	56.1	2,575	71.6
≥55	3,081	2,168	70.4	1,687	54.8	2,044	66.3
Transmission category^e
Male-to-male sexual contact^f	10,714	8,104	75.6	5,922	55.3	7,617	71.1
Injection drug use^g	415	258	62.3	191	46.0	241	58.1
Male-to-male sexual contact^f and injection drug use^g	406	300	73.9	208	51.3	277	68.2
Heterosexual contact^h	947	695	73.4	546	57.6	652	68.9
Otherⁱ	120	86	71.8	61	50.9	78	64.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	11,520	8,668	75.2	6,393	55.5	8,156	70.8
Metropolitan areas (pop. 50,000-499,999)	695	516	74.2	363	52.2	474	68.2
Nonmetropolitan areas (pop. <50,000)	186	135	72.6	97	52.2	122	65.6
Subtotal	12,601	9,443	74.9	6,928	55.0	8,865	70.4
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	90	73	81.1	46	51.1	70	77.8
25-34	276	213	77.2	165	59.8	195	70.7
35-44	757	561	74.1	407	53.8	528	69.7
45-54	736	514	69.8	381	51.8	477	64.8
≥55	728	517	71.0	400	54.9	479	65.8
Transmission category^e
Injection drug use^g	172	113	66.0	82	47.6	107	62.3
Heterosexual contact^h	2,294	1,676	73.1	1,253	54.7	1,557	67.9
Otherⁱ	122	89	73.2	64	52.5	85	70.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	2,213	1,611	72.8	1,212	54.8	1,504	68.0
Metropolitan areas (pop. 50,000-499,999)	235	167	71.1	127	54.0	154	65.5
Nonmetropolitan areas (pop. <50,000)	75	58	77.3	38	50.7	51	68.0
Subtotal	2,587	1,878	72.6	1,399	54.1	1,749	67.6
Total	15,188	11,321	74.5	8,327	54.8	10,614	69.9
Black/African American
Gender
Male	253,694	184,743	72.8	129,892	51.2	154,389	60.9
Female	127,294	94,348	74.1	67,611	53.1	80,324	63.1
Transgender woman^c	5,376	4,417	82.2	3,087	57.4	3,424	63.7
Transgender man^c	203	179	88.2	114	56.2	138	68.0
Additional Gender identity^d	121	97	80.2	77	63.6	78	64.5
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	11,858	9,379	79.1	6,354	53.6	7,517	63.4
25-34	59,288	45,006	75.9	29,707	50.1	35,646	60.1
35-44	48,584	36,386	74.9	24,807	51.1	29,810	61.4
45-54	52,037	38,257	73.5	27,490	52.8	32,632	62.7
≥55	87,410	60,219	68.9	44,688	51.1	52,278	59.8
Transmission category^e
Male-to-male sexual contact^f	173,951	130,922	75.3	90,775	52.2	109,425	62.9
Injection drug use^g	24,920	15,274	61.3	11,069	44.4	12,810	51.4
Male-to-male sexual contact^f and injection drug use^g	13,950	10,450	74.9	7,562	54.2	8,338	59.8
Heterosexual contact^h	43,066	30,348	70.5	22,086	51.3	25,611	59.5
Otherⁱ	3,290	2,253	68.5	1,555	47.3	1,699	51.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	215,118	157,504	73.2	109,976	51.1	131,215	61.0
Metropolitan areas (pop. 50,000-499,999)	23,830	17,579	73.8	12,732	53.4	14,740	61.9
Nonmetropolitan areas (pop. <50,000)	14,181	10,467	73.8	7,937	56.0	8,839	62.3
Subtotal	259,177	189,247	73.0	133,046	51.3	157,883	60.9
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	3,270	2,511	76.8	1,836	56.1	1,879	57.5
25-34	14,204	10,408	73.3	6,951	48.9	8,021	56.5
35-44	26,435	19,126	72.4	13,065	49.4	15,721	59.5
45-54	35,772	26,725	74.7	19,004	53.1	22,990	64.3
≥55	47,830	35,767	74.8	26,879	56.2	31,859	66.6
Transmission category^e
Injection drug use^g	19,231	13,623	70.8	9,768	50.8	11,534	60.0
Heterosexual contact^h	104,386	78,028	74.7	55,873	53.5	66,764	64.0
Otherⁱ	3,893	2,887	74.1	2,094	53.8	2,172	55.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	106,083	78,592	74.1	56,178	53.0	66,816	63.0
Metropolitan areas (pop. 50,000-499,999)	12,212	9,420	77.1	6,907	56.6	8,043	65.9
Nonmetropolitan areas (pop. <50,000)	6,388	4,722	73.9	3,481	54.5	4,080	63.9
Subtotal	127,511	94,537	74.1	67,735	53.1	80,470	63.1
Total	386,688	283,784	73.4	200,781	51.9	238,353	61.6
Hispanic/Latino^k
Gender
Male	183,521	131,299	71.5	97,966	53.4	116,938	63.7
Female	39,790	30,121	75.7	22,992	57.8	26,469	66.5
Transgender woman^c	3,884	3,149	81.1	2,464	63.4	2,609	67.2
Transgender man^c	112	96	85.7	70	62.5	83	74.1
Additional Gender identity^d	80	73	91.3	60	75.0	64	80.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	5,498	4,418	80.4	3,144	57.2	3,788	68.9
25-34	35,257	27,732	78.7	19,404	55.0	23,935	67.9
35-44	43,547	31,296	71.9	22,780	52.3	27,479	63.1
45-54	48,006	33,507	69.8	25,354	52.8	30,027	62.5
≥55	55,168	37,559	68.1	29,801	54.0	34,375	62.3
Transmission category^e
Male-to-male sexual contact^f	143,970	106,515	74.0	79,380	55.1	95,745	66.5
Injection drug use^g	15,510	8,566	55.2	6,574	42.4	7,326	47.2
Male-to-male sexual contact^f and injection drug use^g	12,456	9,295	74.6	6,896	55.4	7,679	61.6
Heterosexual contact^h	14,058	9,118	64.9	6,909	49.1	8,049	57.3
Otherⁱ	1,482	1,018	68.7	724	48.9	806	54.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	165,997	120,863	72.8	90,822	54.7	107,615	64.8
Metropolitan areas (pop. 50,000-499,999)	12,290	8,374	68.1	5,992	48.8	7,379	60.0
Nonmetropolitan areas (pop. <50,000)	6,525	3,717	57.0	2,674	41.0	3,235	49.6
Subtotal	187,476	134,512	71.7	100,483	53.6	119,604	63.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	965	772	80.0	568	58.9	607	62.9
25-34	4,287	3,264	76.1	2,338	54.5	2,687	62.7
35-44	8,010	5,914	73.8	4,306	53.8	5,031	62.8
45-54	11,025	8,361	75.8	6,331	57.4	7,341	66.6
≥55	15,624	11,915	76.3	9,526	61.0	10,893	69.7
Transmission category^e
Injection drug use^g	8,021	5,866	73.1	4,500	56.1	4,995	62.3
Heterosexual contact^h	30,418	23,209	76.3	17,709	58.2	20,674	68.0
Otherⁱ	1,471	1,151	78.2	860	58.5	890	60.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	35,193	26,762	76.0	20,576	58.5	23,526	66.8
Metropolitan areas (pop. 50,000-499,999)	2,678	2,076	77.5	1,510	56.4	1,820	68.0
Nonmetropolitan areas (pop. <50,000)	1,343	958	71.3	713	53.1	832	62.0
Subtotal	39,911	30,226	75.7	23,069	57.8	26,559	66.5
Total	227,387	164,738	72.4	123,552	54.3	146,163	64.3
Native Hawaiian/other Pacific Islander
Gender
Male	686	505	73.6	342	49.9	439	64.0
Female	136	94	69.1	67	49.3	84	61.8
Transgender woman^c	33	23	69.7	15	45.5	19	57.6
Transgender man^c	0	0	0.0	0	0.0	0	0.0
Additional Gender identity^d	0	0	0.0	0	0.0	0	0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	28	19	67.9	9	32.1	16	57.1
25-34	168	124	73.8	74	44.0	107	63.7
35-44	197	136	69.0	89	45.2	115	58.4
45-54	151	118	78.1	82	54.3	106	70.2
≥55	175	131	74.9	103	58.9	114	65.1
Transmission category^e
Male-to-male sexual contact^f	615	455	74.1	310	50.4	404	65.7
Injection drug use^g	22	13	60.4	9	41.0	6	27.6
Male-to-male sexual contact^f and injection drug use^g	49	34	70.6	19	39.1	29	60.3
Heterosexual contact^h	30	21	70.7	17	58.2	15	51.9
Otherⁱ	4	4	100	2	50.0	3	73.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	592	430	72.6	295	49.8	376	63.5
Metropolitan areas (pop. 50,000-499,999)	79	63	79.7	42	53.2	55	69.6
Nonmetropolitan areas (pop. <50,000)	34	27	79.4	16	47.1	21	61.8
Subtotal	719	528	73.4	357	49.7	458	63.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	4	3	75.0	2	50.0	2	50.0
25-34	19	14	73.7	7	36.8	12	63.2
35-44	33	23	69.7	17	51.5	21	63.6
45-54	30	20	66.7	15	50.0	18	60.0
≥55	50	34	68.0	26	52.0	31	62.0
Transmission category^e
Injection drug use^g	23	14	62.2	11	47.4	14	61.3
Heterosexual contact^h	112	79	70.8	56	49.9	70	62.1
Otherⁱ	1	0	0.0	0	0.0	0	0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	96	65	67.7	47	49.0	57	59.4
Metropolitan areas (pop. 50,000-499,999)	22	17	77.3	11	50.0	15	68.2
Nonmetropolitan areas (pop. <50,000)	13	9	69.2	7	53.8	9	69.2
Subtotal	136	94	69.1	67	49.3	84	61.8
Total	855	622	72.7	424	49.6	542	63.4
White
Gender
Male	243,121	193,315	79.5	135,703	55.8	176,842	72.7
Female	35,681	26,251	73.6	17,603	49.3	23,012	64.5
Transgender woman^c	1,212	1,021	84.2	742	61.2	886	73.1
Transgender man^c	122	109	89.3	74	60.7	99	81.1
Additional Gender identity^d	63	57	90.5	46	73.0	53	84.1
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	2,865	2,344	81.8	1,605	56.0	2,080	72.6
25-34	23,716	18,882	79.6	12,372	52.2	16,656	70.2
35-44	35,276	27,965	79.3	18,205	51.6	24,825	70.4
45-54	58,758	47,120	80.2	32,233	54.9	42,754	72.8
≥55	123,773	98,076	79.2	72,070	58.2	91,461	73.9
Transmission category^e
Male-to-male sexual contact^f	201,273	161,582	80.3	113,955	56.6	149,247	74.2
Injection drug use^g	11,488	7,855	68.4	5,357	46.6	6,704	58.4
Male-to-male sexual contact^f and injection drug use^g	21,626	17,367	80.3	12,013	55.5	14,979	69.3
Heterosexual contact^h	8,342	6,373	76.4	4,399	52.7	5,746	68.9
Otherⁱ	1,659	1,210	73.0	761	45.9	1,100	66.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	188,320	149,089	79.2	105,170	55.8	136,883	72.7
Metropolitan areas (pop. 50,000-499,999)	30,651	25,111	81.9	17,517	57.1	22,637	73.9
Nonmetropolitan areas (pop. <50,000)	18,962	15,582	82.2	10,883	57.4	14,102	74.4
Subtotal	244,388	194,387	79.5	136,485	55.8	177,776	72.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	718	553	77.0	392	54.6	470	65.5
25-34	3,949	2,875	72.8	1,791	45.4	2,304	58.3
35-44	6,883	4,966	72.1	3,123	45.4	4,176	60.7
45-54	9,720	7,168	73.7	4,695	48.3	6,244	64.2
≥55	14,541	10,804	74.3	7,682	52.8	9,922	68.2
Transmission category^e
Injection drug use^g	11,037	7,766	70.4	5,143	46.6	6,507	59.0
Heterosexual contact^h	23,786	17,885	75.2	12,046	50.6	15,973	67.2
Otherⁱ	988	715	72.4	494	50.0	636	64.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	23,930	17,437	72.9	11,829	49.4	15,342	64.1
Metropolitan areas (pop. 50,000-499,999)	6,200	4,785	77.2	3,201	51.6	4,128	66.6
Nonmetropolitan areas (pop. <50,000)	4,450	3,347	75.2	2,180	49.0	2,947	66.2
Subtotal	35,811	26,366	73.6	17,683	49.4	23,116	64.5
Total	280,199	220,753	78.8	154,168	55.0	200,892	71.7
Multiracial
Gender
Male	37,789	32,347	85.6	23,171	61.3	27,949	74.0
Female	11,276	9,593	85.1	6,938	61.5	8,143	72.2
Transgender woman^c	921	811	88.1	601	65.3	630	68.4
Transgender man^c	49	44	89.8	33	67.3	40	81.6
Additional Gender identity^d	32	29	90.6	26	81.3	24	75.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	976	827	84.7	576	59.0	660	67.6
25-34	7,277	5,948	81.7	3,925	53.9	4,906	67.4
35-44	7,891	6,618	83.9	4,550	57.7	5,512	69.9
45-54	9,173	7,935	86.5	5,693	62.1	6,902	75.2
≥55	13,421	11,855	88.3	9,050	67.4	10,619	79.1
Transmission category^e
Male-to-male sexual contact^f	29,045	24,894	85.7	17,713	61.0	21,708	74.7
Injection drug use^g	2,218	1,882	84.8	1,419	64.0	1,575	71.0
Male-to-male sexual contact^f and injection drug use^g	4,241	3,711	87.5	2,723	64.2	3,042	71.7
Heterosexual contact^h	2,780	2,322	83.5	1,686	60.6	1,976	71.1
Otherⁱ	455	374	82.2	253	55.6	297	65.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	31,949	27,417	85.8	19,639	61.5	23,618	73.9
Metropolitan areas (pop. 50,000-499,999)	3,664	3,133	85.5	2,275	62.1	2,695	73.6
Nonmetropolitan areas (pop. <50,000)	2,282	1,996	87.5	1,450	63.5	1,748	76.6
Subtotal	38,738	33,183	85.7	23,794	61.4	28,599	73.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24	350	288	82.3	207	59.1	215	61.4
25-34	1,312	1,058	80.6	747	56.9	824	62.8
35-44	2,395	1,967	82.1	1,354	56.5	1,613	67.3
45-54	3,148	2,672	84.9	1,904	60.5	2,268	72.0
≥55	4,124	3,656	88.7	2,763	67.0	3,267	79.2
Transmission category^e
Injection drug use^g	2,611	2,238	85.7	1,645	63.0	1,848	70.8
Heterosexual contact^h	8,270	7,016	84.8	5,051	61.1	6,031	72.9
Otherⁱ	448	387	86.4	279	62.3	308	68.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	8,969	7,679	85.6	5,570	62.1	6,530	72.8
Metropolitan areas (pop. 50,000-499,999)	1,288	1,081	83.9	784	60.9	912	70.8
Nonmetropolitan areas (pop. <50,000)	832	696	83.7	509	61.2	590	70.9
Subtotal	11,329	9,641	85.1	6,975	61.6	8,187	72.3
Total	50,067	42,824	85.5	30,769	61.5	36,786	73.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a Performed ≥3 months apart during 2021.
^b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
^c “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^j Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^k Hispanic/Latino persons can be of any race.

Table 3d. Receipt of HIV medical care and viral suppression during 2021 among males, based on assigned sex at birth, aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age group—47 states and the District of Columbia
	Males alive at year-end 2021	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
American Indian/Alaska Native
13–24	75	58	77.5	35	46.7	49	65.5
25-34	408	330	80.9	218	53.4	272	66.7
35-44	403	309	76.7	215	53.3	275	68.1
45-54	368	275	74.6	199	53.9	249	67.7
≥55	360	259	71.9	193	53.5	233	64.8
Subtotal	1,614	1,231	76.3	859	53.2	1,078	66.8
Asian^c
13–24	340	277	81.4	183	53.8	256	75.3
25-34	2,412	1,862	77.2	1,328	55.1	1,751	72.6
35-44	2,573	1,936	75.2	1,392	54.1	1,816	70.6
45-54	2,976	2,290	76.9	1,671	56.1	2,146	72.1
≥55	2,412	1,740	72.1	1,349	55.9	1,648	68.3
Subtotal	10,714	8,104	75.6	5,922	55.3	7,617	71.1
Black/African American
13–24	9,983	8,013	80.3	5,429	54.4	6,479	64.9
25-34	52,325	40,119	76.7	26,454	50.6	31,976	61.1
35-44	38,284	29,114	76.0	19,756	51.6	24,016	62.7
45-54	32,854	24,573	74.8	17,577	53.5	21,235	64.6
≥55	40,504	29,103	71.9	21,558	53.2	25,720	63.5
Subtotal	173,951	130,922	75.3	90,775	52.2	109,425	62.9
Hispanic/Latino^d
13–24	4,800	3,900	81.2	2,789	58.1	3,384	70.5
25-34	31,135	24,688	79.3	17,334	55.7	21,567	69.3
35-44	35,995	26,386	73.3	19,308	53.6	23,488	65.3
45-54	36,435	26,108	71.7	19,799	54.3	23,724	65.1
≥55	35,606	25,433	71.4	20,150	56.6	23,583	66.2
Subtotal	143,970	106,515	74.0	79,380	55.1	95,745	66.5
Native Hawaiian/other Pacific Islander
13–24	24	15	63.0	8	33.6	13	54.6
25-34	143	110	77.2	66	46.0	96	67.5
35-44	177	124	69.9	84	47.5	108	60.9
45-54	128	100	78.1	68	53.2	90	70.5
≥55	143	106	74.3	84	58.6	97	67.6
Subtotal	615	455	74.1	310	50.4	404	65.7
White
13–24	2,310	1,924	83.3	1,326	57.4	1,719	74.4
25-34	19,500	15,594	80.0	10,265	52.6	14,020	71.9
35-44	28,456	22,645	79.6	14,768	51.9	20,435	71.8
45-54	48,023	38,685	80.6	26,550	55.3	35,487	73.9
≥55	102,983	82,734	80.3	61,045	59.3	77,587	75.3
Subtotal	201,273	161,582	80.3	113,955	56.6	149,247	74.2
Multiracial
13–24	764	653	85.4	460	60.2	525	68.7
25-34	6,294	5,160	82.0	3,403	54.1	4,298	68.3
35-44	6,407	5,370	83.8	3,686	57.5	4,530	70.7
45-54	6,782	5,894	86.9	4,202	61.9	5,224	77.0
≥55	8,797	7,818	88.9	5,962	67.8	7,131	81.1
Subtotal	29,045	24,894	85.7	17,713	61.0	21,708	74.7
All races
13–24	18,297	14,840	81.1	10,229	55.9	12,423	67.9
25-34	112,216	87,863	78.3	59,068	52.6	73,979	65.9
35-44	112,306	85,885	76.5	59,210	52.7	74,668	66.5
45-54	127,623	97,931	76.7	70,072	54.9	88,162	69.1
≥55	191,051	147,215	77.1	110,357	57.8	136,021	71.2
Total	561,493	433,734	77.2	308,936	55.0	385,254	68.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for those diagnosed by year-end 2020, and age groups are based on age at year-end 2020. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Persons whose transmission category is classified as male-to-male sexual contact are presented based on assigned sex at birth and include transgender and additional gender identity persons. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a Performed ≥3 months apart during 2021.
^b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
^c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^d Hispanic/Latino persons can be of any race.

Table 3e. Receipt of HIV medical care and viral suppression during 2021 among transgender and additional gender identity persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
	Persons alive at year-end 2021	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
	Total No.	No.	%	No.	%	No.	%
Transgender woman^c
Age at year-end 2020 (yr)
13–24	790	654	82.8	432	54.7	472	59.7
25-34	4,197	3,435	81.8	2,393	57.0	2,641	62.9
35-44	3,093	2,515	81.3	1,881	60.8	2,033	65.7
45-54	2,150	1,797	83.6	1,383	64.3	1,531	71.2
≥55	1,444	1,226	84.9	969	67.1	1,080	74.8
Race/ethnicity
American Indian/Alaska Native	53	44	83.0	29	54.7	35	66.0
Asian^d	195	162	83.1	120	61.5	154	79.0
Black/African American	5,376	4,417	82.2	3,087	57.4	3,424	63.7
Hispanic/Latino^e	3,884	3,149	81.1	2,464	63.4	2,609	67.2
Native Hawaiian/other Pacific Islander	33	23	69.7	15	45.5	19	57.6
White	1,212	1,021	84.2	742	61.2	886	73.1
Multiracial	921	811	88.1	601	65.3	630	68.4
Exposure category^f
Sexual contact^g	9,909	8,176	82.5	5,978	60.3	6,647	67.1
Injection drug use^h	25	19	76.0	14	56.0	12	48.0
Sexual contact^g and injection drug use^h	1,531	1,300	84.9	975	63.7	996	65.1
Otherⁱ	209	132	63.2	91	43.5	102	48.8
Subtotal	11,674	9,627	82.5	7,058	60.5	7,757	66.4
Transgender man^c
Age at year-end 2020 (yr)
13–24	42	37	88.1	31	73.8	32	76.2
25-34	161	142	88.2	94	58.4	119	73.9
35-44	127	111	87.4	79	62.2	100	78.7
45-54	96	82	85.4	55	57.3	69	71.9
≥55	73	66	90.4	39	53.4	50	68.5
Race/ethnicity
American Indian/Alaska Native	4	3	75.0	3	75.0	3	75.0
Asian^d	9	7	77.8	4	44.4	7	77.8
Black/African American	203	179	88.2	114	56.2	138	68.0
Hispanic/Latino^e	112	96	85.7	70	62.5	83	74.1
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0.0	0	0.0
White	122	109	89.3	74	60.7	99	81.1
Multiracial	49	44	89.8	33	67.3	40	81.6
Exposure category^f
Sexual contact^g	375	330	88.0	223	59.5	288	76.8
Injection drug use^h	10	8	80.0	5	50.0	6	60.0
Sexual contact^g and injection drug use^h	61	55	90.2	38	62.3	35	57.4
Otherⁱ	53	45	84.9	32	60.4	41	77.4
Subtotal	499	438	87.8	298	59.7	370	74.1
Additional gender identity^j
Age at year-end 2020 (yr)
13–24	40	34	85.0	29	72.5	32	80.0
25-34	119	107	89.9	76	63.9	89	74.8
35-44	59	51	86.4	45	76.3	43	72.9
45-54	48	39	81.3	34	70.8	32	66.7
≥55	36	30	83.3	29	80.6	27	75.0
Race/ethnicity
American Indian/Alaska Native	1	1	100	0	0.0	1	100
Asian^d	5	4	80.0	4	80.0	3	60.0
Black/African American	121	97	80.2	77	63.6	78	64.5
Hispanic/Latino^e	80	73	91.3	60	75.0	64	80.0
Native Hawaiian/other Pacific Islander	0	0	0.0	0	0.0	0	0.0
White	63	57	90.5	46	73.0	53	84.1
Multiracial	32	29	90.6	26	81.3	24	75.0
Exposure category^f
Sexual contact^g	265	230	86.8	185	69.8	196	74.0
Injection drug use^h	1	1	100	1	100	1	100
Sexual contact^g and injection drug use^h	25	23	92.0	20	80.0	19	76.0
Otherⁱ	11	7	63.6	7	63.6	7	63.6
Subtotal	302	261	86.4	213	70.5	223	73.8
Total	12,475	10,326	82.8	7,569	60.7	8,350	66.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a Performed ≥3 months apart during 2021.
^b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
^c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^g For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 4a. HIV viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
							VL <200 copies/mL
	Persons alive at year-end 2021		Persons with ≥1 CD4 or VL tests		Persons with ≥1 VL tests			Among persons alive at year-end 2021	Among persons with ≥1 CD4 or VL tests	Among persons with ≥1 VL tests
	No.	%a	No.	%	No.	%	No.	%	%	%
Gender
Male	733,871	76.1	553,173	75.4	531,938	72.5	486,719	66.3	88.0	91.5
Female	217,656	22.6	162,841	74.8	156,749	72.0	140,231	64.4	86.1	89.5
Transgender woman^b	11,674	1.2	9,627	82.5	9,334	80.0	7,757	66.4	80.6	83.1
Transgender man^b	499	0.1	438	87.8	417	83.6	370	74.1	84.5	88.7
Additional gender identity^c	302	0.0	261	86.4	259	85.8	223	73.8	85.4	86.1
Age at year-end (yr)
13-24	27,140	2.8	21,599	79.6	20,925	77.1	17,677	65.1	81.8	84.5
25-34	152,935	15.9	117,976	77.1	113,823	74.4	97,532	63.8	82.7	85.7
35-44	183,689	19.1	137,728	75.0	132,453	72.1	117,369	63.9	85.2	88.6
45-54	233,009	24.2	175,697	75.4	169,154	72.6	154,813	66.4	88.1	91.5
≥55	367,229	38.1	273,340	74.4	262,342	71.4	247,909	67.5	90.7	94.5
Race/ethnicity
American Indian/Alaska Native	2,992	0.3	2,254	75.3	2,171	72.6	1,908	63.8	84.6	87.9
Asian^d	15,188	1.6	11,321	74.5	10,924	71.9	10,614	69.9	93.8	97.2
Black/African American	386,688	40.1	283,784	73.4	272,495	70.5	238,353	61.6	84.0	87.5
Hispanic/Latino^e	227,387	23.6	164,738	72.4	159,325	70.1	146,163	64.3	88.7	91.7
Native Hawaiian/Other Pacific Islander	855	0.1	622	72.7	591	69.1	542	63.4	87.1	91.7
White	280,199	29.1	220,753	78.8	211,960	75.6	200,892	71.7	91.0	94.8
Multiracial	50,067	5.2	42,824	85.5	41,189	82.3	36,786	73.5	85.9	89.3
Transmission category^f
Male-to-male sexual contact^g	561,493	58.2	433,734	77.2	417,648	74.4	385,253	68.6	88.8	92.2
Injection drug use^h	96,246	10.0	63,798	66.3	61,096	63.5	53,923	56.0	84.5	88.3
Male	54,849	5.7	33,996	62.0	32,460	59.2	28,778	52.5	84.7	88.7
Female	41,397	4.3	29,802	72.0	28,636	69.2	25,145	60.7	84.4	87.8
Male-to-male sexual contact^g and injection drug use^h	53,043	5.5	41,363	78.0	39,633	74.7	34,514	65.1	83.4	87.1
Heterosexual contactⁱ	239,228	24.8	177,248	74.1	170,438	71.2	153,516	64.2	86.6	90.1
Male	69,386	7.2	48,979	70.6	46,955	67.7	42,133	60.7	86.0	89.7
Female	169,842	17.6	128,269	75.5	123,483	72.7	111,383	65.6	86.8	90.2
Other^j	13,992	1.5	10,198	72.9	9,882	70.6	8,094	57.8	79.4	81.9
Male	7,039	0.7	4,960	70.5	4,805	68.3	3,996	56.8	80.6	83.2
Female	6,953	0.7	5,239	75.3	5,077	73.0	4,098	58.9	78.2	80.7
Population area of residence
Metropolitan statistical areas (pop. >=500,000)	792,024	82.2	597,277	75.4	575,011	72.6	522,654	66.0	87.5	90.9
Metropolitan areas (pop. 50,000-499,999)	94,410	9.8	72,773	77.1	69,769	73.9	63,423	67.2	87.2	90.9
Nonmetropolitan areas (pop. <50,000)	56,132	5.8	42,356	75.5	40,645	72.4	37,105	66.1	87.6	91.3
Total^k	964,002	100	726,340	75.3	698,697	72.5	635,300	65.9	87.5	90.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a Represents percentage of the total number for the column.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Includes 626 persons of unknown race/ethnicity. .

Table 4b. HIV viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by area of residence—47 states and the District of Columbia
							VL <200 copies/mL
	Persons alive at year-end 2021	Persons with ≥1 CD4 or VL tests		Persons with ≥1 VL tests			Among persons alive at year-end 2021	Among persons with ≥1 CD4 or VL tests	Among persons with ≥1 VL tests
	No.	No.	%	No.	%	No.	%	%	%
Alabama	13,774	9,898	71.9	9,180	66.6	8,146	59.1	82.3	88.7
Alaska	718	631	87.9	614	85.5	572	79.7	90.6	93.2
Arizona	17,490	12,733	72.8	11,875	67.9	10,955	62.6	86.0	92.3
Arkansas	5,900	3,953	67.0	3,502	59.4	3,097	52.5	78.3	88.4
California	131,709	98,344	74.7	94,179	71.5	87,675	66.6	89.2	93.1
Colorado	13,022	8,584	65.9	8,291	63.7	7,890	60.6	91.9	95.2
Connecticut	10,406	8,270	79.5	8,022	77.1	7,484	71.9	90.5	93.3
Delaware	3,439	2,822	82.1	2,772	80.6	2,525	73.4	89.5	91.1
District of Columbia	13,401	8,798	65.7	8,302	62.0	7,418	55.4	84.3	89.4
Florida	113,218	87,864	77.6	85,233	75.3	77,793	68.7	88.5	91.3
Georgia	57,083	41,473	72.7	40,137	70.3	35,470	62.1	85.5	88.4
Hawaii	2,323	2,007	86.4	1,973	84.9	1,839	79.2	91.6	93.2
Illinois	34,556	26,373	76.3	24,329	70.4	21,881	63.3	83.0	89.9
Indiana	11,821	9,376	79.3	9,125	77.2	8,322	70.4	88.8	91.2
Iowa	2,923	2,576	88.1	2,546	87.1	2,389	81.7	92.7	93.8
Kansas	3,340	2,749	82.3	2,716	81.3	2,523	75.5	91.8	92.9
Kentucky	7,759	6,236	80.4	5,558	71.6	5,062	65.2	81.2	91.1
Louisiana	20,700	16,273	78.6	16,063	77.6	14,263	68.9	87.6	88.8
Maine	1,650	1,360	82.4	1,336	81.0	1,279	77.5	94.0	95.7
Maryland	32,719	23,559	72.0	22,366	68.4	20,214	61.8	85.8	90.4
Massachusetts	20,672	15,742	76.2	15,203	73.5	14,483	70.1	92.0	95.3
Michigan	16,652	13,486	81.0	13,125	78.8	11,987	72.0	88.9	91.3
Minnesota	8,915	6,531	73.3	6,378	71.5	5,962	66.9	91.3	93.5
Mississippi^a	9,474	6,727	71.0	6,406	67.6	5,646	59.6	83.9	88.1
Missouri	12,570	9,697	77.1	9,260	73.7	8,403	66.8	86.7	90.7
Montana	698	614	88.0	599	85.8	564	80.8	91.9	94.2
Nebraska	2,274	1,751	77.0	1,641	72.2	1,541	67.8	88.0	93.9
Nevada	10,921	8,033	73.6	7,593	69.5	6,971	63.8	86.8	91.8
New Hampshire	1,333	1,076	80.7	1,047	78.5	1,006	75.5	93.5	96.1
New Mexico	3,873	2,957	76.3	2,407	62.1	2,183	56.4	73.8	90.7
New York	122,351	89,211	72.9	88,096	72.0	79,119	64.7	88.7	89.8
North Carolina	32,933	25,496	77.4	24,833	75.4	22,383	68.0	87.8	90.1
North Dakota	506	402	79.4	352	69.6	317	62.6	78.9	90.1
Ohio	23,181	17,368	74.9	16,871	72.8	15,307	66.0	88.1	90.7
Oklahoma	6,585	4,720	71.7	4,520	68.6	4,046	61.4	85.7	89.5
Oregon	7,268	6,237	85.8	5,943	81.8	5,616	77.3	90.0	94.5
Rhode Island	2,647	1,969	74.4	1,889	71.4	1,809	68.3	91.9	95.8
South Carolina	17,474	14,315	81.9	13,875	79.4	12,679	72.6	88.6	91.4
South Dakota	687	606	88.2	433	63.0	380	55.3	62.7	87.8
Tennessee	17,938	14,133	78.8	13,624	76.0	12,005	66.9	84.9	88.1
Texas	96,292	72,212	75.0	68,304	70.9	60,494	62.8	83.8	88.6
Utah	3,317	2,518	75.9	2,480	74.8	2,338	70.5	92.9	94.3
Vermont	712	561	78.8	556	78.1	531	74.6	94.7	95.5
Virginia	23,635	16,959	71.8	16,653	70.5	15,378	65.1	90.7	92.3
Washington	14,141	12,012	84.9	11,761	83.2	11,121	78.6	92.6	94.6
West Virginia^a	2,056	1,417	68.9	1,256	61.1	1,118	54.4	78.9	89.0
Wisconsin	6,579	5,409	82.2	5,207	79.1	4,869	74.0	90.0	93.5
Wyoming	367	302	82.3	266	72.5	247	67.3	81.8	92.9
Region of residence^b
Northeast (excluding NJ & PA)	159,771	118,189	74.0	116,149	72.7	105,711	66.2	89.4	91.0
Midwest	124,004	96,324	77.7	91,983	74.2	83,881	67.6	87.1	91.2
South	474,380	356,855	75.2	342,584	72.2	307,737	64.9	86.2	89.8
West (excluding ID)	205,847	154,972	75.3	147,981	71.9	137,971	67.0	89.0	93.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and VL test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

^a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.
^b Data should be interpreted with caution as areas with incomplete reporting to CDC are not included.

Table 5. Prevalence-based HIV care continuum for persons aged ≥13 years living with HIV infection (diagnosed or undiagnosed) at year-end 2021, by selected characteristics—United States
	Persons with HIV infection alive at year-end 2021^a	Persons with diagnosed HIV infection alive at year-end 2021^b		Receipt of care^c		Retention in care^c		Viral suppression^c
	Total No.	No.	%	No.	%	No.	%	No	%
Sex at birth
Male	946,500	819,141	87	618,451	65	441,517	47	543,090	57
Female	265,900	239,759	90	179,340	67	128,990	49	154,645	58
Age at year-end 2021 (yr)
13–24	41,900	23,671	56	18,842	45	13,090	31	15,410	37
25–34	217,100	157,035	72	121,074	56	81,344	37	100,188	46
35–44	238,300	202,019	85	151,514	64	104,040	44	129,090	54
45–54	263,000	243,001	92	183,223	70	130,978	50	161,353	61
≥55	452,000	433,174	96	322,281	71	242,144	54	292,392	65
Race/ethnicity
American Indian/Alaska Native	4,100	3,245	80	2,443	60	1,700	41	2,070	50
Asian^d	18,600	16,455	89	12,259	66	9,017	48	11,502	62
Black/African American	487,500	425,519	87	312,331	64	220,844	45	262,120	54
Hispanic/Latino^e	297,200	252,342	85	182,696	61	137,022	46	162,256	55
Native Hawaiian/other Pacific Islander	1,200	948	81	689,196	57	470	39	601	50
White	342,000	304,871	89	240,238	70	167,679	49	218,593	64
Multiracial	61,200	54,864	90	46,909	77	33,741	55	40,325	66
Transmission category^f
Male-to-male sexual contact^g	716,900	615,019	86	474,795	66	338,260	47	421,903	59
Injection drug use^h	121,900	112,395	92	74,518	61	53,725	44	62,941	52
Male	70,400	64,530	92	40,009	57	29,103	41	33,878	48
Female	51,600	47,864	93	34,462	67	24,602	48	29,053	56
Male-to-male sexual contact^g and injection drug use^h	62,900	57,559	92	44,896	71	32,060	51	37,471	60
Heterosexual contactⁱ	306,700	270,255	88	200,259	65	144,586	47	173,504	57
Male	94,100	79,991	85	56,474	60	41,195	44	48,555	52
Female	212,600	190,265	90	143,650	68	103,314	49	124,814	59
Total^j	1,212,400	1,058,900	87	797,352	66	570,747	47	697,815	58

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; RSE, relative standard error [footnotes only].

^a Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis (i.e., persons living with diagnosed or undiagnosed HIV infection). Estimates for year 2021 should be interpreted with caution due to adjustments made to the CD4+ T-lymphocyte (CD4)-based depletion model to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤ 1,000 to reflect model uncertainty. Estimates with a relative standard error 30%-50% are preceded by an asterisk (*) and should be interpreted with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and replaced by an ellipsis (…). Data previously published in the HIV Surveillance Supplemental Report 2023;28(No. 3). http://www.cy118119.com/hiv/library/reports/hiv-surveillance.html.
^b Reported to National HIV Surveillance System. Data previously published in the HIV Surveillance Supplemental Report 2021;28(No. 3). http://www.cy118119.com/hiv/library/reports/hiv-surveillance.html.
^c Estimates are the result of extrapolating data from the 48 jurisdictions with complete CD4 and viral load reporting by applying the percentage in the 48 jurisdictions (found in Tables 4a and 5a) to the total number of people living with diagnosed HIV in the United States. Estimates were calculated by sex at birth and are rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 6a. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by year of diagnosis and selected characteristics, 2017–2021—United States
	2017			2018			2019			2020 (COVID-19 pandemic)			2021
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender
Male	30,398	6,315	20.8	29,563	6,129	20.7	28,779	5,906	20.5	24,148	5,206	21.6	28,283	6,031	21.3
Female	7,229	1,598	22.1	7,008	1,532	21.9	6,873	1,415	20.6	5,387	1,236	22.9	6,522	1,385	21.2
Transgender woman^b	651	84	12.9	661	85	12.9	692	94	13.6	676	82	12.1	811	96	11.8
Transgender man^b	32	5	15.6	48	2	4.2	45	5	11.1	41	2	4.9	56	2	3.6
Additional gender identity^c	18	3	16.7	19	1	5.3	32	0	0.0	23	4	17.4	44	6	13.6
Age at diagnosis (yr)
13–24	8,297	741	8.9	7,865	710	9.0	7,660	634	8.3	6,125	560	9.1	6,927	688	9.9
25–34	13,400	2,153	16.1	13,346	2,119	15.9	13,027	2,125	16.3	11,279	1,949	17.3	13,081	2,208	16.9
35–44	7,235	1,869	25.8	7,150	1,846	25.8	7,048	1,780	25.3	5,874	1,490	25.4	7,543	1,914	25.4
45–54	5,563	1,880	33.8	5,194	1,746	33.6	4,874	1,555	31.9	3,872	1,368	35.3	4,442	1,438	32.4
≥55	3,833	1,362	35.5	3,744	1,328	35.5	3,812	1,326	34.8	3,125	1,163	37.2	3,723	1,272	34.2
Race/ethnicity
American Indian/Alaska Native	193	41	21.2	170	28	16.5	193	26	13.5	189	42	22.2	223	43	19.3
Asian	911	231	25.4	844	224	26.5	722	175	24.2	610	168	27.5	737	188	25.5
Black/African American	16,107	3,227	20.0	15,593	3,077	19.7	15,296	2,956	19.3	12,643	2,528	20.0	14,522	2,882	19.8
Hispanic/Latino^d	9,995	2,104	21.1	9,921	2,148	21.7	9,851	2,098	21.3	8,037	1,831	22.8	10,059	2,227	22.1
Native Hawaiian/other Pacific Islander	46	12	26.1	57	12	21.1	59	11	18.6	63	12	19.0	76	18	23.7
White	9,543	2,087	21.9	9,323	2,009	21.5	8,985	1,889	21.0	7,732	1,745	22.6	9,058	1,938	21.4
Multiracial	1,533	303	19.8	1,391	251	18.0	1,315	265	20.2	1,001	204	20.4	1,041	224	21.5
Transmission category^e
Male-to-male sexual contact^f	25,345	4,813	19.0	24,464	4,717	19.3	23,870	4,491	18.8	20,460	4,102	20.0	23,855	4,753	19.9
Injection drug use^g	2,400	563	23.5	2,493	555	22.3	2,545	551	21.6	2,064	462	22.4	2,490	543	21.8
Male	1,291	348	26.9	1,376	326	23.7	1,362	340	25.0	1,170	276	23.6	1,415	330	23.3
Female	1,109	215	19.4	1,117	229	20.5	1,182	210	17.8	895	186	20.8	1,075	213	19.9
Male-to-male sexual contact^f and injection drug use^g	1,517	223	14.7	1,531	222	14.5	1,581	261	16.5	1,185	193	16.3	1,373	215	15.7
Heterosexual contact^h	8,988	2,385	26.5	8,731	2,235	25.6	8,339	2,093	25.1	6,500	1,753	27.0	7,916	1,986	25.1
Male	2,882	1,009	35.0	2,839	943	33.2	2,643	893	33.8	2,006	709	35.4	2,460	825	33.5
Female	6,106	1,377	22.5	5,892	1,292	21.9	5,695	1,200	21.1	4,494	1,044	23.2	5,456	1,161	21.3
Otherⁱ	78	21	26.4	80	19	23.7	87	24	27.8	66	20	29.7	83	22	26.6
Male	32	10	30.1	32	6	17.6	42	14	34.1	26	11	41.6	29	9	30.1
Female	46	11	23.9	48	13	27.9	45	10	22.0	41	9	22.2	54	13	24.7
Region of residence
Northeast	5,988	1,286	21.5	5,552	1,257	22.6	5,317	1,161	21.8	4,241	948	22.4	4,988	1,107	22.2
Midwest	5,099	1,084	21.3	4,941	1,109	22.4	4,767	997	20.9	4,106	875	21.3	4,815	979	20.3
South	19,645	4,154	21.1	19,225	3,898	20.3	18,950	3,841	20.3	15,537	3,360	21.6	18,703	3,961	21.2
West	7,596	1,481	19.5	7,581	1,485	19.6	7,387	1,421	19.2	6,391	1,347	21.1	7,210	1,473	20.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	31,366	6,319	20.1	30,411	6,105	20.1	29,658	5,884	19.8	24,446	5,089	20.8	28,822	5,886	20.4
Metropolitan areas (pop. 50,000–499,999)	4,475	1,042	23.3	4,462	1,027	23.0	4,347	951	21.9	3,738	890	23.8	4,478	1,009	22.5
Nonmetropolitan areas (pop. <50,000)	2,249	596	26.5	2,318	604	26.1	2,280	569	25.0	1,940	525	27.1	2,290	605	26.4
Total	38,328	8,005	20.9	37,299	7,749	20.8	36,421	7,420	20.4	30,275	6,530	21.6	35,716	7,520	21.1

Abbreviations: pop, population; CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 6b. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017			2018			2019			2020 (COVID-19 pandemic)			2021
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Gender
Male	30,765	6,380	20.7	29,941	6,214	20.8	29,118	5,982	20.5	24,409	5,262	21.6	28,620	6,113	21.4
Female	7,323	1,622	22.1	7,089	1,549	21.9	6,956	1,442	20.7	5,433	1,248	23.0	6,604	1,404	21.3
Transgender woman^b	653	84	12.9	665	86	12.9	694	94	13.5	679	83	12.2	812	96	11.8
Transgender man^b	32	5	15.6	48	2	4.2	45	5	11.1	41	2	4.9	56	2	3.6
Additional gender identity^c	18	3	16.7	19	1	5.3	32	0	0.0	23	4	17.4	44	6	13.6
Age at diagnosis (yr)
13–24	8,376	746	8.9	7,948	715	9.0	7,724	640	8.3	6,177	563	9.1	6,987	693	9.9
25–34	13,523	2,171	16.1	13,482	2,137	15.9	13,145	2,148	16.3	11,361	1,958	17.2	13,204	2,233	16.9
35–44	7,323	1,893	25.9	7,227	1,867	25.8	7,126	1,797	25.2	5,940	1,508	25.4	7,634	1,935	25.3
45–54	5,655	1,903	33.7	5,289	1,775	33.6	4,943	1,583	32.0	3,926	1,387	35.3	4,519	1,467	32.5
≥55	3,914	1,381	35.3	3,816	1,358	35.6	3,907	1,355	34.7	3,181	1,183	37.2	3,792	1,293	34.1
Race/ethnicity
American Indian/Alaska Native	193	41	21.2	170	28	16.5	193	26	13.5	189	42	22.2	223	43	19.3
Asian	914	233	25.5	848	224	26.4	729	178	24.4	610	168	27.5	738	188	25.5
Black/African American	16,112	3,228	20.0	15,605	3,080	19.7	15,304	2,959	19.3	12,650	2,528	20.0	14,528	2,883	19.8
Hispanic/Latino^d	10,441	2,187	20.9	10,359	2,245	21.7	10,250	2,193	21.4	8,338	1,900	22.8	10,467	2,326	22.2
Native Hawaiian/other Pacific Islander	49	14	28.6	59	14	23.7	63	12	19.0	64	12	18.8	76	18	23.7
White	9,547	2,088	21.9	9,329	2,010	21.5	8,991	1,890	21.0	7,733	1,745	22.6	9,063	1,939	21.4
Multiracial	1,535	303	19.7	1,392	251	18.0	1,315	265	20.2	1,001	204	20.4	1,041	224	21.5
Transmission category^e
Male-to-male sexual contact^f	25,587	4,851	19.0	24,742	4,766	19.3	24,110	4,533	18.8	20,660	4,130	20.0	24,107	4,810	20.0
Injection drug use^g	2,444	569	23.3	2,521	563	22.3	2,572	561	21.8	2,087	470	22.5	2,512	550	21.9
Male	1,325	354	26.7	1,401	335	23.9	1,385	348	25.2	1,189	284	23.9	1,436	337	23.5
Female	1,118	215	19.3	1,120	229	20.4	1,188	213	17.9	898	186	20.7	1,077	213	19.8
Male-to-male sexual contact^f and injection drug use^g	1,529	224	14.7	1,542	228	14.8	1,594	265	16.7	1,190	194	16.3	1,375	215	15.7
Heterosexual contact^h	9,153	2428	26.5	8,877	2,275	25.6	8,482	2,139	25.2	6,582	1,785	27.1	8,059	2,023	25.1
Male	2,962	1,028	34.7	2,906	966	33.2	2,709	915	33.8	2,046	729	35.6	2,523	843	33.4
Female	6,190	1,401	22.6	5,970	1,309	21.9	5,773	1,224	21.2	4,536	1,056	23.3	5,536	1,180	21.3
Otherⁱ	79	21	26.2	80	19	23.7	87	24	27.7	66	20.0	29.6	83	22	26.6
Male	33	10	30.0	32	6	17.6	42	14	34.1	26	11	41.4	29	9	30.0
Female	46	11	23.5	48	13	27.9	45	10	21.9	41	9	22.1	54	13	24.7
Region of residence
Northeast	5,988	1,286	21.5	5,552	1,257	22.6	5,317	1,161	21.8	4,241	948	22.4	4,988	1,107	22.2
Midwest	5,099	1,084	21.3	4,941	1,109	22.4	4,767	997	20.9	4,106	875	21.3	4,815	979	20.3
South	19,645	4,154	21.1	19,225	3,898	20.3	18,950	3,841	20.3	15,537	3,36	21.6	18,703	3,961	21.2
West	7,596	1,481	19.5	7,581	1,485	19.6	7,387	1,421	19.2	6,391	1,347	21.1	7,210	1,473	20.4
U.S. dependent areas	463	89	19.2	463	103	22.2	424	103	24.3	310	69	22.3	420	101	24.0
Total	38,791	8,094	20.9	37,762	7,852	20.8	36,845	7,523	20.4	30,585	6,599	21.6	36,136	7,621	21.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Hispanic/Latino persons can be of any race.
^e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱ Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 6c. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by year of diagnosis and area of residence, 2017–2021—United States and 6 dependent areas
	2017			2018			2019			2020 (COVID-19 pandemic)			2021
		Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a			Stage 3 (AIDS) at diagnosis^a
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Alabama	647	141	21.8	606	128	21.1	635	135	21.3	590	126	21.4	625	115	18.4
Alaska	29	7	24.1	23	4	17.4	27	2	7.4	29	3	10.3	30	10	33.3
Arizona	721	134	18.6	752	159	21.1	748	134	17.9	657	146	22.2	781	146	18.7
Arkansas	285	50	17.5	283	60	21.2	289	72	24.9	245	60	24.5	338	82	24.3
California	4,856	923	19.0	4,764	884	18.6	4,508	836	18.5	4,010	851	21.2	4,399	906	20.6
Colorado	433	78	18.0	400	95	23.8	463	85	18.4	327	69	21.1	406	72	17.7
Connecticut	274	65	23.7	258	64	24.8	213	60	28.2	171	42	24.6	233	48	20.6
Delaware	125	32	25.6	92	22	23.9	93	20	21.5	92	26	28.3	81	25	30.9
District of Columbia	315	40	12.7	278	43	15.5	248	36	14.5	194	41	21.1	195	37	19.0
Florida	4,546	973	21.4	4,352	928	21.3	4,150	910	21.9	3,230	707	21.9	4,072	847	20.8
Georgia	2,607	567	21.7	2,505	495	19.8	2,408	491	20.4	1,974	435	22.0	2,371	543	22.9
Hawaii	76	13	17.1	72	15	20.8	63	13	20.6	50	18	36.0	65	15	23.1
Idaho	45	11	24.4	36	14	38.9	34	14	41.2	35	13	37.1	54	14	25.9
Illinois	1,382	295	21.3	1,379	277	20.1	1,281	246	19.2	1,081	224	20.7	1,195	212	17.7
Indiana	514	126	24.5	514	127	24.7	484	100	20.7	430	104	24.2	528	106	20.1
Iowa	125	31	24.8	114	26	22.8	101	22	21.8	100	25	25.0	124	31	25.0
Kansas	119	25	21.0	155	40	25.8	132	26	19.7	140	35	25.0	154	41	26.6
Kentucky	368	88	23.9	377	76	20.2	326	68	20.9	300	63	21.0	390	71	18.2
Louisiana	987	226	22.9	954	182	19.1	879	183	20.8	718	159	22.1	899	206	22.9
Maine	29	11	37.9	31	10	32.3	30	11	36.7	16	8	50.0	31	14	45.2
Maryland	1,014	249	24.6	994	202	20.3	914	206	22.5	709	152	21.4	749	183	24.4
Massachusetts	600	123	20.5	645	150	23.3	537	112	20.9	430	99	23.0	440	103	23.4
Michigan	771	153	19.8	718	167	23.3	675	148	21.9	517	97	18.8	633	121	19.1
Minnesota	278	76	27.3	288	68	23.6	276	64	23.2	230	47	20.4	297	66	22.2
Mississippi	431	116	26.9	475	129	27.2	469	119	25.4	404	90	22.3	419	87	20.8
Missouri	505	84	16.6	449	96	21.4	488	88	18.0	369	68	18.4	549	99	18.0
Montana	29	6	20.7	24	5	20.8	25	5	20.0	14	5	35.7	22	5	22.7
Nebraska	87	13	14.9	77	25	32.5	80	21	26.3	73	18	24.7	105	23	21.9
Nevada	497	107	21.5	498	95	19.1	517	120	23.2	397	71	17.9	501	120	24.0
New Hampshire	32	5	15.6	38	10	26.3	31	5	16.1	32	8	25.0	32	9	28.1
New Jersey	1,110	239	21.5	1,015	234	23.1	1,084	234	21.6	799	175	21.9	1,143	228	19.9
New Mexico	148	30	20.3	155	37	23.9	176	29	16.5	129	24	18.6	149	20	13.4
New York	2,741	567	20.7	2,454	541	22.0	2,345	494	21.1	1,975	430	21.8	2,116	479	22.6
North Carolina	1,289	264	20.5	1,180	204	17.3	1,367	213	15.6	1,079	226	20.9	1,390	265	19.1
North Dakota	39	10	25.6	35	5	14.3	40	9	22.5	37	16	43.2	37	10	27.0
Ohio	980	212	21.6	977	225	23.0	965	213	22.1	882	189	21.4	909	206	22.7
Oklahoma	302	63	20.9	278	61	21.9	346	55	15.9	342	71	20.8	387	69	17.8
Oregon	203	49	24.1	227	51	22.5	198	49	24.7	179	28	15.6	202	43	21.3
Pennsylvania	1,097	243	22.2	1,018	218	21.4	994	229	23.0	753	175	23.2	913	204	22.3
Rhode Island	85	24	28.2	75	22	29.3	72	14	19.4	52	8	15.4	68	17	25.0
South Carolina	704	178	25.3	726	174	24.0	721	164	22.7	660	163	24.7	652	168	25.8
South Dakota	41	8	19.5	29	7	24.1	34	8	23.5	34	4	11.8	31	9	29.0
Tennessee	720	123	17.1	740	145	19.6	768	133	17.3	646	109	16.9	831	140	16.8
Texas	4,363	857	19.6	4,429	858	19.4	4,350	843	19.4	3,596	744	20.7	4,363	912	20.9
Utah	116	22	19.0	121	17	14.0	135	27	20.0	133	30	22.6	133	26	19.5
Vermont	20	9	45.0	18	8	44.4	11	2	18.2	13	3	23.1	12	5	41.7
Virginia	864	169	19.6	863	170	19.7	832	169	20.3	618	164	26.5	792	180	22.7
Washington	433	97	22.4	497	108	21.7	480	105	21.9	417	87	20.9	461	94	20.4
West Virginia	78	18	23.1	93	21	22.6	155	24	15.5	140	24	17.1	149	31	20.8
Wisconsin	258	51	19.8	206	46	22.3	211	52	24.6	213	48	22.5	253	55	21.7
Wyoming	10	4	40.0	12	1	8.3	13	2	15.4	14	2	14.3	7	2	28.6
Total	38,328	8,005	20.9	37,299	7,749	20.8	36,421	7,420	20.4	30,275	6,530	21.6	35,716	7,520	21.1
U.S. dependent areas
American Samoa	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
Guam	6	4	66.7	7	3	42.9	11	3	27.3	1	0	0.0	0	0	0.0
Northern Mariana Islands	1	0	0.0	1	0	0.0	2	1	50.0	0	0	0.0	0	0	0.0
Puerto Rico	447	84	18.8	437	96	22.0	396	93	23.5	300	69	23.0	410	100	24.4
Republic of Palau	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0
U.S. Virgin Islands	9	1	11.1	18	4	22.2	15	6	40.0	9	0	0.0	10	1	10.0
Subtotal	463	89	19.2	463	103	22.2	424	103	24.3	310	69	22.3	420	101	24.0
Total	38,791	8,094	20.9	37,762	7,852	20.8	36,845	7,523	20.4	30,585	6,599	21.6	36,136	7,621	21.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

^a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.

Table 6d. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by race/ethnicity and area of residence, 2021—United States
	Black/African American			Hispanic/Latino^a			White			Other^b
		Stage 3 (AIDS) at diagnosis^c			Stage 3 (AIDS) at diagnosis^c			Stage 3 (AIDS) at diagnosis^c			Stage 3 (AIDS) at diagnosis^c
	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%	Total No.	No.	%
Alabama	380	65	17.1	26	6	23.1	189	38	20.1	30	6	20.0
Alaska	2	0	0.0	4	2	50.0	13	4	30.8	11	4	36.4
Arizona	125	23	18.4	355	66	18.6	244	46	18.9	57	11	19.3
Arkansas	150	36	24.0	28	7	25.0	138	34	24.6	22	5	22.7
California	754	133	17.6	2,285	505	22.1	1,005	190	18.9	355	78	22.0
Colorado	68	11	16.2	130	23	17.7	187	34	18.2	21	4	19.0
Connecticut	84	11	13.1	74	21	28.4	69	14	20.3	6	2	33.3
Delaware	44	15	34.1	12	3	25.0	21	7	33.3	4	0	0.0
District of Columbia	135	25	18.5	29	5	17.2	20	5	25.0	11	2	18.2
Florida	1,671	342	20.5	1,434	279	19.5	878	197	22.4	89	29	32.6
Georgia	1,690	374	22.1	245	66	26.9	345	80	23.2	91	23	25.3
Hawaii	6	0	0.0	11	1	9.1	18	2	11.1	30	12	40.0
Idaho	3	2	66.7	14	6	42.9	35	6	17.1	2	0	0.0
Illinois	531	84	15.8	311	58	18.6	270	51	18.9	83	19	22.9
Indiana	209	39	18.7	78	18	23.1	219	46	21.0	22	3	13.6
Iowa	29	9	31.0	20	5	25.0	63	14	22.2	12	3	25.0
Kansas	35	8	22.9	36	11	30.6	76	20	26.3	7	2	28.6
Kentucky	118	18	15.3	30	12	40.0	221	40	18.1	21	1	4.8
Louisiana	578	119	20.6	73	26	35.6	229	54	23.6	19	7	36.8
Maine	4	0	0.0	1	0	0.0	22	11	50.0	4	3	75.0
Maryland	529	125	23.6	102	32	31.4	87	16	18.4	31	10	32.3
Massachusetts	148	52	35.1	119	24	20.2	155	23	14.8	18	4	22.2
Michigan	343	62	18.1	45	11	24.4	217	42	19.4	28	6	21.4
Minnesota	124	30	24.2	43	14	32.6	103	14	13.6	27	8	29.6
Mississippi	309	67	21.7	13	0	0.0	93	17	18.3	4	3	75.0
Missouri	244	32	13.1	52	9	17.3	220	53	24.1	33	5	15.2
Montana	0	0	0.0	1	0	0	18	4	22.2	3	1	33.3
Nebraska	23	2	8.7	20	7	35.0	53	13	24.5	9	1	11.1
Nevada	149	31	20.8	182	40	22.0	131	40	30.5	39	9	23.1
New Hampshire	3	2	66.7	2	1	50.0	26	5	19.2	1	1	100
New Jersey	450	91	20.2	457	96	21.0	170	27	15.9	66	14	21.2
New Mexico	7	2	28.6	80	11	13.8	34	2	5.9	28	5	17.9
New York	827	166	20.1	773	178	23.0	341	92	27.0	175	43	24.6
North Carolina	804	145	18.0	214	45	21.0	296	65	22.0	76	10	13.2
North Dakota	12	4	33.3	3	1	33.3	17	4	23.5	5	1	20.0
Ohio	448	92	20.5	56	17	30.4	362	88	24.3	43	9	20.9
Oklahoma	109	18	16.5	70	12	17.1	144	30	20.8	64	9	14.1
Oregon	16	2	12.5	53	11	20.8	113	25	22.1	20	5	25.0
Pennsylvania	419	101	24.1	172	37	21.5	273	59	21.6	49	7	14.3
Rhode Island	13	4	30.8	24	4	16.7	29	9	31.0	2	0	0.0
South Carolina	361	86	23.8	74	21	28.4	157	41	26.1	60	20	33.3
South Dakota	4	1	25.0	2	0	0.0	13	4	30.8	12	4	33.3
Tennessee	444	60	13.5	87	21	24.1	275	52	18.9	25	7	28.0
Texas	1,467	264	18.0	1,880	428	22.8	788	167	21.2	228	53	23.2
Utah	9	1	11.1	55	13	23.6	59	9	15.3	10	3	30.0
Vermont	3	0	0.0	1	1	100	8	4	50.0	0	0	0.0
Virginia	440	94	21.4	95	27	28.4	213	51	23.9	44	8	18.2
Washington	96	18	18.8	121	26	21.5	185	41	22.2	59	9	15.3
West Virginia	13	3	23.1	6	2	33.3	124	24	19.4	6	2	33.3
Wisconsin	92	13	14.1	59	17	28.8	87	23	26.4	15	2	13.3
Wyoming	0	0	0.0	2	1	50.0	5	1	20.0	0	0	0.0
Total	14,522	2,882	19.8	10,059	2,227	22.1	9,058	1,938	21.4	2,077	473	22.8
Region of residence
Northeast	1,951	427	21.9	1,623	362	22.3	1093	244	22.3	321	74	23.1
Midwest	2,094	376	18.0	725	168	23.2	1,700	372	21.9	296	63	21.3
South	9,242	1,856	20.1	4,418	992	22.5	4,218	918	21.8	825	195	23.6
West	1,235	223	18.1	3,293	705	21.4	2,047	404	19.7	635	141	22.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection.

^a Hispanic/Latino persons can be of any race.
^b Includes American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and multiracial persons.
^c Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.

Table 7a. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States
	2017			2018			2019			2020 (COVID-19 pandemic)			2021
	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a
Gender
Male	12,239	–	16.1	12,102	–	15.5	12,307	–	15.4	14,208	–	17.5	14,663	–	17.7
Female	3,988	–	16.8	3,985	–	16.5	3,841	–	15.7	4,627	–	18.7	4,742	–	19.0
Transgender woman^b	108	–	9.9	118	–	10.3	145	–	12.0	207	–	16.4	215	–	16.1
Transgender man^b	5	–	12.3	5	–	11.1	5	–	10.1	10	–	18.9	2	–	3.5
Additional gender identity^c	3	–	12.4	1	–	3.8	2	–	6.8	0	–	0.0	1	–	2.8
Age at death (yr)
13–24	152	0.3	3.5	130	0.3	3.1	135	0.3	3.4	153	0.3	4.1	109	0.2	3.0
25–34	1,047	2.3	6.5	1,034	2.3	6.2	1,100	2.4	6.4	1,258	2.8	7.2	1,360	3.0	7.7
35–44	1,833	4.5	9.5	1,774	4.3	9.1	1,795	4.3	9.1	2,074	4.8	10.4	2,247	5.2	11.0
45–54	4,469	10.6	14.6	4,183	10.1	14.1	3,648	8.9	12.8	3,858	9.4	14.2	3,783	9.3	14.6
≥55	8,842	9.5	29.1	9,090	9.6	27.4	9,622	10.0	26.7	11,709	12.0	30.1	12,124	12.3	29.3
Race/ethnicity
American Indian/Alaska Native	47	2.4	16.8	49	2.5	16.8	57	2.9	18.6	82	4.1	25.6	80	3.9	23.9
Asian^d	88	0.6	6.4	83	0.5	5.7	100	0.6	6.5	103	0.6	6.5	125	0.7	7.5
Black/African American	7,193	21.6	17.6	6,981	20.7	16.7	7,008	20.6	16.4	8,327	24.2	19.2	8,402	24.2	19.1
Hispanic/Latino^e	2,693	6.0	11.8	2,838	6.2	12.0	2,770	5.9	11.3	3,452	7.1	13.8	3,498	7.1	13.5
Native Hawaiian/other Pacific Islander	9	1.9	12.0	13	2.7	16.2	14	2.8	16.5	11	2.2	12.3	14	2.7	14.5
White	5,234	3.1	17.6	5,150	3.0	17.0	5,256	3.1	17.2	5,754	3.3	18.6	6,025	3.5	19.3
Multiracial	1,077	23.7	19.0	1,097	23.3	19.2	1,091	22.4	19.0	1,322	26.1	23.0	1,478	28.2	25.9
Transmission category^f
Male-to-male sexual contact^g	7,010	–	12.6	6,888	–	12.0	7,184	–	12.1	8,237	–	13.6	8,672	–	13.9
Injection drug use^h	3,527	–	29.3	3,504	–	29.3	3,403	–	28.7	3,922	–	33.4	3,801	–	32.7
Male	2,154	–	30.8	2,169	–	31.3	2,087	–	30.4	2,427	–	35.8	2,335	–	34.9
Female	1,373	–	27.3	1,335	–	26.6	1,316	–	26.3	1,494	–	30.1	1,466	–	29.7
Male-to-male sexual contact^g and injection drug use^h	1,383	–	23.3	1,453	–	24.4	1,395	–	23.4	1,665	–	28.0	1,687	–	28.5
Heterosexual contactⁱ	4,242	–	16.3	4,194	–	15.9	4,157	–	15.4	5,021	–	18.5	5,262	–	19.1
Male	1,694	–	21.6	1,600	–	20.1	1,688	–	20.8	1,961	–	24.1	2,071	–	25.2
Female	2,548	–	14.1	2,594	–	14.0	2,470	–	13.1	3,060	–	16.1	3,191	–	16.5
Other^j	180	–	12.3	172	–	11.6	161	–	10.6	206	–	13.4	201	–	12.8
Male	108	–	14.3	110	–	14.4	100	–	12.9	124	–	15.8	113	–	14.3
Female	72	–	10.2	62	–	8.6	61	–	8.2	82	–	10.8	87	–	11.2
Region of residence
Northeast	3,693	7.7	15.7	3,522	7.4	14.9	3,653	7.6	15.3	4,522	9.2	19.0	4,324	8.8	18.1
Midwest	1,914	3.4	15.9	2,003	3.5	16.2	1,960	3.4	15.6	2,316	4.0	18.0	2,284	3.9	17.4
South	7,996	7.8	17.5	7,880	7.6	16.8	7,916	7.5	16.4	9,076	8.6	18.5	9,539	8.9	19.0
West	2,740	4.3	13.8	2,806	4.3	13.7	2,771	4.2	13.2	3,138	4.8	14.7	3,476	5.2	16.0
Total^k	16,343	6.0	16.2	16,211	5.9	15.7	16,300	5.9	15.4	19,052	6.8	17.8	19,623	7.0	18.0

Abbreviations: pop, population; PWDH, persons with diagnosed HIV infection; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see http://www.cy118119.com/nchs/nvss/vsrr/covid19/excess_deaths.htm.

^a Denominator was calculated as (No. PWDH at the end of [year X − 1]) + (No. new diagnoses during year X).
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Includes persons of unknown race/ethnicity.

Table 7b. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017			2018			2019			2020 (COVID-19 pandemic)			2021
	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a	No.	Rate per 100,000 population	Rate per 1,000 PWDH^a
Gender
Male	12,540	–	16.2	12,392	–	15.7	12,583	–	15.6	14,482	–	17.6	14,942	–	17.8
Female	4,096	–	16.9	4,061	–	16.5	3,920	–	15.7	4,713	–	18.7	4,824	–	18.9
Transgender woman^b	110	–	10.1	119	–	10.3	147	–	12.1	208	–	16.4	216	–	16.2
Transgender man^b	5	–	12.3	5	–	11.0	5	–	10.1	10	–	18.8	2	–	3.5
Additional gender identity^c	3	–	12.4	1	–	3.8	2	–	6.8	0	–	0.0	1	–	2.8
Age at death (yr)
13–24	154	0.3	3.5	134	0.3	3.2	137	0.3	3.4	155	0.3	4.1	110	0.2	3.0
25–34	1,068	2.3	6.6	1,054	2.3	6.2	1,118	2.4	6.4	1,266	2.7	7.2	1,373	3.0	7.7
35–44	1,883	4.6	9.6	1,822	4.4	9.2	1,851	4.4	9.2	2,128	4.9	10.5	2,290	5.2	11.0
45–54	4,598	10.8	14.7	4,272	10.2	14.1	3,757	9.1	13.0	3,939	9.5	14.3	3,854	9.4	14.7
≥55	9,051	9.6	29.1	9,296	9.7	27.4	9,794	10.0	26.6	11,925	12.1	30.1	12,358	12.4	29.3
Race/ethnicity
American Indian/Alaska Native	47	–	16.8	49	–	16.7	57	–	18.6	82	–	25.6	80	–	23.9
Asian^d	88	–	6.4	83	–	5.7	100	–	6.5	104	–	6.5	125	–	7.4
Black/African American	7,198	–	17.6	6,981	–	16.7	7,009	–	16.4	8,330	–	19.2	8,405	–	19.1
Hispanic/Latino^e	3,098	–	12.7	3,200	–	12.7	3,119	–	12.0	3,807	–	14.3	3,857	–	14.0
Native Hawaiian/other Pacific Islander	9	–	11.5	16	–	19.2	16	–	18.1	11	–	11.8	14	–	14.0
White	5,235	–	17.6	5,151	–	17.0	5,258	–	17.2	5,756	–	18.6	6,025	–	19.3
Multiracial	1,077	–	19.0	1,098	–	19.2	1,094	–	19.0	1,322	–	23.0	1,478	–	25.8
Transmission category^f
Male-to-male sexual contact^g	7,081	–	12.6	6,967	–	12.0	7,257	–	12.1	8,319	–	13.6	8,730	–	13.9
Injection drug use^h	3,694	–	29.6	3,658	–	29.5	3,555	–	28.9	4,055	–	33.3	3,937	–	32.7
Male	2,286	–	31.1	2,290	–	31.5	2,209	–	30.7	2,534	–	35.7	2,451	–	35.0
Female	1,409	–	27.4	1,368	–	26.7	1,345	–	26.4	1,521	–	30.0	1,486	–	29.6
Male-to-male sexual contact^g and injection drug use^h	1,408	–	23.4	1,475	–	24.4	1,420	–	23.5	1,695	–	28.1	1,714	–	28.6
Heterosexual contactⁱ	4,387	–	16.5	4,297	–	15.9	4,260	–	15.5	5,134	–	18.4	5,402	–	19.2
Male	1,768	–	21.8	1,663	–	20.2	1,744	–	20.9	2,015	–	24.0	2,149	–	25.4
Female	2,620	–	14.2	2,635	–	14.0	2,517	–	13.1	3,119	–	16.0	3,253	–	16.5
Other^j	182	–	12.2	181	–	11.9	165	–	10.7	210	–	13.3	202	–	12.6
Male	109	–	14.2	117	–	15.0	102	–	12.9	127	–	15.9	114	–	14.2
Female	73	–	10.1	64	–	8.7	63	–	8.3	83	–	10.7	87	–	11.0
Region of residence
Northeast	3,693	7.7	15.7	3,522	7.4	14.9	3,653	7.6	15.3	4,522	9.2	19.0	4,324	8.8	18.1
Midwest	1,914	3.4	15.9	2,003	3.5	16.2	1,960	3.4	15.6	2,316	4.0	18.0	2,284	3.9	17.4
South	7,996	7.8	17.5	7,880	7.6	16.8	7,916	7.5	16.4	9,076	8.6	18.5	9,539	8.9	19.0
West	2,740	4.3	13.8	2,806	4.3	13.7	2,771	4.2	13.2	3,138	4.8	14.7	3,476	5.2	16.0
U.S. dependent areas	411	12.9	24.3	367	11.8	21.9	357	11.4	21.2	361	11.2	21.5	362	11.2	21.5
Total^k	16,754	6.1	16.3	16,578	6.0	15.8	16,657	6.0	15.5	19,413	6.9	17.8	19,985	7.1	18.0

Abbreviations: pop, population; PWDH, persons with diagnosed HIV infection; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see http://www.cy118119.com/nchs/nvss/vsrr/covid19/excess_deaths.htm..

^a Denominator was calculated as (No. PWDH at the end of [year X − 1]) + (No. new diagnoses during year X).
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Includes persons of unknown race/ethnicity.

Table 7c. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2017–2021—United States and 6 dependent areas
	2017					2018					2019
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH
Alabama	261	6.4	6.3	19.7	18.1	236	5.7	5.5	17.3	15.4	271	6.6	6.2	19.2	16.8
Alaska	7	1.2	1.2	9.7	8.6	9	1.5	1.4	12.7	9.4	12	2.0	2.0	16.4	13.4
Arizona	248	4.2	4.0	15.5	13.8	251	4.2	4.0	15.1	12.7	233	3.8	3.7	13.4	11.4
Arkansas	105	4.2	4.1	18.7	17.0	83	3.3	3.4	14.5	12.9	112	4.4	4.3	18.8	17.8
California	1,723	5.2	5.0	13.3	11.1	1,732	5.3	4.9	13.1	10.6	1,764	5.3	5.0	13.1	10.8
Colorado	133	2.8	2.7	10.9	8.5	142	3.0	2.9	11.2	8.5	131	2.7	2.6	10.1	8.6
Connecticut	199	6.5	5.4	18.9	15.1	182	5.9	5.0	17.1	11.7	204	6.7	5.5	18.9	12.8
Delaware	67	8.3	7.0	20.1	13.8	68	8.3	7.1	20.3	14.9	77	9.3	8.6	22.3	17.7
District of Columbia	234	39.1	41.3	16.3	13.3	203	33.6	36.8	14.3	11.5	203	33.5	35.6	14.3	11.0
Florida	2,045	11.4	10.2	18.4	15.0	1,941	10.6	9.4	17.2	13.7	1,996	10.8	9.3	17.3	13.7
Georgia	839	9.7	9.4	15.7	14.8	863	9.9	9.5	15.5	14.3	836	9.4	9.0	14.5	13.2
Hawaii	37	3.1	2.9	15.3	15.7	36	3.0	2.6	15.2	10.4	44	3.7	3.1	18.3	13.0
Idaho	20	1.4	1.4	17.7	13.9	16	1.1	1.1	13.6	9.7	11	0.7	0.7	8.8	6.3
Illinois	507	4.7	4.4	14.4	13.2	559	5.2	4.8	15.5	13.8	550	5.2	4.7	15.2	13.2
Indiana	210	3.8	3.7	18.8	16.9	195	3.5	3.4	16.9	15.0	165	2.9	2.8	14.1	11.9
Iowa	44	1.7	1.7	16.3	13.2	50	1.9	1.8	17.8	14.2	61	2.3	2.0	20.9	17.0
Kansas	47	2.0	1.9	15.4	14.3	51	2.1	2.0	16.3	14.8	57	2.4	2.3	17.8	15.5
Kentucky	139	3.7	3.5	19.6	16.9	136	3.6	3.5	18.5	16.2	109	2.9	2.7	14.3	12.8
Louisiana	411	10.6	10.5	20.0	18.7	429	11.1	10.8	20.4	18.3	380	9.8	9.7	17.7	16.0
Maine	34	2.9	2.3	21.4	15.0	20	1.7	1.5	12.3	8.4	41	3.5	2.9	24.5	18.0
Maryland	603	11.9	10.9	18.2	14.9	635	12.5	11.1	18.8	15.3	614	12.1	10.7	18.1	14.6
Massachusetts	305	5.2	4.6	14.8	11.6	305	5.1	4.6	14.6	10.9	300	5.0	4.5	14.2	10.8
Michigan	276	3.3	3.1	17.4	15.8	313	3.7	3.3	19.3	17.2	277	3.3	3.0	16.5	14.5
Minnesota	91	2.0	1.9	10.9	9.4	85	1.8	1.7	9.9	7.7	83	1.8	1.7	9.4	8.3
Mississippi^b	218	8.8	8.7	23.2	21.3	229	9.2	9.2	23.9	21.2	192	7.7	7.6	19.5	17.6
Missouri	213	4.2	4.0	17.1	14.6	234	4.6	4.3	18.3	15.6	231	4.5	4.2	17.8	16.2
Montana	15	1.7	1.7	24.1	21.3	13	1.5	1.4	20.2	16.5	13	1.4	1.4	19.4	15.2
Nebraska	33	2.1	2.0	15.4	14.5	31	2.0	1.8	14.2	12.9	33	2.1	2.1	14.7	11.6
Nevada	176	7.1	6.6	18.3	16.5	160	6.3	5.9	15.7	13.7	155	6.0	5.8	14.4	13.6
New Hampshire	21	1.8	1.6	17.6	13.8	18	1.5	1.4	14.3	15.5	18	1.5	1.4	13.7	8.8
New Jersey	646	8.6	7.5	18.5	14.0	635	8.5	7.3	18.1	13.7	626	8.3	7.0	17.6	12.6
New Mexico	62	3.6	3.3	17.9	13.6	76	4.3	4.3	20.7	16.3	57	3.2	3.0	14.9	11.5
New York	1,797	10.8	9.6	14.2	10.8	1,737	10.5	9.2	13.6	10.1	1,807	10.9	9.4	14.2	10.4
North Carolina	552	6.4	5.9	17.7	15.4	532	6.1	5.5	16.5	13.8	508	5.7	5.2	15.2	12.5
North Dakota	3	0.5	0.4	7.2	8.7	8	1.3	1.3	17.5	23.8	5	0.8	0.8	10.0	10.0
Ohio	380	3.9	3.7	17.2	15.7	373	3.8	3.6	16.5	14.2	399	4.0	3.8	17.0	15.1
Oklahoma	108	3.3	3.4	17.7	16.9	117	3.6	3.4	18.7	17.3	144	4.4	4.2	22.1	19.7
Oregon	116	3.3	3.0	16.7	12.6	106	3.0	2.7	14.9	12.6	129	3.6	3.3	17.5	13.5
Pennsylvania	645	5.9	5.3	18.1	14.6	573	5.2	4.7	15.8	12.6	603	5.5	4.9	16.3	12.8
Rhode Island	34	3.7	3.3	13.2	9.8	41	4.5	4.0	15.6	10.9	41	4.5	3.7	15.2	11.1
South Carolina	338	8.0	7.2	20.2	17.7	316	7.4	6.9	18.4	15.6	313	7.2	6.5	17.7	15.2
South Dakota	9	1.3	1.3	15.5	12.5	13	1.8	1.9	20.9	16.3	11	1.5	1.7	16.7	13.7
Tennessee	334	5.9	5.6	19.6	18.2	359	6.3	6.0	20.3	18.2	315	5.5	5.2	17.4	14.8
Texas	1,413	6.1	6.2	15.8	15.1	1,379	5.9	5.9	14.8	14.0	1,472	6.2	6.2	15.3	14.0
Utah	22	0.9	1.0	7.9	8.4	45	1.8	2.0	15.1	13.3	37	1.5	1.5	11.8	9.9
Vermont	12	2.2	1.9	17.4	11.6	11	2.0	1.5	15.6	9.4	13	2.4	2.1	18.1	11.5
Virginia	298	4.2	3.8	13.2	10.9	308	4.3	4.0	13.3	11.3	327	4.5	4.1	13.7	11.1
Washington	176	2.8	2.6	13.3	10.5	213	3.4	3.1	15.5	12.0	180	2.8	2.6	12.8	10.3
West Virginia^b	31	2.0	1.8	16.9	13.9	46	3.0	2.7	23.6	20.5	47	3.1	2.8	22.9	18.0
Wisconsin	101	2.1	1.9	16.3	12.9	91	1.9	1.7	14.4	12.1	88	1.8	1.6	13.5	10.7
Wyoming	5	1.0	0.9	15.1	25.3	7	1.5	1.4	19.7	15.3	5	1.0	0.8	14.2	10.3
Subtotal	16,343	6.0	5.6	16.2	13.7	16,211	5.9	5.5	15.7	13.0	16,300	5.9	5.4	15.4	12.7
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0	2	5.5	6.6	666.7	365.5
Guam^b	0	0.0	0.0	0.0	0.0	4	3.1	3.7	37.4	38.6	4	3.1	3.2	34.8	25.1
Northern Mariana Islands	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
Puerto Rico	405	14.0	13.1	24.9	19.4	359	12.8	11.6	22.3	18.6	351	12.5	11.9	21.7	17.4
Republic of Palau	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	6	6.8	6.5	11.1	8.6	4	4.5	3.1	7.2	4.6	0	0.0	0.0	0.0	0.0
Subtotal	411	12.9	12.0	24.3	18.9	367	11.8	10.8	21.9	18.3	357	11.4	10.9	21.2	16.9
Total	16,754	6.1	5.7	16.3	13.8	16,578	6.0	5.5	15.8	13.1	16,657	6.0	5.5	15.5	12.8

Table 7c. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2017–2021—United States and 6 dependent areas
	2020 (COVID-19 pandemic)					2021
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWDH^a	Age-adjusted rate per 1,000 PWDH
Alabama	288	6.8	6.4	20.0	17.9	331	7.8	7.1	22.4	18.9
Alaska	16	2.7	2.6	21.5	17.3	18	3.0	3.0	23.5	18.8
Arizona	286	4.7	4.5	16.0	13.2	339	5.5	5.1	18.3	14.9
Arkansas	109	4.3	4.1	17.9	16.5	124	4.9	4.7	19.5	16.9
California	1,982	6.0	5.5	14.5	11.5	2,149	6.5	6.0	15.5	12.0
Colorado	176	3.6	3.5	13.2	10.4	185	3.7	3.5	13.6	11.6
Connecticut	216	7.0	5.8	20.0	13.3	209	6.7	5.5	19.3	13.3
Delaware	75	8.9	7.7	21.4	19.1	75	8.8	6.9	20.9	14.2
District of Columbia	264	44.7	46.6	18.8	13.5	265	46.3	48.4	19.1	15.0
Florida	2,251	12.1	10.4	19.2	14.9	2,429	12.9	11.0	20.3	15.4
Georgia	919	10.3	9.8	15.6	14.1	967	10.7	10.0	16.0	14.0
Hawaii	39	3.2	2.8	16.2	16.4	48	3.9	3.3	19.7	12.7
Idaho	21	1.4	1.2	16.3	11.0	19	1.2	1.1	14.3	10.9
Illinois	709	6.6	5.9	19.5	16.6	609	5.7	5.2	16.8	13.8
Indiana	222	3.9	3.7	18.4	15.2	228	4.0	3.7	18.1	16.2
Iowa	63	2.4	2.3	21.1	17.2	44	1.6	1.4	14.2	11.1
Kansas	62	2.5	2.4	18.4	14.8	63	2.6	2.4	17.7	14.2
Kentucky	159	4.2	4.1	19.9	17.7	152	4.0	3.8	18.3	15.6
Louisiana	467	12.1	11.7	21.5	19.5	501	13.0	12.6	22.7	19.6
Maine	25	2.1	1.7	15.0	9.3	44	3.7	2.7	25.3	15.9
Maryland	657	12.7	11.3	19.3	15.5	692	13.3	11.8	20.3	15.5
Massachusetts	313	5.2	4.5	14.7	10.3	340	5.6	4.9	15.8	10.8
Michigan	350	4.1	3.7	20.4	17.4	295	3.5	3.1	16.8	14.2
Minnesota	96	2.0	1.7	10.6	9.1	107	2.2	2.1	11.5	9.6
Mississippi^b	244	9.9	9.2	24.6	21.4	197	8.0	7.7	19.6	16.6
Missouri	247	4.8	4.4	18.9	15.9	278	5.4	4.9	20.8	17.2
Montana	6	0.7	0.7	8.7	17.4	13	1.4	1.3	17.7	14.3
Nebraska	27	1.7	1.6	11.5	9.4	39	2.4	2.2	16.1	13.1
Nevada	179	6.8	6.3	16.1	13.6	207	7.8	7.3	17.8	14.5
New Hampshire	20	1.7	1.4	15.0	11.2	22	1.8	1.5	15.9	9.8
New Jersey	724	9.2	7.8	20.3	15.0	723	9.2	7.8	20.1	14.7
New Mexico	88	4.9	4.6	22.1	16.9	83	4.6	4.5	20.2	16.5
New York	2,443	14.3	12.2	19.2	14.0	2,211	13.1	11.1	17.4	12.3
North Carolina	657	7.4	6.6	19.2	16.1	654	7.3	6.6	18.7	15.2
North Dakota	8	1.2	1.2	15.2	14.1	6	0.9	0.8	11.0	10.9
Ohio	422	4.2	3.9	17.6	15.1	511	5.1	4.7	20.8	17.3
Oklahoma	156	4.8	4.5	23.1	19.9	147	4.4	4.4	20.7	17.5
Oregon	126	3.5	3.0	16.9	13.0	141	3.9	3.4	18.5	13.0
Pennsylvania	718	6.5	5.6	19.3	15.1	721	6.5	5.6	19.2	14.2
Rhode Island	50	5.3	4.6	18.4	12.5	42	4.4	3.7	15.2	10.0
South Carolina	375	8.6	7.7	20.7	16.6	411	9.3	8.2	22.2	17.9
South Dakota	6	0.8	0.9	8.6	6.5	15	2.0	2.1	20.4	15.5
Tennessee	441	7.6	7.1	23.5	21.0	439	7.5	7.1	22.9	19.4
Texas	1,565	6.5	6.5	15.8	14.2	1,748	7.2	7.1	17.1	15.2
Utah	30	1.1	1.3	9.1	7.3	43	1.6	1.8	12.3	9.8
Vermont	13	2.3	1.9	18.1	13.4	12	2.1	1.9	16.2	12.5
Virginia	398	5.5	5.0	16.4	13.4	351	4.8	4.3	14.2	11.3
Washington	182	2.8	2.6	12.6	10.7	228	3.5	3.2	15.4	11.9
West Virginia^b	51	3.3	3.4	23.5	20.1	56	3.7	3.5	24.9	22.9
Wisconsin	104	2.1	1.9	15.5	11.7	89	1.8	1.6	12.9	10.5
Wyoming	7	1.4	1.3	19.3	15.0	3	0.6	0.7	7.9	6.2
Subtotal	19,052	6.8	6.2	17.8	14.4	19,623	7.0	6.3	18.0	14.2
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
Guam^b	1	0.8	0.8	9.1	6.6	0	0.0	0.0	0.0	0.0
Northern Mariana Islands	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
Puerto Rico	353	12.1	10.9	22.0	16.9	359	12.3	10.7	22.2	16.3
Republic of Palau	1	5.5	6.0	100	87.5	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	6	6.8	6.1	10.7	8.6	3	3.4	2.2	5.3	2.9
Subtotal	361	11.2	10.1	21.5	16.6	362	11.2	9.8	21.5	15.7
Total	19,413	6.9	6.2	17.8	14.4	19,985	7.1	6.4	18.0	14.2

Abbreviations: PWDH, persons with diagnosed HIV infection; pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see http://www.cy118119.com/nchs/nvss/vsrr/covid19/excess_deaths.htm.

^a Denominator was calculated as (No. PWDH at the end of [year X − 1]) + (No. new diagnoses during year X).
^b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 7d. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2017–2021—United States
	2017			2018			2019			2020 (COVID-19 pandemic)			2021
	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a
Gender
Male	9,655	–	24.0	9,448	–	23.3	9,449	–	23.1	10,832	–	26.4	11,051	–	26.9
Female	3,090	–	24.4	3,115	–	24.4	2,925	–	22.8	3,470	–	26.9	3,565	–	27.6
Transgender woman^b	77	–	15.3	88	–	16.8	105	–	19.5	151	–	27.4	141	–	25.2
Transgender man^b	4	–	22.7	2	–	11.2	3	–	16.0	6	–	31.9	2	–	10.6
Additional gender identity^c	3	–	31.6	1	–	10.4	2	–	20.4	0	–	0.0	0	–	0.0
Age at death (yr)
13–24	89	0.2	10.8	77	0.2	10.5	72	0.1	11.2	74	0.1	13.2	48	0.1	9.4
25–34	710	1.6	14.2	722	1.6	14.5	714	1.6	14.5	755	1.7	15.7	787	1.7	16.7
35–44	1,403	3.4	15.3	1,341	3.3	15.1	1,296	3.1	14.8	1,487	3.5	17.4	1,502	3.5	17.8
45–54	3,615	8.6	19.6	3,371	8.1	19.2	2,892	7.1	17.5	3,034	7.4	19.7	2,923	7.2	20.3
≥55	7,012	7.6	35.1	7,143	7.6	32.9	7,510	7.8	32.1	9,109	9.3	36.3	9,499	9.6	35.8
Race/ethnicity
American Indian/Alaska Native	36	1.8	26.0	35	1.8	24.9	44	2.2	30.7	56	2.8	38.2	54	2.6	36.0
Asian^d	67	0.4	10.7	64	0.4	9.8	76	0.5	11.3	77	0.5	11.1	104	0.6	14.6
Black/African American	5,641	16.9	26.2	5,451	16.2	25.1	5,365	15.8	24.5	6,277	18.2	28.5	6,273	18.1	28.4
Hispanic/Latino^e	2,242	5.0	18.0	2,307	5.0	18.2	2,227	4.7	17.4	2,740	5.7	21.1	2,771	5.6	21.2
Native Hawaiian/other Pacific Islander	8	1.7	21.4	9	1.9	23.4	12	2.4	30.3	10	2.0	25.2	11	2.1	26.3
White	3,940	2.3	25.6	3,881	2.3	25.2	3,860	2.3	25.1	4,223	2.5	27.5	4,375	2.5	28.6
Multiracial	895	19.7	27.5	907	19.3	27.9	899	18.5	27.7	1,076	21.2	33.3	1,171	22.4	36.6
Transmission category^f
Male-to-male sexual contact^g	5,432	–	20.0	5,241	–	19.0	5,404	–	19.3	6,175	–	21.9	6,398	–	22.4
Injection drug use^h	2,844	–	36.6	2,775	–	36.3	2,643	–	35.1	3,037	–	41.0	2,937	–	40.5
Male	1,752	–	37.4	1,724	–	37.5	1,632	–	36.1	1,882	–	42.6	1,814	–	42.0
Female	1,092	–	35.5	1,051	–	34.5	1,012	–	33.5	1,154	–	38.7	1,123	–	38.3
Male-to-male sexual contact^g and injection drug use^h	1,145	–	31.3	1,227	–	33.8	1,130	–	31.5	1,328	–	37.4	1,292	–	37.0
Heterosexual contactⁱ	3,255	–	23.2	3,266	–	23.0	3,167	–	22.1	3,734	–	25.9	3,963	–	27.4
Male	1,318	–	27.5	1,251	–	25.9	1,305	–	26.7	1,489	–	30.5	1,596	–	32.6
Female	1,937	–	21.0	2,015	–	21.6	1,861	–	19.7	2,245	–	23.6	2,367	–	24.7
Other^j	152	–	17.8	146	–	17.0	140	–	16.3	185	–	21.5	169	–	19.6
Male	87	–	19.3	94	–	20.7	86	–	18.9	109	–	24.0	92	–	20.3
Female	64	–	16.2	52	–	12.9	55	–	13.4	76	–	18.7	77	–	18.8
Region of residence
Northeast	2,881	6.0	21.7	2,750	5.7	20.8	2,849	6.0	21.6	3,484	7.1	26.7	3,318	6.8	25.7
Midwest	1,446	2.5	24.0	1,532	2.7	25.1	1,447	2.5	23.5	1,733	3.0	27.9	1,669	2.9	26.7
South	6,264	6.1	26.6	6,094	5.8	25.6	6,022	5.7	24.9	6,804	6.4	27.9	7,124	6.7	29.0
West	2,238	3.5	21.1	2,278	3.5	21.3	2,166	3.3	20.1	2,438	3.7	22.6	2,648	4.0	24.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	8,356	4.5	19.2	8,117	4.3	18.6	8,367	4.4	18.8	9,444	4.9	21.2	9,587	5.0	21.5
Metropolitan areas (pop. 50,000-499,999)	1,154	2.4	23.1	1,150	2.4	22.6	1,193	2.5	22.7	1,247	2.6	23.6	1,344	2.8	25.0
Nonmetropolitan areas (pop. <50,000)	758	2.0	25.4	670	1.7	22.3	734	1.9	23.9	806	2.1	26.0	856	2.2	27.4
Total^k	12,829	4.7	24.0	12,654	4.6	23.5	12,484	4.5	23.0	14,459	5.2	26.6	14,759	5.3	27.0

Abbreviations: pop, population; PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see http://www.cy118119.com/nchs/nvss/vsrr/covid19/excess_deaths.htm.

^a Denominator was calculated as (No. PWA at the end of [year X − 1]) + (No. new diagnoses during year X).
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Includes persons of unknown race/ethnicity.

Table 7e. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
	2017			2018			2019			2020 (COVID-19 pandemic)			2021
	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a	No.	Rate per 100,000 population	Rate per 1,000 PWA^a
Gender
Male	9,861	–	24.1	9,645	–	23.4	9,641	–	23.2	11,024	–	26.5	11,233	–	26.9
Female	3,163	–	24.4	3,163	–	24.3	2,980	–	22.7	3,523	–	26.8	3,617	–	27.5
Transgender woman^b	79	–	15.6	89	–	17.0	107	–	19.8	152	–	27.5	141	–	25.1
Transgender man^b	4	–	22.6	2	–	11.1	3	–	15.9	6	–	31.7	2	–	10.5
Additional gender identity^c	3	–	31.6	1	–	10.4	2	–	20.4	0	–	0.0	0	–	0.0
Age at death (yr)
13–24	91	0.2	10.9	81	0.2	10.9	73	0.1	11.3	74	0.1	13.1	49	0.1	9.6
25–34	724	1.6	14.4	735	1.6	14.7	723	1.6	14.5	760	1.6	15.6	792	1.7	16.7
35–44	1,438	3.5	15.5	1,374	3.3	15.2	1,325	3.1	15.0	1,520	3.5	17.6	1,526	3.5	17.8
45–54	3,701	8.7	19.7	3,430	8.2	19.2	2,974	7.2	17.7	3,089	7.4	19.7	2,971	7.2	20.3
≥55	7,156	7.6	35.1	7,280	7.6	32.9	7,638	7.8	32.0	9,262	9.4	36.2	9,655	9.7	35.6
Race/ethnicity
American Indian/Alaska Native	36	–	26.0	35	–	24.9	44	–	30.7	56	–	38.1	54	–	36.0
Asian^d	67	–	10.6	64	–	9.8	76	–	11.2	78	–	11.2	104	–	14.5
Black/African American	5,644	–	26.2	5,451	–	25.1	5,365	–	24.4	6,279	–	28.5	6,273	–	28.4
Hispanic/Latino^e	2,520	–	18.9	2,549	–	18.8	2,470	–	18.0	2,982	–	21.6	3,005	–	21.5
Native Hawaiian/other Pacific Islander	8	–	20.5	11	–	27.2	14	–	33.7	10	–	24.2	11	–	25.2
White	3,940	–	25.6	3,882	–	25.2	3,861	–	25.1	4,224	–	27.5	4,375	–	28.6
Multiracial	895	–	27.5	908	–	27.9	902	–	27.8	1,076	–	33.3	1,171	–	36.6
Transmission category^f
Male-to-male sexual contact^g	5,483	–	20.0	5,292	–	19.0	5,460	–	19.4	6,232	–	21.9	6,439	–	22.4
Injection drug use^h	2,954	–	36.7	2,879	–	36.3	2,746	–	35.2	3,127	–	40.8	3,022	–	40.3
Male	1,841	–	37.6	1,805	–	37.5	1,714	–	36.3	1,957	–	42.3	1,888	–	41.8
Female	1,113	–	35.4	1,073	–	34.5	1,032	–	33.5	1,169	–	38.5	1,134	–	37.9
Male-to-male sexual contact^g and injection drug use^h	1,164	–	31.3	1,244	–	33.8	1,146	–	31.5	1,349	–	37.5	1,307	–	36.9
Heterosexual contactⁱ	3,355	–	23.4	3,332	–	23.0	3,238	–	22.1	3,811	–	25.8	4,055	–	27.4
Male	1,366	–	27.7	1,293	–	26.0	1,342	–	26.8	1,528	–	30.4	1,647	–	32.7
Female	1,989	–	21.1	2,039	–	21.4	1,895	–	19.7	2,283	–	23.5	2,408	–	24.6
Other^j	154	–	17.7	154	–	17.6	143	–	16.3	186	–	21.2	170	–	19.4
Male	88	–	19.1	100	–	21.6	88	–	18.9	110	–	23.8	93	–	20.2
Female	65	–	16.1	54	–	13.1	56	–	13.4	76	–	18.3	77	–	18.5
Region of residence
Northeast	2,881	6.0	21.7	2,750	5.7	20.8	2,849	6.0	21.6	3,484	7.1	26.7	3,318	6.8	25.7
Midwest	1,446	2.5	24.0	1,532	2.7	25.1	1,447	2.5	23.5	1,733	3.0	27.9	1,669	2.9	26.7
South	6,264	6.1	26.6	6,094	5.8	25.6	6,022	5.7	24.9	6,804	6.4	27.9	7,124	6.7	29.0
West	2,238	3.5	21.1	2,278	3.5	21.3	2,166	3.3	20.1	2,438	3.7	22.6	2,648	4.0	24.4
U.S. dependent areas	281	8.8	30.8	246	7.9	27.4	249	8.0	27.7	246	7.6	27.6	234	7.3	26.4
Total^k	13,110	4.8	24.1	12,900	4.7	23.6	12,733	4.6	23.1	14,705	5.2	26.6	14,993	5.3	27.0

Abbreviations: pop, population; PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see http://www.cy118119.com/nchs/nvss/vsrr/covid19/excess_deaths.htm.

^a Denominator was calculated as (No. PWA at the end of [year X − 1]) + (No. new diagnoses during year X).
^b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
^e Hispanic/Latino persons can be of any race.
^f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
ⁱ Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
^k Includes persons of unknown race/ethnicity.

Table 7f. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2017–2021—United States and 6 dependent areas
	2017					2018					2019
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA
Alabama	199	4.9	4.8	33.6	28.4	169	4.1	3.9	27.9	24.6	171	4.1	4.0	27.6	21.9
Alaska	4	0.7	0.7	10.2	7.6	8	1.3	1.2	20.9	13.4	9	1.5	1.4	23.7	18.2
Arizona	195	3.3	3.1	25.3	26.0	200	3.3	3.2	25.4	22.9	170	2.8	2.7	21.1	15.9
Arkansas	79	3.2	3.1	30.5	25.6	62	2.5	2.5	23.8	20.7	79	3.1	3.0	29.2	31.7
California	1,433	4.4	4.2	20.2	17.3	1,412	4.3	4.0	19.9	17.3	1,383	4.2	3.9	19.4	19.7
Colorado	107	2.3	2.2	19.9	18.9	115	2.4	2.3	20.9	15.0	100	2.1	2.0	17.9	12.9
Connecticut	160	5.2	4.3	24.6	23.0	147	4.8	4.0	22.6	14.0	168	5.5	4.5	25.8	17.7
Delaware	58	7.1	6.0	28.3	18.0	54	6.6	5.6	26.6	18.1	64	7.7	7.4	30.9	27.7
District of Columbia	161	26.9	28.4	21.0	18.1	156	25.8	28.1	20.3	19.2	148	24.4	26.2	19.6	13.9
Florida	1,643	9.1	8.2	27.2	21.9	1,537	8.4	7.4	25.4	20.1	1,558	8.4	7.2	25.5	20.8
Georgia	655	7.6	7.3	23.9	21.6	662	7.6	7.3	23.6	20.1	642	7.3	6.9	22.5	19.2
Hawaii	31	2.6	2.5	22.0	36.3	31	2.6	2.2	22.7	15.5	39	3.3	2.7	28.6	22.2
Idaho	15	1.1	1.1	26.6	20.2	13	0.9	0.9	22.4	14.9	11	0.7	0.7	17.7	11.2
Illinois	381	3.6	3.3	21.4	19.2	429	4.0	3.7	23.9	20.2	413	3.9	3.5	23.2	19.1
Indiana	164	3.0	2.8	29.2	26.2	144	2.6	2.5	25.1	23.5	131	2.3	2.2	22.8	16.3
Iowa	30	1.1	1.2	19.9	13.9	37	1.4	1.3	24.1	16.2	45	1.7	1.5	29.3	20.9
Kansas	37	1.5	1.5	23.3	25.7	40	1.7	1.5	24.7	26.7	42	1.7	1.7	26.0	27.8
Kentucky	108	2.9	2.7	30.4	23.3	101	2.7	2.6	28.4	25.1	84	2.2	2.1	23.2	18.2
Louisiana	313	8.1	8.0	29.2	28.6	330	8.5	8.3	30.5	26.0	298	7.7	7.6	27.2	26.3
Maine	24	2.1	1.7	29.7	22.9	16	1.4	1.3	19.4	13.9	32	2.7	2.3	38.1	34.1
Maryland	476	9.4	8.6	26.7	19.7	502	9.9	8.8	28.0	21.9	459	9.0	8.0	25.8	19.8
Massachusetts	232	3.9	3.4	20.3	13.0	230	3.9	3.4	20.2	13.4	224	3.8	3.3	19.7	14.6
Michigan	225	2.7	2.5	27.4	23.3	242	2.9	2.5	29.2	24.8	217	2.6	2.2	25.8	22.3
Minnesota	70	1.5	1.4	18.0	14.7	66	1.4	1.3	16.7	12.1	58	1.2	1.2	14.5	14.2
Mississippi^b	173	7.0	7.0	36.8	31.8	187	7.5	7.6	39.3	34.5	135	5.4	5.4	28.1	21.6
Missouri	154	3.0	2.9	23.9	18.4	179	3.5	3.2	27.4	23.6	168	3.3	3.0	25.6	26.1
Montana	13	1.5	1.4	37.7	37.5	10	1.1	1.0	28.4	21.3	9	1.0	1.0	26.2	18.5
Nebraska	23	1.5	1.4	21.5	17.2	24	1.5	1.4	22.3	17.3	17	1.1	1.1	15.6	10.6
Nevada	138	5.6	5.2	29.4	29.6	135	5.3	4.9	27.7	24.7	119	4.6	4.4	23.6	21.0
New Hampshire	15	1.3	1.1	24.6	19.0	15	1.3	1.2	24.0	14.2	14	1.2	1.1	22.0	13.6
New Jersey	475	6.3	5.5	26.0	18.8	471	6.3	5.4	25.9	22.1	474	6.3	5.3	26.2	19.7
New Mexico	49	2.8	2.5	25.7	16.6	53	3.0	3.0	26.9	23.5	38	2.2	2.0	18.9	14.0
New York	1,468	8.8	7.8	19.9	15.0	1,409	8.5	7.4	19.2	13.3	1,448	8.7	7.5	20.0	14.4
North Carolina	392	4.5	4.2	27.7	23.7	363	4.1	3.8	25.0	19.3	355	4.0	3.7	23.8	19.2
North Dakota	3	0.5	0.4	15.2	14.3	6	1.0	0.9	28.8	24.4	5	0.8	0.8	22.1	17.9
Ohio	279	2.8	2.7	26.3	22.7	289	2.9	2.8	26.8	23.1	277	2.8	2.6	24.9	23.5
Oklahoma	82	2.5	2.6	27.5	25.2	86	2.6	2.5	28.2	32.7	120	3.7	3.5	38.6	31.5
Oregon	85	2.4	2.2	21.6	14.2	89	2.5	2.3	22.4	15.7	105	2.9	2.7	25.9	19.8
Pennsylvania	474	4.3	3.9	24.1	18.9	422	3.9	3.4	21.3	14.9	444	4.1	3.5	22.2	15.7
Rhode Island	28	3.1	2.6	19.4	14.3	32	3.5	3.1	22.0	13.7	35	3.8	3.0	24.0	15.5
South Carolina	263	6.2	5.6	28.9	23.3	240	5.6	5.3	26.0	19.7	232	5.3	4.8	24.8	18.4
South Dakota	3	0.4	0.5	11.2	8.0	11	1.5	1.6	37.8	32.8	8	1.1	1.2	26.1	16.6
Tennessee	259	4.6	4.4	30.4	27.2	275	4.8	4.6	31.4	27.1	246	4.3	4.1	27.9	21.4
Texas	1,147	5.0	5.0	25.0	23.5	1,108	4.8	4.8	23.7	22.7	1,143	4.8	4.8	24.0	21.1
Utah	19	0.8	0.8	13.5	9.5	35	1.4	1.6	23.8	37.8	31	1.2	1.3	20.8	15.6
Vermont	5	0.9	0.8	13.6	11.2	8	1.5	1.1	21.1	11.2	10	1.8	1.6	26.6	17.4
Virginia	231	3.2	2.9	21.3	18.0	225	3.1	2.9	20.3	17.9	255	3.5	3.2	22.5	18.9
Washington	145	2.3	2.2	20.3	14.7	170	2.7	2.5	23.4	16.7	148	2.3	2.1	20.2	18.7
West Virginia^b	25	1.6	1.5	24.6	19.0	37	2.4	2.1	35.5	36.1	33	2.1	1.8	31.4	22.7
Wisconsin	77	1.6	1.5	25.2	18.0	65	1.3	1.2	21.2	17.4	66	1.3	1.2	21.0	15.1
Wyoming	4	0.8	0.7	22.3	51.7	7	1.5	1.4	38.7	25.6	4	0.8	0.6	22.0	12.5
Subtotal	12,829	4.7	4.4	24.0	20.1	12,654	4.6	4.3	23.5	19.4	12,484	4.5	4.1	23.0	19.0
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0	2	5.5	6.6	1,000	365.5
Guam^b	0	0.0	0.0	0.0	0.0	3	2.4	3.0	66.7	84.1	4	3.1	3.2	88.9	53.5
Northern Mariana Islands	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
Puerto Rico	277	9.6	8.9	31.5	28.9	241	8.6	7.8	27.9	32.1	243	8.6	8.0	28.2	24.7
Republic of Palau	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	4	4.5	4.0	13.8	10.4	2	2.3	1.5	6.8	3.7	0	0.0	0.0	0.0	0.0
Subtotal	281	8.8	8.2	30.8	28.2	246	7.9	7.2	27.4	31.4	249	8.0	7.4	27.7	24.1
Total	13,110	4.8	4.4	24.1	20.2	12,900	4.7	4.3	23.6	19.5	12,733	4.6	4.2	23.1	19.1

Table 7f. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2017–2021—United States and 6 dependent areas
	2020 (COVID-19 pandemic)					2021
	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA	No.	Rate per 100,000 pop	Age-adjusted rate per 100,000 pop	Rate per 1,000 PWA^a	Age-adjusted rate per 1,000 PWA
Alabama	183	4.3	4.1	29.0	25.1	228	5.4	4.9	35.6	26.4
Alaska	11	1.8	1.8	28.9	22.3	16	2.7	2.6	41.7	32.6
Arizona	204	3.4	3.1	24.8	21.0	258	4.2	3.8	30.7	23.9
Arkansas	77	3.1	2.8	27.9	25.5	90	3.6	3.2	31.9	27.4
California	1,572	4.7	4.4	22.1	18.3	1,640	5.0	4.5	23.1	18.3
Colorado	120	2.5	2.4	21.2	19.4	145	2.9	2.7	25.6	21.7
Connecticut	166	5.4	4.5	25.7	16.5	156	5.0	4.0	24.4	22.0
Delaware	57	6.8	5.8	27.3	27.6	58	6.8	5.0	27.1	16.9
District of Columbia	197	33.4	35.3	26.5	17.7	199	34.8	36.5	26.8	17.7
Florida	1,767	9.5	8.2	28.9	22.9	1,866	9.9	8.3	30.3	24.0
Georgia	721	8.1	7.7	24.8	22.5	731	8.1	7.5	24.8	20.5
Hawaii	29	2.4	2.1	21.5	16.7	41	3.4	2.8	30.6	18.1
Idaho	12	0.8	0.7	19.0	11.7	12	0.8	0.7	18.9	11.3
Illinois	534	5.0	4.5	30.0	23.9	446	4.2	3.8	25.4	20.6
Indiana	152	2.7	2.5	26.0	19.0	164	2.9	2.7	27.2	28.9
Iowa	50	1.9	1.8	32.5	25.3	33	1.2	1.0	21.3	15.4
Kansas	46	1.9	1.7	27.2	18.5	44	1.8	1.6	25.1	17.8
Kentucky	118	3.1	3.1	31.6	29.6	100	2.6	2.5	26.3	19.8
Louisiana	338	8.7	8.5	30.8	26.6	360	9.3	9.0	32.7	26.8
Maine	18	1.5	1.1	21.5	11.8	30	2.5	1.9	34.3	20.5
Maryland	496	9.6	8.5	27.9	21.3	514	9.9	8.7	29.1	20.0
Massachusetts	234	3.9	3.3	20.7	13.5	240	4.0	3.4	21.3	13.8
Michigan	260	3.0	2.7	30.7	27.8	221	2.6	2.3	25.9	20.6
Minnesota	69	1.4	1.2	17.0	12.4	69	1.4	1.3	16.8	15.9
Mississippi^b	173	7.0	6.7	35.9	31.8	139	5.6	5.3	28.8	21.7
Missouri	189	3.7	3.3	28.8	26.3	212	4.1	3.6	32.2	29.4
Montana	4	0.4	0.4	11.3	6.0	8	0.9	0.8	21.3	13.5
Nebraska	23	1.4	1.4	20.1	15.8	30	1.9	1.7	25.7	21.9
Nevada	148	5.7	5.1	28.6	25.1	166	6.3	5.8	31.3	23.7
New Hampshire	14	1.2	0.8	21.8	14.9	15	1.2	1.1	22.6	13.8
New Jersey	527	6.7	5.7	29.3	22.3	541	6.9	5.8	30.3	21.8
New Mexico	62	3.5	3.2	30.3	19.5	56	3.1	2.9	27.1	22.6
New York	1,956	11.4	9.7	27.3	20.3	1,768	10.5	8.8	25.1	18.1
North Carolina	442	5.0	4.4	29.1	22.8	445	5.0	4.5	29.0	21.8
North Dakota	7	1.1	1.0	28.9	25.6	6	0.9	0.8	25.1	19.2
Ohio	322	3.2	2.9	28.6	25.4	369	3.7	3.4	32.4	26.7
Oklahoma	122	3.7	3.5	38.4	34.5	105	3.2	3.1	32.7	29.7
Oregon	101	2.8	2.4	25.4	21.4	114	3.1	2.7	28.7	19.0
Pennsylvania	519	4.7	4.0	26.1	18.3	532	4.8	4.1	26.7	17.6
Rhode Island	41	4.3	3.6	28.4	16.3	29	3.1	2.3	20.2	10.0
South Carolina	283	6.5	5.9	29.9	24.4	319	7.2	6.3	33.2	28.4
South Dakota	3	0.4	0.5	9.8	6.7	14	1.9	2.0	41.3	25.6
Tennessee	305	5.2	4.9	33.7	30.7	317	5.4	5.1	35.0	26.8
Texas	1,197	5.0	4.9	24.8	21.4	1,346	5.6	5.5	27.5	22.7
Utah	22	0.8	0.9	14.4	10.5	30	1.1	1.2	18.8	13.0
Vermont	9	1.6	1.4	23.7	23.9	7	1.2	1.0	18.2	9.4
Virginia	295	4.1	3.6	25.7	21.3	269	3.7	3.3	23.0	18.4
Washington	146	2.2	2.1	19.9	16.9	159	2.4	2.2	21.4	18.0
West Virginia^b	33	2.1	2.0	31.0	27.6	38	2.5	2.1	34.9	24.5
Wisconsin	78	1.6	1.4	24.4	16.5	61	1.2	1.1	19.1	13.0
Wyoming	7	1.4	1.3	37.4	28.5	3	0.6	0.7	15.9	12.7
Subtotal	14,459	5.2	4.7	26.6	21.6	14,759	5.3	4.7	27.0	21.0
U.S. dependent area
American Samoa	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
Guam^b	1	0.8	0.8	23.8	13.8	0	0.0	0.0	0.0	0.0
Northern Mariana Islands	0	0.0	0.0	0.0	0.0	0	0.0	0.0	0.0	0.0
Puerto Rico	240	8.3	7.3	28.1	21.0	233	8.0	6.8	27.4	24.5
Republic of Palau	1	5.5	6.0	166.7	87.5	0	0.0	0.0	0.0	0.0
U.S. Virgin Islands^b	4	4.6	4.7	13.6	15.1	1	1.1	0.7	3.4	1.6
Subtotal	246	7.6	6.8	27.6	20.7	234	7.3	6.2	26.4	23.5
Total	14,705	5.2	4.7	26.6	21.6	14,993	5.3	4.7	27.0	21.0

Abbreviations: PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see http://www.cy118119.com/nchs/nvss/vsrr/covid19/excess_deaths.htm.

^a Denominator was calculated as (No. PWA at the end of [year X − 1]) + (No. new diagnoses during year X).
^b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 8a. Persons aged ≥13 years surviving >3 years after a diagnosis of HIV infection during 2013–2018, by year of diagnosis and selected characteristics—United States
		Proportion survived >3 years
	No.	2013	2014	2015	2016	2017	2018
Gender
Male	184,437	0.94	0.95	0.95	0.95	0.95	0.95
Female	43,828	0.92	0.94	0.94	0.94	0.94	0.94
Transgender woman^a	3,784	0.98	0.98	0.97	0.97	0.98	0.98
Transgender man^a	182	*	*	*	*	*	*
Additional gender identity^b	95	*	*	*	*	*	*
Age at diagnosis
13-24	51,459	0.99	0.99	0.99	0.99	0.99	0.99
25-34	77,163	0.97	0.97	0.98	0.98	0.97	0.97
35-44	44,967	0.94	0.95	0.95	0.95	0.95	0.95
45-54	36,084	0.90	0.91	0.92	0.91	0.91	0.91
≥55	22,653	0.80	0.82	0.82	0.83	0.84	0.85
Race/ethnicity
American Indian/Alaska Native	1,023	0.89	0.94	0.94	0.95	0.91	0.91
Asian	5,116	0.96	0.97	0.97	0.96	0.97	0.97
Black/African American	97,919	0.94	0.95	0.95	0.95	0.95	0.96
Hispanic/Latino^c	58,439	0.95	0.96	0.96	0.96	0.96	0.96
Native Hawaiian/other Pacific Islander	282	*	*	*	*	*	*
White	58,877	0.93	0.94	0.94	0.93	0.93	0.93
Multiracial	10,670	0.95	0.96	0.95	0.95	0.96	0.95
Transmission category^d
Male-to-male sexual contact^e	152,545	0.95	0.96	0.96	0.96	0.96	0.96
Injection drug use^f	14,010	0.86	0.87	0.89	0.88	0.88	0.88
Male	7,643	0.85	0.86	0.88	0.87	0.87	0.88
Female	6,368	0.88	0.89	0.91	0.89	0.90	0.88
Male-to-male sexual contact^e and injection drug use^f	9,331	0.94	0.96	0.95	0.95	0.95	0.94
Heterosexual contact^g	55,984	0.92	0.93	0.93	0.94	0.93	0.94
Male	18,596	0.89	0.91	0.91	0.91	0.91	0.91
Female	37,389	0.93	0.95	0.95	0.95	0.94	0.95
Other^h	456	*	*	*	*	*	*
Male	196	*	*	*	*	*	*
Female	259	*	*	*	*	*	*
Region of residence
Northeast	37,557	0.94	0.95	0.95	0.95	0.95	0.95
Midwest	30,634	0.94	0.95	0.95	0.95	0.95	0.95
South	118,795	0.94	0.94	0.95	0.95	0.95	0.95
West	45,340	0.94	0.95	0.95	0.95	0.95	0.96
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	190,785	0.94	0.95	0.95	0.95	0.95	0.95
Metropolitan areas (pop. 50,000-499,999)	26,305	0.92	0.93	0.94	0.94	0.94	0.94
Nonmetropolitan areas (pop. <50,000)	13,878	0.90	0.92	0.92	0.93	0.93	0.94
Total	232,326	0.94	0.95	0.95	0.95	0.95	0.95

Abbreviation: pop, population.

Note. Data are based on residence at time of diagnosis of HIV infection. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8b. Persons aged ≥13 years surviving >3 years after a diagnosis of HIV infection during 2013–2018, by year of diagnosis and selected characteristics—United States and 6 dependent areas
		Proportion survived >3 years
	No.	2013	2014	2015	2016	2017	2018
Gender
Male	187,086	0.94	0.95	0.95	0.95	0.95	0.95
Female	44,522	0.92	0.94	0.94	0.94	0.94	0.94
Transgender woman^a	3,803	0.98	0.98	0.97	0.97	0.98	0.98
Transgender man^a	183	*	*	*	*	*	*
Additional gender identity^b	96	*	*	*	*	*	*
Age at diagnosis
13-24	52,028	0.99	0.99	0.99	0.99	0.99	0.99
25-34	78,044	0.97	0.97	0.98	0.98	0.97	0.97
35-44	45,666	0.94	0.95	0.95	0.95	0.95	0.95
45-54	36,764	0.90	0.91	0.92	0.91	0.91	0.91
≥55	23,188	0.80	0.81	0.82	0.83	0.84	0.84
Race/ethnicity
American Indian/Alaska Native	1,023	0.89	0.94	0.94	0.95	0.91	0.91
Asian	5,130	0.96	0.97	0.97	0.96	0.97	0.97
Black/African American	97,984	0.94	0.95	0.95	0.95	0.95	0.96
Hispanic/Latino^c	61,678	0.94	0.95	0.96	0.96	0.96	0.96
Native Hawaiian/other Pacific Islander	296	*	*	*	*	*	*
White	58,902	0.93	0.94	0.94	0.93	0.93	0.93
Multiracial	10,677	0.95	0.96	0.95	0.95	0.96	0.95
Transmission category^d
Male-to-male sexual contact^e	154,296	0.95	0.96	0.96	0.96	0.96	0.96
Injection drug use^f	14,359	0.86	0.87	0.89	0.87	0.88	0.88
Male	7,919	0.84	0.85	0.88	0.86	0.86	0.88
Female	6,439	0.88	0.89	0.91	0.89	0.90	0.88
Male-to-male sexual contact^e and injection drug use^f	9,423	0.94	0.96	0.95	0.94	0.95	0.94
Heterosexual contact^g	57,156	0.91	0.93	0.93	0.94	0.93	0.94
Male	19,144	0.89	0.91	0.90	0.91	0.91	0.91
Female	38,011	0.93	0.94	0.94	0.95	0.94	0.95
Other^h	457	*	*	*	*	*	*
Male	197	*	*	*	*	*	*
Female	260	*	*	*	*	*	*
Region of residence
Northeast	37,557	0.94	0.95	0.95	0.95	0.95	0.95
Midwest	30,634	0.94	0.95	0.95	0.95	0.95	0.95
South	118,795	0.94	0.94	0.95	0.95	0.95	0.95
West	45,340	0.94	0.95	0.95	0.95	0.95	0.96
U.S. dependent areas	3,364	0.86	0.89	0.90	0.88	0.90	0.91
Total	235,690	0.94	0.95	0.95	0.95	0.95	0.95

Note. Data are based on residence at time of diagnosis of HIV infection. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^c Hispanic/Latino persons can be of any race.
^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8c. Persons aged ≥13 years surviving >3 years after a diagnosis of HIV infection during 2013–2018, by year of diagnosis and area of residence—United States and 6 dependent areas
		Proportion survived >3 years
Area of residence	No.	2013	2014	2015	2016	2017	2018
Alabama	3,850	0.93	0.92	0.94	0.95	0.95	0.93
Alaska	173	*	*	*	*	*	*
Arizona	4,278	0.94	0.95	0.94	0.94	0.94	0.96
Arkansas	1,716	0.92	0.92	0.93	0.95	0.96	0.94
California	29,219	0.94	0.95	0.96	0.96	0.96	0.96
Colorado	2,310	0.97	0.95	0.95	0.95	0.97	0.97
Connecticut	1,669	0.94	0.96	0.99	0.98	0.92	0.97
Delaware	659	0.96	0.96	0.97	0.94	0.94	0.95
District of Columbia	2,188	0.96	0.96	0.96	0.96	0.96	0.94
Florida	26,801	0.93	0.94	0.94	0.95	0.95	0.95
Georgia	14,890	0.94	0.95	0.94	0.95	0.95	0.95
Hawaii	530	*	*	*	*	*	*
Idaho	213	*	*	*	*	*	*
Illinois	8,874	0.95	0.95	0.96	0.96	0.96	0.96
Indiana	3,080	0.93	0.94	0.94	0.95	0.94	0.94
Iowa	705	0.92	0.93	0.97	0.95	0.92	0.93
Kansas	850	0.90	0.96	0.94	0.95	0.97	0.96
Kentucky	2,112	0.92	0.92	0.95	0.93	0.93	0.95
Louisiana	6,423	0.94	0.94	0.94	0.95	0.95	0.94
Maine	256	*	*	*	*	*	*
Maryland	6,752	0.94	0.96	0.96	0.96	0.94	0.95
Massachusetts	3,773	0.97	0.97	0.97	0.95	0.96	0.96
Michigan	4,479	0.93	0.95	0.95	0.95	0.95	0.95
Minnesota	1,766	0.93	0.95	0.97	0.98	0.97	0.96
Mississippi^a	2,768	0.92	0.93	0.93	0.92	0.94	0.93
Missouri	2,849	0.94	0.96	0.96	0.95	0.93	0.95
Montana	127	*	*	*	*	*	*
Nebraska	484	*	*	*	*	*	*
Nevada	2,833	0.94	0.95	0.95	0.94	0.94	0.97
New Hampshire	209	*	*	*	*	*	*
New Jersey	6,847	0.91	0.94	0.95	0.95	0.94	0.94
New Mexico	840	0.94	0.93	0.91	0.99	0.94	0.93
New York	17,399	0.95	0.95	0.96	0.95	0.96	0.95
North Carolina	7,752	0.95	0.95	0.94	0.95	0.96	0.96
North Dakota	178	*	*	*	*	*	*
Ohio	5,798	0.95	0.94	0.94	0.93	0.95	0.94
Oklahoma	1,816	0.92	0.94	0.94	0.95	0.92	0.93
Oregon	1,338	0.96	0.93	0.96	0.95	0.94	0.96
Pennsylvania	6,863	0.93	0.93	0.94	0.96	0.96	0.94
Rhode Island	457	*	*	*	*	*	*
South Carolina	4,287	0.93	0.93	0.94	0.94	0.94	0.96
South Dakota	197	*	*	*	*	*	*
Tennessee	4,418	0.92	0.93	0.93	0.95	0.94	0.95
Texas	26,476	0.94	0.95	0.95	0.95	0.95	0.95
Utah	717	0.94	0.98	0.97	0.94	0.97	0.96
Vermont	84	*	*	*	*	*	*
Virginia	5,419	0.95	0.96	0.97	0.95	0.96	0.96
Washington	2,676	0.95	0.95	0.98	0.95	0.97	0.95
West Virginia^a	468	*	*	*	*	*	*
Wisconsin	1,374	0.95	0.94	0.98	0.97	0.93	0.98
Wyoming	86	*	*	*	*	*	*
Subtotal	232,326	0.94	0.95	0.95	0.95	0.95	0.95
U.S. dependent areas
American Samoa	0	*	*	*	*	*	*
Guam^a	28	*	*	*	*	*	*
Northern Mariana Islands	5	*	*	*	*	*	*
Puerto Rico	3,223	0.86	0.89	0.90	0.88	0.89	0.91
Republic of Palau	3	*	*	*	*	*	*
U.S. Virgin Islands^a	105	*	*	*	*	*	*
Subtotal	3,364	0.86	0.89	0.90	0.88	0.90	0.91
Total	235,690	0.94	0.95	0.95	0.95	0.95	0.95

Abbreviation: pop, population.

Note. Data are based on residence at time of diagnosis of HIV infection. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

^a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 8d. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2013–2018, by year of diagnosis and selected characteristics—United States
		Proportion survived >3 years
	No.	2013	2014	2015	2016	2017	2018
Gender
Male	85,480	0.86	0.85	0.86	0.86	0.86	0.86
Female	27,437	0.84	0.84	0.84	0.86	0.84	0.83
Transgender woman^a	1,498	0.93	0.92	0.91	0.92	0.93	0.90
Transgender man^a	52	*	*	*	*	*	*
Additional gender identity^b	30	*	*	*	*	*	*
Age at diagnosis
13-24	9,624	0.96	0.94	0.95	0.96	0.94	0.95
25-34	29,675	0.92	0.92	0.92	0.93	0.92	0.92
35-44	27,792	0.89	0.88	0.88	0.88	0.88	0.89
45-54	27,967	0.83	0.83	0.83	0.83	0.83	0.83
≥55	19,439	0.71	0.68	0.70	0.71	0.72	0.70
Race/ethnicity
American Indian/Alaska Native	434	*	*	*	*	*	*
Asian	1,921	0.90	0.91	0.91	0.89	0.92	0.92
Black/African American	52,096	0.85	0.84	0.86	0.86	0.86	0.86
Hispanic/Latino^c	25,810	0.89	0.87	0.87	0.89	0.88	0.89
Native Hawaiian/other Pacific Islander	110	*	*	*	*	*	*
White	27,493	0.84	0.83	0.82	0.82	0.82	0.81
Multiracial	6,633	0.89	0.88	0.87	0.86	0.85	0.85
Transmission category^d
Male-to-male sexual contact^e	62,520	0.88	0.87	0.87	0.88	0.88	0.88
Injection drug use^f	11,040	0.77	0.76	0.76	0.76	0.76	0.76
Male	6,042	0.75	0.74	0.74	0.73	0.75	0.76
Female	4,998	0.79	0.77	0.78	0.79	0.77	0.77
Male-to-male sexual contact^e and injection drug use^f	5,466	0.84	0.85	0.85	0.84	0.85	0.82
Heterosexual contact^g	34,351	0.84	0.84	0.85	0.86	0.85	0.84
Male	12,449	0.82	0.82	0.83	0.83	0.83	0.83
Female	21,903	0.85	0.85	0.86	0.87	0.86	0.85
Other^h	1,120	0.93	0.90	0.93	0.90	0.91	0.91
Male	527	*	*	*	*	*	*
Female	592	*	*	*	*	*	*
Region of residence
Northeast	19,994	0.87	0.87	0.87	0.87	0.87	0.87
Midwest	14,848	0.88	0.87	0.87	0.87	0.86	0.87
South	60,138	0.85	0.84	0.84	0.85	0.85	0.85
West	19,517	0.87	0.86	0.85	0.86	0.85	0.85
Population area of residence
Metropolitan statistical areas (pop. ≥500,000)	92,647	0.87	0.86	0.86	0.86	0.86	0.86
Metropolitan areas (pop. 50,000-499,999)	13,418	0.83	0.82	0.84	0.83	0.83	0.84
Nonmetropolitan areas (pop. <50,000)	7,889	0.82	0.81	0.81	0.84	0.82	0.84
Total	114,497	0.86	0.85	0.85	0.86	0.86	0.86

Abbreviation: pop, population.

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^c Hispanic/Latino persons can be of any race.
^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8e. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2013–2018, by year of diagnosis and selected characteristics—United States and 6 dependent areas
		Proportion survived >3 years
	No.	2013	2014	2015	2016	2017	2018
Gender
Male	86,799	0.86	0.85	0.85	0.86	0.86	0.86
Female	27,922	0.84	0.84	0.84	0.86	0.84	0.83
Transgender woman^a	1,503	0.93	0.92	0.91	0.92	0.93	0.90
Transgender man^a	52	*	*	*	*	*	*
Additional gender identity^b	30	*	*	*	*	*	*
Age at diagnosis
13-24	9,730	0.96	0.94	0.95	0.95	0.94	0.95
25-34	29,975	0.92	0.92	0.92	0.93	0.92	0.92
35-44	28,248	0.89	0.87	0.88	0.88	0.88	0.89
45-54	28,512	0.83	0.83	0.82	0.83	0.83	0.83
≥55	19,841	0.71	0.68	0.70	0.71	0.72	0.70
Race/ethnicity
American Indian/Alaska Native	434	*	*	*	*	*	*
Asian	1,927	0.90	0.91	0.91	0.89	0.92	0.92
Black/African American	52,133	0.85	0.84	0.86	0.86	0.86	0.86
Hispanic/Latino^c	27,553	0.88	0.86	0.86	0.88	0.87	0.88
Native Hawaiian/other Pacific Islander	122	*	*	*	*	*	*
White	27,502	0.84	0.83	0.82	0.82	0.82	0.81
Multiracial	6,635	0.89	0.88	0.87	0.86	0.85	0.85
Transmission category^d
Male-to-male sexual contact^e	63,108	0.88	0.87	0.87	0.88	0.87	0.88
Injection drug use^f	11,430	0.77	0.75	0.75	0.76	0.75	0.76
Male	6,339	0.75	0.74	0.73	0.73	0.75	0.75
Female	5,091	0.79	0.77	0.78	0.79	0.77	0.77
Male-to-male sexual contact^e and injection drug use^f	5,548	0.84	0.85	0.84	0.84	0.85	0.82
Heterosexual contact^g	35,077	0.84	0.84	0.85	0.86	0.85	0.84
Male	12,798	0.82	0.81	0.83	0.83	0.83	0.83
Female	22,280	0.85	0.85	0.85	0.87	0.86	0.85
Other^h	1,143	0.93	0.90	0.92	0.91	0.91	0.90
Male	535	*	*	*	*	*	*
Female	608	0.93	0.92	0.90	0.93	0.92	0.94
Region of residence
Northeast	19,994	0.87	0.87	0.87	0.87	0.87	0.87
Midwest	14,848	0.88	0.87	0.87	0.87	0.86	0.87
South	60,138	0.85	0.84	0.84	0.85	0.85	0.85
West	19,517	0.87	0.86	0.85	0.86	0.85	0.85
U.S. dependent areas	1,809	0.77	0.74	0.72	0.74	0.79	0.77
Total	116,306	0.86	0.85	0.85	0.86	0.85	0.85

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

^a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^c Hispanic/Latino persons can be of any race.
^d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
^e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
^f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
^g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
^h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8f. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2013–2018, by year of diagnosis and area of residence—United States and 6 dependent areas
		Proportion survived >3 years
Area of residence	No.	2013	2014	2015	2016	2017	2018
Alabama	1,929	0.82	0.81	0.83	0.85	0.86	0.85
Alaska	91	*	*	*	*	*	*
Arizona	1,825	0.84	0.85	0.81	0.83	0.83	0.86
Arkansas	783	0.87	0.77	0.84	0.89	0.88	0.82
California	12,209	0.87	0.85	0.86	0.86	0.85	0.84
Colorado	1,091	0.89	0.88	0.84	0.87	0.89	0.92
Connecticut	937	0.88	0.88	0.93	0.91	0.84	0.88
Delaware	413	*	*	*	*	*	*
District of Columbia	1,221	0.88	0.82	0.85	0.90	0.83	0.88
Florida	13,834	0.82	0.81	0.83	0.84	0.84	0.84
Georgia	7,506	0.86	0.86	0.87	0.87	0.87	0.87
Hawaii	241	*	*	*	*	*	*
Idaho	122	*	*	*	*	*	*
Illinois	4,165	0.89	0.86	0.87	0.87	0.87	0.89
Indiana	1,475	0.85	0.86	0.84	0.84	0.82	0.86
Iowa	374	*	*	*	*	*	*
Kansas	404	*	*	*	*	*	*
Kentucky	980	0.81	0.84	0.81	0.86	0.85	0.83
Louisiana	3,236	0.84	0.81	0.84	0.86	0.86	0.86
Maine	132	*	*	*	*	*	*
Maryland	3,786	0.87	0.88	0.87	0.85	0.86	0.87
Massachusetts	1,769	0.91	0.90	0.92	0.88	0.87	0.87
Michigan	2,201	0.85	0.88	0.83	0.87	0.83	0.86
Minnesota	906	0.90	0.90	0.91	0.96	0.95	0.91
Mississippi^a	1,741	0.84	0.81	0.83	0.82	0.83	0.84
Missouri	1,344	0.87	0.90	0.88	0.86	0.88	0.82
Montana	65	*	*	*	*	*	*
Nebraska	263	*	*	*	*	*	*
Nevada	1,296	0.87	0.83	0.83	0.82	0.83	0.84
New Hampshire	97	*	*	*	*	*	*
New Jersey	3,584	0.84	0.86	0.85	0.85	0.87	0.85
New Mexico	365	*	*	*	*	*	*
New York	9,606	0.88	0.86	0.86	0.88	0.87	0.87
North Carolina	3,944	0.87	0.84	0.83	0.83	0.86	0.86
North Dakota	76	*	*	*	*	*	*
Ohio	2,901	0.89	0.85	0.89	0.85	0.87	0.85
Oklahoma	908	0.76	0.84	0.86	0.87	0.83	0.73
Oregon	694	0.88	0.86	0.89	0.86	0.82	0.86
Pennsylvania	3,585	0.85	0.86	0.86	0.88	0.86	0.87
Rhode Island	226	*	*	*	*	*	*
South Carolina	2,349	0.84	0.82	0.85	0.84	0.83	0.88
South Dakota	104	*	*	*	*	*	*
Tennessee	2,297	0.85	0.83	0.83	0.85	0.86	0.82
Texas	12,488	0.86	0.85	0.85	0.86	0.86	0.86
Utah	279	*	*	*	*	*	*
Vermont	58	*	*	*	*	*	*
Virginia	2,479	0.90	0.84	0.85	0.87	0.85	0.84
Washington	1,195	0.91	0.89	0.86	0.88	0.87	0.83
West Virginia^a	244	*	*	*	*	*	*
Wisconsin	635	0.85	0.82	0.91	0.86	0.83	0.86
Wyoming	44	*	*	*	*	*	*
Subtotal	114,497	0.86	0.85	0.85	0.86	0.86	0.86
U.S. dependent areas
American Samoa	0	*	*	*	*	*	*
Guam^a	17	*	*	*	*	*	*
Northern Mariana Islands	5	*	*	*	*	*	*
Puerto Rico	1,729	0.76	0.73	0.72	0.74	0.79	0.76
Republic of Palau	1	*	*	*	*	*	*
U.S. Virgin Islands^a	57	*	*	*	*	*	*
Subtotal	1,809	0.77	0.74	0.72	0.74	0.79	0.77
Total	116,306	0.86	0.85	0.85	0.86	0.85	0.85

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

^a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 9a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2021 among persons aged ≥16 years, by selected characteristics—United States
	Persons prescribed PrEP^a	Persons with PrEP indications^b	PrEP coverage^c (%)
Sex at birth
Male	337,697	989,200	34.1
Female	28,014	227,010	12.3
Age (yr)
16–24	48,552	246,290	19.7
25–34	145,758	434,680	33.5
35–44	88,516	238,470	37.1
45–54	46,224	173,420	26.7
≥55	36,740	123,350	29.8
Race/ethnicity^d
Black/African American	51,878	468,540	11.1
Hispanic/Latino^e	64,018	312,820	20.5
Other	15,779	131,180	12.0
White	234,318	300,650	77.9
Total	365,994	1,216,210	30.1

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. PrEP coverage data are considered preliminary. Data for year 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.
^b Estimated by using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.
^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
^d Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Race/ethnicity data were imputed, and the data source was based on a consumer database which might underrepresent certain populations. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted by applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.
^e Hispanic/Latino persons can be of any race.

Table 9b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2021 among persons aged ≥16 years, by area of residence—United States and Puerto Rico
Area of residence	Persons prescribed PrEP^a	Persons with PrEP indications^b	PrEP coverage^c (%)
Alabama	2,764	11,020	25.1
Alaska	308	1,780	17.3
Arizona	6,571	25,780	25.5
Arkansas	1,275	5,130	24.9
California	50,239	165,030	30.4
Colorado	6,187	25,120	24.6
Connecticut	3,036	9,560	31.8
Delaware	645	4,400	14.7
District of Columbia	6,790	12,950	52.4
Florida	42,584	125,330	34.0
Georgia	12,173	39,030	31.2
Hawaii	1,134	4,360	26.0
Idaho	878	4,790	18.3
Illinois	18,417	55,860	33.0
Indiana	4,261	22,170	19.2
Iowa	1,951	4,760	41.0
Kansas	1,278	5,060	25.3
Kentucky	2,225	12,990	17.1
Louisiana	4,152	15,920	26.1
Maine	908	3,950	23.0
Maryland	5,793	27,300	21.2
Massachusetts	10,164	24,900	40.8
Michigan	5,900	29,570	20.0
Minnesota	5,251	21,720	24.2
Mississippi	1,592	4,530	35.1
Missouri	4,173	18,370	22.7
Montana	395	2,290	17.2
Nebraska	1,004	2,180	46.1
Nevada	4,877	11,390	42.8
New Hampshire	803	3,020	26.6
New Jersey	7,267	25,280	28.7
New Mexico	1,594	6,800	23.4
New York	39,082	72,640	53.8
North Carolina	7,964	32,490	24.5
North Dakota	246	1,520	16.2
Ohio	8,465	40,320	21.0
Oklahoma	2,321	11,030	21.0
Oregon	4,691	19,750	23.8
Pennsylvania	13,049	36,490	35.8
Puerto Rico	608	9,700	6.3
Rhode Island	1,512	3,880	39.0
South Carolina	2,934	10,390	28.2
South Dakota	214	910	23.5
Tennessee	7,227	22,460	32.2
Texas	34,728	123,790	28.1
Utah	3,262	6,840	47.7
Vermont	480	1,060	45.3
Virginia	6,280	31,430	20.0
Washington	11,377	40,050	28.4
West Virginia	707	5,250	13.5
Wisconsin	2,816	12,980	21.7
Wyoming	139	890	15.6

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

Note. PrEP coverage data are considered preliminary. Data for year 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

^a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported.
^b Estimated by using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.
^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 10a. Perinatally acquired HIV infection, by year of birth and mother’s race/ethnicity, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 pandemic)		2021
Race/ethnicity^a	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate
Black/African American	29	5.2	22	4.0	17	3.1	24	4.5	16	3.1
Hispanic/Latino^b	7	0.8	7	0.8	8	0.9	6	0.7	5	0.5
White	7	0.4	6	0.3	5	0.3	7	0.4	0	0.0
Other^c	8	2.2	7	1.9	3	0.8	1	0.3	1	0.3
Total	51	1.3	42	1.1	33	0.9	38	1.1	22	0.6

Note. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Please use caution when interpreting perinatally acquired HIV infection numbers.

^a Live-birth data reflect race/ethnicity of the infant’s mother.
^b Hispanic/Latino persons can be of any race.
^c Includes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and multiracial persons.

Table 10b. Perinatally acquired HIV infection among persons born in the United States, by year of birth and mother’s race/ethnicity, 2017–2021—United States
	2017		2018		2019		2020 (COVID-19 pandemic)		2021
Race/ethnicity^a	No.	Rate	No.	Rate	No.	Rate	No.	Rate	No.	Rate
Black/African American	26	4.6	19	3.4	17	3.1	23	4.3	15	2.9
Hispanic/Latino^b	5	0.6	7	0.8	8	0.9	6	0.7	5	0.5
White	6	0.3	6	0.3	5	0.3	6	0.3	0	0.0
Other^c	8	2.2	5	1.4	3	0.8	1	0.3	1	0.3
Total	45	1.2	37	1.0	33	0.9	36	1.0	21	0.6

Note. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Please use caution when interpreting perinatally acquired HIV infection numbers.

^a Live-birth data reflect race/ethnicity of the infant’s mother.
^b Hispanic/Latino persons can be of any race.
^c Includes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and multiracial persons.

Table 11. Status of CD4 and viral load reporting by HIV surveillance reporting area, as of December 2022—United States and 6 dependent areas
	CD4 count (cells/µL) or CD4 percentage		Viral load
	Lab reporting required^a	Reportable level^b	Lab reporting required^a	Reportable level^b
Alabama	Yes	All values	Yes	Any result
Alaska	Yes	All values	Yes	Any result
American Samoa	No	—	No	—
Arizona	Yes	All values	Yes	Any result
Arkansas	Yes	All values	Yes	Any result
California	Yes	All values	Yes	Any result
Colorado	Yes	All values	Yes	Any result
Connecticut	Yes	All values	Yes	Any result
Delaware	Yes	All values	Yes	Any result
District of Columbia	Yes	All values	Yes	Any result
Federated States of Micronesia	No	—	No	—
Florida	Yes	All values	Yes	Any result
Georgia	Yes	All values	Yes	Any result
Guam	Yes	All values	Yes	Any result
Hawaii	Yes	All values	Yes	Any result
Idaho	Yes	<200 or <14%	Yes	Detectable
Illinois	Yes	All values	Yes	Any result
Indiana	Yes	All values	Yes	Any result
Iowa	Yes	All values	Yes	Any result
Kansas	Yes	All values	Yes	Any result
Kentucky	Yes	All values	Yes	Any result
Louisiana	Yes	All values	Yes	Any result
Maine	Yes	All values	Yes	Any result
Marshall Islands	No	—	No	—
Maryland	Yes	All values	Yes	Any result
Massachusetts	Yes	All values	Yes	Any result
Michigan	Yes	All values	Yes	Any result
Minnesota	Yes	All values	Yes	Any result
Mississippi	Yes	All values	Yes	Any result
Missouri	Yes	All values	Yes	Any result
Montana	Yes	All values	Yes	Any result
Nebraska	Yes	All values	Yes	Any result
Nevada	Yes	All values	Yes	Any result
New Hampshire	Yes	All values	Yes	Any result
New Jersey	Yes	All values	Yes	Any result
New Mexico	Yes	All values	Yes	Any result
New York	Yes	All values	Yes	Any result
North Carolina	Yes	All values	Yes	Any result
North Dakota	Yes	All values	Yes	Any result
Northern Mariana Islands	No	—	No	—
Ohio	Yes	All values	Yes	Any result
Oklahoma	Yes	All values	Yes	Any result
Oregon	Yes	All values	Yes	Any result
Pennsylvania	Yes	All values	Yes	Any result
Puerto Rico	Yes	All values	Yes	Any result
Republic of Palau	No	—	No	—
Rhode Island	Yes	All values	Yes	Any result
South Carolina	Yes	All values	Yes	Any result
South Dakota	Yes	All values	Yes	Any result
Tennessee	Yes	All values	Yes	Any result
Texas	Yes	All values	Yes	Any result
U.S. Virgin Islands	Yes	<200 or <14%	Yes	Detectable
Utah	Yes	All values	Yes	Any result
Vermont	Yes	All values	Yes	Any result
Virginia	Yes	All values	Yes	Any result
Washington	Yes	All values	Yes	Any result
West Virginia	Yes	All values	Yes	Any result
Wisconsin	Yes	All values	Yes	Any result
Wyoming	Yes	All values	Yes	Any result

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage.

^a Laws, regulations, or statutes in most areas require laboratories to report, but in some instances the language is not specific.
^b Level at which CD4 or viral load reporting is required by laws, regulations, or statutes.

Table A1. Stage of disease at time of diagnosis of HIV infection during 2021 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions
		Stage 0^a		Stage 1 (CD4 ≥ 500 cells/µL or ≥ 26%)		Stage 2 (CD4 = 200–499 cells/µL or 14%–25%)		Stage 3 (AIDS) (OI or CD4 < 200 cells/µL or <14%)		Stage unknown^b
Area of residence	Total No.	No.	%	No.	%	No.	%	No.	%	No.	%
Arizona
Maricopa County	518	52	10.0	128	24.7	165	31.9	109	21.0	64	12.4
California
Alameda County	185	9	4.9	57	30.8	53	28.6	43	23.2	23	12.4
Los Angeles County	1,486	123	8.3	354	23.8	486	32.7	301	20.3	222	14.9
Orange County	266	28	10.5	63	23.7	91	34.2	56	21.1	28	10.5
Riverside County	258	15	5.8	62	24.0	85	32.9	56	21.7	40	15.5
Sacramento County	175	12	6.9	38	21.7	68	38.9	40	22.9	17	9.7
San Bernardino County	301	23	7.6	78	25.9	93	30.9	56	18.6	51	16.9
San Diego County	369	13	3.5	125	33.9	99	26.8	85	23.0	47	12.7
San Francisco County	185	33	17.8	54	29.2	59	31.9	28	15.1	11	5.9
District of Columbia	195	14	7.2	49	25.1	58	29.7	37	19.0	37	19.0
Florida
Broward County	570	12	2.1	156	27.4	196	34.4	110	19.3	96	16.8
Duval County	280	18	6.4	62	22.1	77	27.5	66	23.6	57	20.4
Hillsborough County	294	24	8.2	61	20.7	100	34.0	67	22.8	42	14.3
Miami-Dade County	937	47	5.0	277	29.6	311	33.2	167	17.8	135	14.4
Orange County	416	24	5.8	143	34.4	128	30.8	64	15.4	57	13.7
Palm Beach County	273	3	1.1	72	26.4	99	36.3	65	23.8	34	12.5
Pinellas County	122	5	4.1	30	24.6	39	32.0	28	23.0	20	16.4
Georgia
Cobb County	152	7	4.6	35	23.0	57	37.5	35	23.0	18	11.8
DeKalb County	342	11	3.2	90	26.3	126	36.8	69	20.2	46	13.5
Fulton County	525	17	3.2	141	26.9	187	35.6	102	19.4	78	14.9
Gwinnett County	165	5	3.0	36	21.8	63	38.2	38	23.0	23	13.9
Illinois
Cook County	843	80	9.5	217	25.7	244	28.9	143	17.0	159	18.9
Indiana
Marion County	216	5	2.3	62	28.7	72	33.3	40	18.5	37	17.1
Louisiana
East Baton Rouge Parish	141	24	17.0	25	17.7	50	35.5	25	17.7	17	12.1
Orleans Parish	145	23	15.9	38	26.2	47	32.4	30	20.7	7	4.8
Maryland
Baltimore City	156	21	13.5	43	27.6	47	30.1	27	17.3	18	11.5
Montgomery County	96	9	9.4	24	25.0	27	28.1	30	31.3	6	6.3
Prince George’s County	229	17	7.4	68	29.7	67	29.3	58	25.3	19	8.3
Massachusetts
Suffolk County	132	11	8.3	48	36.4	44	33.3	20	15.2	9	6.8
Michigan
Wayne County	256	26	10.2	68	26.6	83	32.4	54	21.1	25	9.8
Nevada
Clark County	445	25	5.6	123	27.6	155	34.8	100	22.5	42	9.4
New York
Bronx County	416	49	11.8	106	25.5	137	32.9	89	21.4	35	8.4
Kings County	441	47	10.7	124	28.1	144	32.7	94	21.3	32	7.3
New York County	317	25	7.9	85	26.8	107	33.8	57	18.0	43	13.6
Queens County	333	33	9.9	84	25.2	108	32.4	73	21.9	35	10.5
North Carolina
Mecklenburg County	278	28	10.1	48	17.3	80	28.8	43	15.5	79	28.4
Ohio
Cuyahoga County	164	3	1.8	63	38.4	55	33.5	29	17.7	14	8.5
Franklin County	187	8	4.3	54	28.9	58	31.0	46	24.6	21	11.2
Hamilton County	122	7	5.7	29	23.8	41	33.6	32	26.2	13	10.7
Pennsylvania
Philadelphia County	360	33	9.2	97	26.9	107	29.7	70	19.4	53	14.7
Tennessee
Shelby County	294	10	3.4	72	24.5	95	32.3	33	11.2	84	28.6
Texas
Bexar County	328	37	11.3	64	19.5	104	31.7	57	17.4	66	20.1
Dallas County	798	83	10.4	186	23.3	239	29.9	145	18.2	145	18.2
Harris County	1,161	81	7.0	274	23.6	362	31.2	246	21.2	198	17.1
Tarrant County	302	31	10.3	80	26.5	96	31.8	59	19.5	36	11.9
Travis County	225	30	13.3	48	21.3	87	38.7	37	16.4	23	10.2
Washington
King County	218	22	10.1	65	29.8	73	33.5	42	19.3	16	7.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
^b Includes persons with no CD4 information.

Table A2. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions
		Linkage to Care				Viral Suppression
		≤1 month
		≥ 1 CD4 or VL tests		No CD4 or VL test		VL <200 copies/mL ≤6 months
Area of residence	Total No.	No.	%	No.	%	No.	%
Arizona
Maricopa County	518	446	86.1	72	13.9	363	70.1
California
Alameda County	185	162	87.6	23	12.4	139	75.1
Los Angeles County	1,486	1,194	80.3	292	19.7	994	66.9
Orange County	266	230	86.5	36	13.5	204	76.7
Riverside County	258	199	77.1	59	22.9	172	66.7
Sacramento County	175	151	86.3	24	13.7	124	70.9
San Bernardino County	301	230	76.4	71	23.6	195	64.8
San Diego County	369	307	83.2	62	16.8	235	63.7
San Francisco County	185	174	94.1	11	5.9	145	78.4
District of Columbia	195	154	79.0	41	21.0	126	64.6
Florida
Broward County	570	467	81.9	103	18.1	375	65.8
Duval County	280	222	79.3	58	20.7	188	67.1
Hillsborough County	294	234	79.6	60	20.4	202	68.7
Miami-Dade County	937	768	82.0	169	18.0	640	68.3
Orange County	416	340	81.7	76	18.3	288	69.2
Palm Beach County	273	231	84.6	42	15.4	187	68.5
Pinellas County	122	99	81.1	23	18.9	90	73.8
Georgia
Cobb County	152	131	86.2	21	13.8	107	70.4
DeKalb County	342	283	82.7	59	17.3	236	69.0
Fulton County	525	438	83.4	87	16.6	351	66.9
Gwinnett County	165	144	87.3	21	12.7	124	75.2
Illinois
Cook County	843	730	86.6	113	13.4	588	69.8
Indiana
Marion County	216	170	78.7	46	21.3	162	75.0
Louisiana
East Baton Rouge Parish	141	112	79.4	29	20.6	98	69.5
Orleans Parish	145	131	90.3	14	9.7	108	74.5
Maryland
Baltimore City	156	133	85.3	23	14.7	96	61.5
Montgomery County	96	85	88.5	11	11.5	63	65.6
Prince George’s County	229	198	86.5	31	13.5	162	70.7
Massachusetts
Suffolk County	132	127	96.2	5	3.8	108	81.8
Michigan
Wayne County	256	216	84.4	40	15.6	178	69.5
Nevada
Clark County	445	387	87.0	58	13.0	343	77.1
New York
Bronx County	416	359	86.3	57	13.7	322	77.4
Kings County	441	378	85.7	63	14.3	338	76.6
New York County	317	262	82.6	55	17.4	237	74.8
Queens County	333	285	85.6	48	14.4	268	80.5
North Carolina
Mecklenburg County	278	226	81.3	52	18.7	206	74.1
Ohio
Cuyahoga County	164	146	89.0	18	11.0	120	73.2
Franklin County	187	161	86.1	26	13.9	136	72.7
Hamilton County	122	109	89.3	13	10.7	89	73.0
Pennsylvania
Philadelphia County	360	301	83.6	59	16.4	237	65.8
Tennessee
Shelby County	294	177	60.2	117	39.8	177	60.2
Texas
Bexar County	328	263	80.2	65	19.8	190	57.9
Dallas County	798	613	76.8	185	23.2	456	57.1
Harris County	1,161	873	75.2	288	24.8	723	62.3
Tarrant County	302	236	78.1	66	21.9	191	63.2
Travis County	225	195	86.7	30	13.3	172	76.4
Washington
King County	218	194	89.0	24	11.0	176	80.7

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table A3. Receipt of HIV medical care during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by area of residence—Ending the HIV Epidemic Phase I jurisdictions
	Persons alive at year-end 2021	≥1 CD4 or VL tests		≥2 CD4 or VL tests^a		VL <200 copies/mL^b
Area of residence	Total No.	No.	%	No.	%	No.	%
Arizona
Maricopa County	11,910	8,896	74.7	6,635	55.7	7,494	62.9
California
Alameda County	5,808	4,607	79.3	3,067	52.8	4,152	71.5
Los Angeles County	49,007	35,526	72.5	26,579	54.2	31,877	65.0
Orange County	6,963	4,854	69.7	3,711	53.3	4,557	65.4
Riverside County	9,862	8,185	83.0	5,904	59.9	7,691	78.0
Sacramento County	4,467	3,538	79.2	2,228	49.9	3,128	70.0
San Bernardino County	4,769	3,265	68.5	2,221	46.6	2,919	61.2
San Diego County	13,163	9,475	72.0	6,315	48.0	7,748	58.9
San Francisco County	11,437	9,185	80.3	6,168	53.9	8,350	73.0
District of Columbia	13,401	8,798	65.7	5,699	42.5	7,418	55.4
Florida
Broward County	19,788	15,644	79.1	12,730	64.3	13,586	68.7
Duval County	6,218	5,081	81.7	3,898	62.7	4,324	69.5
Hillsborough County	7,162	5,831	81.4	4,747	66.3	5,196	72.5
Miami-Dade County	26,224	18,450	70.4	14,748	56.2	16,142	61.6
Orange County	8,938	7,129	79.8	5,544	62.0	6,433	72.0
Palm Beach County	7,887	5,778	73.3	4,621	58.6	5,100	64.7
Pinellas County	4,812	4,127	85.8	3,524	73.2	3,745	77.8
Georgia
Cobb County	3,501	2,643	75.5	1,926	55.0	2,332	66.6
DeKalb County	8,802	6,546	74.4	4,827	54.8	5,637	64.0
Fulton County	15,851	11,745	74.1	8,646	54.5	9,885	62.4
Gwinnett County	3,199	2,393	74.8	1,787	55.9	2,147	67.1
Illinois
Cook County	24,919	18,811	75.5	11,406	45.8	15,173	60.9
Indiana
Marion County	4,752	3,900	82.1	2,739	57.6	3,507	73.8
Louisiana
East Baton Rouge Parish	3,983	3,412	85.7	2,867	72.0	3,021	75.8
Orleans Parish	4,721	3,640	77.1	2,629	55.7	3,199	67.8
Maryland
Baltimore City	10,110	7,405	73.2	4,924	48.7	6,303	62.3
Montgomery County	3,850	2,366	61.5	1,608	41.8	2,028	52.7
Prince George’s County	7,865	5,608	71.3	3,831	48.7	4,763	60.6
Massachusetts
Suffolk County	5,527	4,076	73.7	2,621	47.4	3,765	68.1
Michigan
Wayne County	6,974	5,547	79.5	3,452	49.5	4,767	68.4
Nevada
Clark County	9,255	6,790	73.4	4,702	50.8	5,909	63.8
New York
Bronx County	26,854	20,781	77.4	16,915	63.0	17,245	64.2
Kings County	25,601	18,516	72.3	14,836	58.0	16,330	63.8
New York County	25,777	17,436	67.6	13,708	53.2	15,598	60.5
Queens County	15,810	10,978	69.4	8,805	55.7	10,089	63.8
North Carolina
Mecklenburg County	6,013	4,667	77.6	3,249	54.0	4,025	66.9
Ohio
Cuyahoga County	4,810	3,636	75.6	2,425	50.4	3,132	65.1
Franklin County	5,072	4,012	79.1	2,494	49.2	3,581	70.6
Hamilton County	3,037	2,247	74.0	1,351	44.5	1,954	64.3
Pennsylvania
Philadelphia County	16,404	11,545	70.4	8,099	49.4	10,051	61.3
Tennessee
Shelby County	6,278	4,873	77.6	3,770	60.1	4,007	63.8
Texas
Bexar County	6,596	4,685	71.0	2,834	43.0	4,112	62.3
Dallas County	18,809	14,704	78.2	10,972	58.3	11,348	60.3
Harris County	26,727	19,882	74.4	14,088	52.7	17,120	64.1
Tarrant County	6,120	4,854	79.3	3,720	60.8	4,162	68.0
Travis County	5,032	4,057	80.6	2,665	53.0	3,506	69.7
Washington
King County	6,965	6,081	87.3	3,829	55.0	5,707	81.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

^a Performed ≥3 months apart during 2021.
^b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.

Table A4. HIV viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by area of residence— Ending the HIV Epidemic Phase I jurisdictions
						VL <200 copies/mL
	Persons alive at year-end 2021	Persons with ≥1 CD4 or VL tests		Persons with ≥1 VL tests		Total	Among persons alive at year-end 2021	Among Persons with ≥1 CD4 or VL tests	Among persons with ≥1 VL tests
Area of residence	No.	No.	%	No.	%	No.	%	%	%
Arizona
Maricopa County	11,910	8,896	74.7	8,158	68.5	7,494	62.9	84.2	91.9
California
Alameda County	5,808	4,607	79.3	4,466	76.9	4,152	71.5	90.1	93.0
Los Angeles County	49,007	35,526	72.5	34,598	70.6	31,877	65.0	89.7	92.1
Orange County	6,963	4,854	69.7	4,807	69.0	4,557	65.4	93.9	94.8
Riverside County	9,862	8,185	83.0	8,085	82.0	7,691	78.0	94.0	95.1
Sacramento County	4,467	3,538	79.2	3,406	76.2	3,128	70.0	88.4	91.8
San Bernardino County	4,769	3,265	68.5	3,176	66.6	2,919	61.2	89.4	91.9
San Diego County	13,163	9,475	72.0	8,264	62.8	7,748	58.9	81.8	93.8
San Francisco County	11,437	9,185	80.3	8,890	77.7	8,350	73.0	90.9	93.9
District of Columbia	13,401	8,798	65.7	8,302	62.0	7,418	55.4	84.3	89.4
Florida
Broward County	19,788	15,644	79.1	14,692	74.2	13,586	68.7	86.8	92.5
Duval County	6,218	5,081	81.7	4,952	79.6	4,324	69.5	85.1	87.3
Hillsborough County	7,162	5,831	81.4	5,741	80.2	5,196	72.5	89.1	90.5
Miami-Dade County	26,224	18,450	70.4	17,775	67.8	16,142	61.6	87.5	90.8
Orange County	8,938	7,129	79.8	7,010	78.4	6,433	72.0	90.2	91.8
Palm Beach County	7,887	5,778	73.3	5,658	71.7	5,100	64.7	88.3	90.1
Pinellas County	4,812	4,127	85.8	4,016	83.5	3,745	77.8	90.7	93.3
Georgia
Cobb County	3,501	2,643	75.5	2,578	73.6	2,332	66.6	88.2	90.5
DeKalb County	8,802	6,546	74.4	6,326	71.9	5,637	64.0	86.1	89.1
Fulton County	15,851	11,745	74.1	11,324	71.4	9,885	62.4	84.2	87.3
Gwinnett County	3,199	2,393	74.8	2,340	73.1	2,147	67.1	89.7	91.8
Illinois
Cook County	24,919	18,811	75.5	17,013	68.3	15,173	60.9	80.7	89.2
Indiana
Marion County	4,752	3,900	82.1	3,858	81.2	3,507	73.8	89.9	90.9
Louisiana
East Baton Rouge Parish	3,983	3,412	85.7	3,380	84.9	3,021	75.8	88.5	89.4
Orleans Parish	4,721	3,640	77.1	3,596	76.2	3,199	67.8	87.9	89.0
Maryland
Baltimore City	10,110	7,405	73.2	7,123	70.5	6,303	62.3	85.1	88.5
Montgomery County	3,850	2,366	61.5	2,213	57.5	2,028	52.7	85.7	91.6
Prince George’s County	7,865	5,608	71.3	5,229	66.5	4,763	60.6	84.9	91.1
Massachusetts
Suffolk County	5,527	4,076	73.7	3,974	71.9	3,765	68.1	92.4	94.7
Michigan
Wayne County	6,974	5,547	79.5	5,413	77.6	4,767	68.4	85.9	88.1
Nevada
Clark County	9,255	6,790	73.4	6,432	69.5	5,909	63.8	87.0	91.9
New York
Bronx County	26,854	20,781	77.4	20,463	76.2	17,245	64.2	83.0	84.3
Kings County	25,601	18,516	72.3	18,322	71.6	16,330	63.8	88.2	89.1
New York County	25,777	17,436	67.6	17,151	66.5	15,598	60.5	89.5	90.9
Queens County	15,810	10,978	69.4	10,873	68.8	10,089	63.8	91.9	92.8
North Carolina
Mecklenburg County	6,013	4,667	77.6	4,510	75.0	4,025	66.9	86.2	89.2
Ohio
Cuyahoga County	4,810	3,636	75.6	3,494	72.6	3,132	65.1	86.1	89.6
Franklin County	5,072	4,012	79.1	3,933	77.5	3,581	70.6	89.3	91.1
Hamilton County	3,037	2,247	74.0	2,192	72.2	1,954	64.3	87.0	89.1
Pennsylvania
Philadelphia County	16,404	11,545	70.4	11,279	68.8	10,051	61.3	87.1	89.1
Tennessee
Shelby County	6,278	4,873	77.6	4,804	76.5	4,007	63.8	82.2	83.4
Texas
Bexar County	6,596	4,685	71.0	4,585	69.5	4,112	62.3	87.8	89.7
Dallas County	18,809	14,704	78.2	13,178	70.1	11,348	60.3	77.2	86.1
Harris County	26,727	19,882	74.4	19,544	73.1	17,120	64.1	86.1	87.6
Tarrant County	6,120	4,854	79.3	4,694	76.7	4,162	68.0	85.7	88.7
Travis County	5,032	4,057	80.6	3,734	74.2	3,506	69.7	86.4	93.9
Washington
King County	6,965	6,081	87.3	6,030	86.6	5,707	81.9	93.8	94.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results during 2021. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table A4. HIV viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by area of residence— Ending the HIV Epidemic Phase I jurisdictions
	2021
Area of residence	No. prescribed PrEP^a	No. with PrEP indications^b	PrEP coveragec (%)
Arizona
Maricopa County	5,026	22,720	22.1
California
Alameda County	2,217	8,930	24.8
Los Angeles County	18,457	67,450	27.4
Orange County	2,832	10,510	26.9
Riverside County	2,538	11,080	22.9
Sacramento County	1,103	5,920	18.6
San Bernardino County	1,190	11,890	10.0
San Diego County	4,430	14,500	30.6
San Francisco County	8,189	10,840	75.5
District of Columbia	6,790	12,950	52.4
Florida
Broward County	8,328	20,470	40.7
Duval County	883	8,970	9.8
Hillsborough County	2,043	12,910	15.8
Miami-Dade County	11,410	21,760	52.4
Orange County	4,722	15,310	30.8
Palm Beach County	2,760	9,170	30.1
Pinellas County	1,655	9,530	17.4
Georgia
Cobb County	812	3,070	26.4
DeKalb County	2,016	6,290	32.1
Fulton County	4,269	13,120	32.5
Gwinnett County	1,005	3,240	31.0
Illinois
Cook County	14,755	39,060	37.8
Indiana
Marion County	1,591	9,150	17.4
Louisiana
East Baton Rouge Parish	584	1,810	32.3
Orleans Parish	1,517	4,590	33.1
Maryland
Baltimore City	974	6,330	15.4
Montgomery County	1,151	5,770	19.9
Prince George’s County	984	4,040	24.4
Massachusetts
Suffolk County	2,809	6,520	43.1
Michigan
Wayne County	1,554	9,270	16.8
Nevada
Clark County	4,284	11,670	36.7
New Jersey
Essex County	836	4,090	20.4
Hudson County	1,301	4,650	28.0
New York
Bronx County	2,074	5,570	37.2
Kings County	8,871	15,650	56.7
New York County	15,745	15,540	101.3
Queens County	4,279	9,230	46.4
North Carolina
Mecklenburg County	1,974	8,450	23.4
Ohio
Cuyahoga County	1,261	7,520	16.8
Franklin County	2,731	11,620	23.5
Hamilton County	815	7,720	10.6
Pennsylvania
Philadelphia County	4,049	9,840	41.1
Tennessee
Shelby County	941	6,450	14.6
Texas
Bexar County	2,355	11,920	19.8
Dallas County	6,544	28,670	22.8
Harris County	7,479	40,670	18.4
Tarrant County	2,104	11,340	18.6
Travis County	5,784	11,590	49.9
Washington
King County	7,634	17,890	42.7
Puerto Rico
San Juan Municipio	62	2,190	2.8

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

^a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported.
^b Estimated by using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.
^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas, 2021: Tables

Report Contents

Other Reports